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Abstract 
Mucous membrane pemphigoid (MMP) and pemphigus vulgaris (PV) are uncommon 
mucocutaneous immunobullous disorders associated with significant morbidity.  The 
aims were to: 1) Investigate the potential of saliva for diagnosis and disease-monitoring 
2) Utilize serum and salivary biomarkers in the analysis of disease severity and 
therapeutic responses 3) Correlate phenotypic subgroups with target antigens to 
potentially explain the spectrum of clinical presentation and disease severity in MMP. 
Methodology: Matched serum and whole saliva samples were taken from a total of 100 
MMP patients, 26 PV patients, 50 healthy controls (HC) and 16 Lichen planus (LP) 
patients.  All LP and PV patients, 40 MMP and 6 HC provided parotid saliva.  
Reactivity with the NC16a epitope on bullous pemphigoid antigen 2 (BP180), the alpha 
6 beta 4 integrin (α6β4) and desmoglein 3 (Dsg3) was determined by Enzyme-linked 
immunosorbent assays (ELISA).  Disease severity was assessed using the Guy’s Oral 
Disease Severity Score.  
Results: In MMP, IgG and/or IgA antibody to BP180-NC16a (44%) in whole saliva 
showed a similar sensitivity to serum (48%).  In parotid saliva IgA to BP180-NC16a 
was positive in 45% and was also secretory component positive (r =0.9141).  A change 
in serum antibodies (IgG and IgA) to BP180-NC16a was significantly related to a 
change in severity scores (p =0.048 and 0.033, respectively).  A positive association was 
found between 1) the presence of serum IgG to BP180-NC16a and the presence of 
lesions in multisite disease (p =0.003) and 2) the presence of IgA to BP180-NC16a in 
whole saliva and the presence of oral and ocular lesions (p =0.016).  IgG antibody to 
α6β4 integrin was positive in 36% of serum and 18% of saliva. 
Regarding PV, anti-Dsg3 IgG antibody was positive in serum (74%) and whole saliva 
(61%) with a positive correlation (r =0.9044).  Serum IgA anti-Dsg3 antibody was 
positive in 61% (with a combined IgG positivity of 78% in PV patients).  A significant 
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relationship between anti-Dsg3 IgG antibody in whole saliva and therapeutic responses 
was found (p =0.004).   
Conclusions: The results show 1) the value of salivary anti-Dsg3 IgG antibodies in 
monitoring PV patients and confirm the sensitivity and specificity of IgG anti-Dsg3 
serum and saliva antibodies in PV diagnosis.  The high positivity of serum IgA anti-
Dsg3 antibodies requires further elucidation in disease pathogenesis. The salivary 
biomarkers, IgG and IgA antibodies to BP180-NC16a and α6β4 may be useful in the 
diagnosis of MMP.  2) IgG and IgA antibodies to BP180-NC16a in serum can be used 
for disease monitoring and therapeutic responses in MMP.  3) Clinical phenotypes did 
not appear to be explained by epitope or isotype specificity.  However, the novel finding 
of locally produced antibodies to BP180-NC16a may provide further insight into the 
pathogenesis of the oral disease.  These new findings demonstrate the value of saliva in 
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1 Introduction: an overview of mucous membrane pemphigoid 
(MMP) and pemphigus vulgaris (PV) 
This chapter provides an overview of the two diseases focused on in this thesis, mucous 
membrane pemphigoid (MMP) and pemphigus vulgaris (PV).  The review covers the 
historical background, epidemiology, clinical presentation, antibody detection, the 
pathogenesis and the target antigens for each disease. In addition, it gives a short 
account on mucosal immunity and the use of saliva as a medium for biomarker 
detection. 
Mucous membrane pemphigoid and pemphigus vulgaris are both autoimmune 
vesiculobullous diseases usually referred to as immunobullous disorders.  In these 
disorders, autoantibodies target antigens in the skin and mucous membranes resulting in 
fragility and blistering.  Vesicles (≤ 5 mm) and bullae (> 5 mm) are fluid-filled lesions 
forming within or just below the epidermis/epithelium. They frequently rupture to form 
an ulcer.  MMP is characterised by sub-epithelial separation as shown in (Fig 1-1) and 
histologically shown in (Fig 1-2 a).  PV is characterised by acantholysis or breakdown 
of cell attachments known as desmosomes leading to intra-epithelial separation usually 
forming a suprabasal cleft (Figs 1-1 and 1-2 b).  In these diseases, damage to the target 
autoantigens results in significant morbidity and occasionally mortality. 
 
 
Figure 1-1 A schematic drawing showing the sites of cleavage in the epithelial level in 












Figure 1-2 Histology of biopsy from an MMP and PV patient.  a) Haematoxylin and eosin 
(H&E) stain of buccal mucosa in an MMP patient showing sub-epithelial separation 
(magnification 40.00x) b) Haematoxylin and eosin (H&E) stain of buccal tissue in a PV patient 
showing intra-epithelial separation (magnification 40.00x) 
 
MMP is a predominantly mucosal disease affecting many possible sites.  It is a 
heterogeneous disease with a wide variation in the number of affected sites as well as 
the disease severity.   In sites such as the oral cavity, the consequences may be relatively 
mild while in others the consequences may be very severe.   Scarring may result in 
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variation in  the target antigens  (Bagan J. et al., 2005).  Therefore, early diagnosis is 
imperative to minimise the risk of complications associated with the disease.   
Bullous diseases are a heterogenous group of disorders that predominantly affect the 
skin and/or mucous membranes.  They are characterised by subepithelial blister 
formation and the target antigens lie within the basement membrane zone (BMZ).  
MMP is part of this spectrum of bullous diseases which also include bullous 
pemphigoid, epidermolysis bullosa acquisita and linear IgA dermatosis (Yeh et al., 
2003). 
Much work has been undertaken to establish the diagnostic criteria for MMP.   The 
leading experts in the field put together the 1st international consensus in 1999 (Chan et 
al., 2002). Currently, direct immunofluorescence (DIF) is the gold-standard for 
diagnosis.  Indirect immunofluorescence (IIF) may also be helpful for diagnosis and 
may be helpful in assessing the patient’s response to treatment and disease activity. 
Enzyme-linked immunosorbent assay (ELISA) should allow determination of response 
to individual antigens, but is not routinely used on account of the presumed diversity of 
target basement membrane zone (BMZ) antigens.  If defined clinical phenotypes could 
be related to specific antigens, this might provide a clearer understanding of the 
pathophysiology of the disease, and potentially, its prognosis and treatment.   
The pemphigus group of diseases include pemphigus vulgaris (PV), pemphigus 
foliaceus (PF), IgA pemphigus and paraneoplastic pemphigus (PNP).  Pemphigus 
foliaceus is a rare, skin disease with mucosal sites rarely involved. PV is the more 
common subtype of pemphigus.  It shows less clinical and immunopathological 
diversity than MMP. The main target antigens are desmoglein 1 (Dsg1) for cutaneous 
lesions and desmoglein 3 (Dsg3) for mucosal lesions.  It is clinically characterised by 
superficial blisters and chronic ulceration frequently affecting the oral mucosa.  DIF is 
considered the gold-standard of diagnosis but IIF and ELISA with serum are routinely 
used to assess disease activity.  While the mortality rate from PV has significantly 
decreased with the introduction of corticosteroids and adjuvant immunomodulating 
therapies, therapy is often associated with side effects such as infection and 
osteoporosis.  
Oral lesions occur frequently in both MMP and PV and yet disease activity is not 
always associated with detectable circulating antibodies. An area of possible interest 
therefore, was to see whether disease specific autoantibodies may be detectable in 
saliva, and if so, to establish whether these might correlate with disease activity.   
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Studies to date have reported serum ELISA results in both MMP and PV (Kwon et al., 
2008, Miyamoto et al., 2014).  However, one study testing saliva in MMP showed no 
reactivity while a few have tested saliva in PV and have shown reactivity (Andreadis D, 
2006, Hallaji et al., 2010, Hosseein Mortazavi, 2015).  
The need for early and rapid diagnosis is important for a better disease outcome.  More 
vital, the need for good prognostic biomarkers underpins the potential value in testing 
saliva as an alternative medium to serum.  Furthermore, it provides an opportunity to 
better understand the disease pathogenesis and potentially the development of targeted 
treatment.   
This project aims to establish whether saliva could provide a sensitive, reliable, cheap 
and non-invasive alternative to serum in the diagnosis and monitoring of MMP and PV.  
In addition, it aims to explore the relationship between specific phenotypes with 
autoantibody subclasses, antibody avidity and target antigens to more fully explain the 
spectrum of clinical presentation and disease severity.   
 
 Background 
1.1.1 Historical Perspective 
1.1.1.1 Mucous membrane pemphigoid (MMP) 
In 1971, Hardy et al gave a concise review of the literature regarding MMP.  It had been 
first described by Wichmann in 1794, in a case of eye involvement with chronic bullous 
disease.  Then, in 1858, Cooper mentioned the first case with mild skin but severe 
scarring of the conjunctivae.  Later, “Essential shrinkage of the conjunctivae” was 
reported in 1878 by Von Kries (Hardy et al., 1971).  The term “chronic pemphigus of 
the mucous membranes” was introduced by Thost in 1896.  Thereafter, in 1919, Thost 
recommended that “benign mucosal pemphigoid” be considered a separate entity 
(Shklar and McCarthy, 1959).  In 1949, “Benign mucous membrane pemphigoid” was 
clearly established as a distinct form, after Civatte based this distinction on 
histopathological studies (Taylor, 1967).  In 1951, Lever confirmed these findings 
finally separating benign mucous membrane pemphigoid from pemphigus vulgaris as 
distinct entities (Hardy et al., 1971).  The term cicatricial pemphigoid was then 
introduced and appeared in the literature in the 1960’s (Sneddon, 1962) and is still 
sometimes used.  More recently, in 2002, the leading experts in the field designated  the 
term MMP to a “group of putative autoimmune chronic inflammatory, sub-epithelial 
1 INTRODUCTION 
25 | P a g e  
 
blistering diseases predominantly affecting mucous membranes that is characterized by 
linear deposition of IgG, IgA, or C3 along the epithelial basement membrane” in the 
first international consensus for MMP (Chan L. et al., 2002). 
1.1.1.2  Pemphigus vulgaris (PV) 
It was first named by Wichman in 1791 when all blistering diseases were grouped 
together under one term, Pemphigus (Korman, 1988).   Lever, in 1953, characterized 
PV, based on its histopathological picture, clinical criteria, and the course of the disease 
as a distinct entity from bullous pemphigoid (Korman, 1988). This was an important 
finding as it provided the base for separating the distinct clinical diseases, bullous 
pemphigoid and mucous membrane pemphigoid which form subepithelial clefts, from 
pemphigus which produces intraepithelial clefts.  Not only that, it also demonstrated the 
difference between  the pemphigus subtypes, as pemphigus vulgaris shows suprabasal 
clefts in contrast to pemphigus foliaceus where clefts occur in the sub-corneal layer (i.e. 
more superficial in the epithelium). The first hint to pemphigus’s pathogenesis was 
identified in 1964 by Beutner and Jordon, who demonstrated that pemphigus patients’ 
sera contained autoantibodies that bind to autoantigens present intercellularly in the skin 
and mucosa (Korman, 1988, Beutner et al., 1967).   
 
1.1.2 Epidemiology 
1.1.2.1 Mucous membrane pemphigoid  
MMP has an estimated incidence of 1.3-2 per 1 million people per year in France and 
Germany respectively (Bernard et al., 1995, Bertram et al., 2009).  It has a female 
predilection and a mean age of presentation between 60-65 years (Shklar and McCarthy, 
1959, Hardy et al., 1971, Ahmed and Hombal, 1986, Silverman Jr et al., 1986, Schmidt 
and Zillikens, 2013).  Very rarely, MMP has been known to affect children (Lara-
Corrales and Pope, 2010, Kharfi et al., 2010, Cheng et al., 2001).  Although 
geographical and racial predilections have not been highlighted in the literature, MMP 
seems to be more common in the European populations in comparison to others as 
clinically observed in this department. 
1.1.2.2 Pemphigus vulgaris 
There are several subtypes of pemphigus of which PV is the most common pemphigus 
subtype (Alpsoy et al., 2015).  PV is a very uncommon disease with an incidence rate of 
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0.5-3.2/100,000 population/year (Korman, 1988).  A recent study showed an 11% 
yearly average increase in the UK population (Langan et al., 2008).  Geographical 
variations play a role in pemphigus incidence.  Northern and Western Europe show a 
lower incidence of disease than Southern and Eastern Europe.  Asian countries have a 
higher incidence than those in Europe (yearly incidence 1.6-16.1/million and 0.5-
8/million respectively).  The highest incidence was reported in Israel at 16.1/million 
(Alpsoy et al., 2015).  This supports the previous association between pemphigus and 
Ashkenazi Jews and those of Mediterranean origins (Pisanti et al., 1974).  It is 
extremely common in Northern India (Kanwar et al., 2006). 
Pemphigus subtypes also differ in their geographical presentation. The endemic form, 
fogo salvagem, is common in Brazil,  while 90% of the cases reported in India are PV 
(Wilson et al., 1993).    With regards to age and sex distribution, PV has a wide range of 
onset and peaks at 50-60 years.  Contrarily, it is only rarely reported in children and 
among these the mean age of presentation is 12 years (Lara-Corrales and Pope, 2010).  
Furthermore, PV is rarer still in neonates.  Neonatal PV, which is caused by the passive 
transfer of autoantibodies (IgG) from the mother, is a transitory condition (Gushi et al., 
2008, Fenniche et al., 2006).  Sex predilection is also variable some reporting a female 
predilection while others report a male dominance mainly in middle-eastern countries 
(Alpsoy et al., 2015).   
 
 Clinical Presentation 
1.2.1 Mucous membrane pemphigoid 
MMP has a wide spectrum of clinical presentation.  It includes patients with oral lesions 
alone, ocular involvement alone, and those with multiple mucosal sites, with or without 
skin involvement.  Patients with pure oral disease; which are further sub-categorised to 
gingival (24%), extra-gingival (12%), or combined (51%) are considered to have a more 
mild form in comparison to those with ocular involvement who may develop severe 
consequences (Setterfield, 2009).  The majority of patients however, generally present 
with multi-site involvement as demonstrated in (Fig 1-3 and 1-4).  The disorder follows 
a chronic course with episodes of acute exacerbation and remission.   
The overall distribution of site involvement varies between studies. However in a 
review of 16 case series (457 cases) the sites of involvement included oral mucosa 85%, 
conjunctiva 64%, skin 24%, nasal mucosa 15%, pharynx 19%, anogenital 17%, larynx 
8%, and oesophagus at 4% (Ahmed and Hombal, 1986).   
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Figure 1-3 Clinical presentation of MMP a) MMP patient with desquamative gingivitis.  b) 
MMP patient with inflammation and blister on the palate. c) MMP patient with skin 










Figure 1-4 Ocular MMP demonstrating a) subconjuctival inflammation and shrinkage of the 
tarsal conjunctiva b) symblepharon formation 
 
1.2.2 Pemphigus vulgaris 
PV is a mucocutaneous disease resulting in superficial blisters and chronic ulceration.  
Mucosal surfaces involved may include the oral cavity, conjunctiva, genitalia, and upper 
respiratory tract (Hasan et al., 2011).  Classically, lesions appear to be flaccid, thin-
walled bullae that may form on normal or erythematous skin and/or mucous 
membranes.  They break leaving partially denuded areas of variable size which enlarge 
as the epithelium detaches from the periphery.  Commonly, skin lesions are seen as 
erosions and heal without scarring.  Skin areas affected are usually the trunk, pressure 
areas, groin, and axillae (Razzaque, 1980).  The first sign of PV in 60% of the cases is 
oral lesions.  At some point over the course of their disease, 80-90% of the patients will 
develop oral lesions as reviewed by (Greenberg and Glick, 2003, Hasan et al., 2011). 
The most predominant sites of involvement are the gingivae, buccal and palatal mucosa 










Figure 1-5 Clinical features of pemphigus vulgaris a) Oral lesions in a PV patient with 
extensive ulceration of the hard palate b) Buccal mucosal ulceration with surrounding mucosal 
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 Aetiopathogenesis 
1.3.1 Mucous membrane pemphigoid 
The precise pathogenesis of MMP is unclear. Much of the work regarding pathogenesis 
of subepidermal blistering diseases has been undertaken on a closely related disorder 
bullous pemphigoid (BP).  Recently two active mouse models have been developed 
which reflect the roles of auto-reactive T cells in the pathogenesis of BP (Ujiie et al., 
2010, Hayashi et al., 2011).  They demonstrated that patients with the HLA-
DQB1*03:01 (formerly known as HLA-DQB1*0301) allele produced both T helper 
(Th) 1 and Th2 cytokines (e.g. IL-2 and IL4 respectively).  Furthermore, the cytokines 
IL-6 and IL-8 as well as tumour necrosis factor (TNF), have been detected in serum 
samples of BP patients and have been reported to reflect disease activity (Schmidt and 
Zillikens, 2013). The pathogenic role of anti-BP180 antibodies (see section 1.5) was 
established in a bullous pemphigoid animal model when sub-epidermal blistering was 
induced by passive transfer (Liu et al., 1993).  The subsequent finding that the BP 
antigens are also targeted in MMP by implication has suggested that animal model 
studies may in part help with the understanding of the pathogenesis of MMP (Liu et al., 
1993). 
MMP is an autoantibody complement mediated disease which results in cytokine and 
leukocyte enzyme release thus detaching the basal cells from the BMZ (Bagan J. et al., 
2005).  Autoantibodies are produced after the presentation of self-antigens which lead to 
T helper cell activation.  This in turn is followed by B cell activation.  Subsequently, 
autoantibodies are produced against the presented antigen by plasma cells.    IgG and/or 
IgA are usually detected with IgG4 as the most common subtype (Black et al., 2004, 
Hertl et al., 2006).  Combined circulating IgG and IgA anti-BMZ autoantibodies have 
been shown to correlate with disease severity (Setterfield J. et al., 1998, Rabelo et al., 
2014). Furthermore, sequential titres of circulating IgG have been associated with 
disease activity (Setterfield  et al., 1999).  These results were established by IIF titres.  
Studies including a large number of MMP patients and testing for different antigen 
reactivity have not been well established. 
An immunogenetic association with HLA-DQB1*03:01 is reported in the literature 
(Setterfield  et al., 2001, Chan et al., 1997, Mondino et al., 1978).  This may contribute 
to the T-cell recognition of basement membrane antigens.  Changes in major 
histocompatablity complex (MHC) which were experimentally induced in animal 
models, showed an effect on the development of autoimmune diseases (Theofilopoulos, 
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1995).  However, the precise role in the pathogenesis has not been established as there 
are patients with the disease but without the allele (Setterfield  et al., 2001).   
Although the mechanism is unclear, drugs such as furosemide have been reported to 
trigger the disease (Van Joost and Van't Veen, 1993).  In addition, penicillamine has 
been shown to produce adverse reactions of altered immunity resulting in  
penicillamine-induced cicatricial pemphigoid (Bialy-Golan and Brenner, 1996). 
Cytokines may play an important role in the scarring process of the disease.  
Interleukins (IL) IL-3, IL-4, IL-5 and Tumour growth factor beta (TGFβ) contribute to 
the scarring which occurs in MMP (Caproni et al., 2002, Caproni et al., 2003, Carrozzo 
et al., 2014).  Furthermore, IL-6 and IL-8 release is triggered by anti-BP180 IgG 
antibodies which are linked to Th 2 cells (Schmidt et al., 2001a).  In addition, regulatory 
T cells (Treg) have been proposed to contribute to the chronicity of MMP as they were 
expressed in MMP lesions (Torchia et al., 2009).  
 
1.3.2 Pemphigus vulgaris 
An association between PV and MHC class II genes has been reported in the literature; 
HLA-DR4, DQ8, DR6 and DQ5 have been implicated (Bhol et al., 1994).  Antigen 
mimicry may be responsible for the appearance of conditions that resemble PV.  This 
has been shown to occur in bacterial and viral infections such as Staphylococcal 
infections or Varicella (Amagai, 2003).  In addition, pemphigus-like lesions may result 
from drugs whether they contain sulfhydryl groups as captopril or not (Tchernev and 
Orfanos, 2006). 
Autoantibodies have been documented as pathogenic in various studies (Anhalt et al., 
1982, Amagai et al., 2000).  The fact that antibodies correlate with disease severity by 
IIF suggests that these intercellular antibodies are pathogenic.  In addition, since 
neonatal autoantibodies cause transient neonatal pemphigus, this further suggests that 
passively transferred antibodies from the mother are pathogenic.  Moreover, 
pathogenicity is supported by plasma exchange studies where there is clinical 
improvement associated with a decrease in antibody titre, (Ruocco et al., 1978) and 
normal human skin explants incubated with PV serum in vitro, resulting in the 
appearance of suprabasal acantholysis (Michel and Ko, 1977).  The development of an 
in vivo model where the IgG fraction of serum from PV patients was injected into 
neonatal mice resulted in the clinical features of PV provided further evidence of 
pathogenicity (Anhalt et al., 1982). 
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Since Dsg3 is the main isoform expressed in mucous membranes, anti-Dsg3 antibodies 
alone are sufficient to cause mucosal lesions.  However, both Dsg 1 and 3 are expressed 
in the skin and therefore both antibodies are needed to result in mucocutaneous lesions 
of PV (compensation theory) (Amagai et al., 2006).  Therefore, anti-Dsg3 antibodies are 
detected in patients suffering from mucosal lesions, while anti-Dsg1 and 3 are detected 
in those with both skin and mucosal involvement.  In addition, the levels of anti-Dsg 
antibodies in serum reflect disease activity (Amagai et al., 1999, Cheng et al., 2002).   
Whether these autoantibodies alone are responsible for the disease pathogenesis is still 
controversial.  Since Th2 cells direct autoantibody production, they are associated with 
disease activity (Amagai et al., 2000).  The IgG4 subtype has been detected in active 
pemphigus which may support the Th2 involvement in the pathogenesis of the disease 
(Bhol et al., 1994, Wilson et al., 1993).  Tregs play a suppressive role in antigen-
specific antibody production (Yokoyama et al., 2011).  Whether  antibodies are behind 
the pathogenesis of the disease or whether they are ‘witnesses of the disease’, still 
remains a point of debate in the literature as does the process of acantholysis (Amagai et 
al., 2006). 
IgA pemphigus is a rare subtype of pemphigus.  It is characterised by detection of IgA 
antibody instead of IgG and is usually directed against desmocollin (Dsc) and in a few 
cases to the Dsg1 and/or 3 antigen (Tajima et al., 2010, Hashimoto, 2003).  Although 
uncommon, there have been some reports in which IgG driven PV has also shown IgA 
antibodies to the PV antigens (Kowalewski et al., 2006).  There is much debate about 
IgA pemphigus in terms of nomenclature and its’ characteristics (Hashimoto and 
Nishikawa, 2015).  Furthermore, IgA autoantibody production and their role in 
pathogenicity of the disease is still unclear (Hashimoto, 2001). 
 
 
 Autoantibody Detection 
1.4.1 Immunofluorescence 
1.4.1.1 Direct immunofluorescence (DIF) 
Direct immunofluorescence is a technique which entails pairing of the patient’s biopsy 
specimen (mucosal or skin) with a fluorophore labelled immunoglobulin (primary 
antibody). Subsequently, the specimen is then studied under a fluorescent microscope.  
The results depend on the wavelength emitted once excitation occurs.  This technique 
depends on the specificity of autoantibodies to certain target antigens thus enabling the 
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visualization of the distribution of these specific antibodies to the target antigen within 
the specimen (Sciubba, 2011). 
1.4.1.1.1 Mucous membrane pemphigoid 
Although DIF is technique sensitive, it is the gold standard for the diagnosis of MMP as 
most studies show that 80-97% of specimens are positive (Fine et al., 1984, Ahmed et 
al., 1991).  However, it is important to note that pure ocular disease patients have a 
lower positivity with over 40% having a negative DIF (Thorne et al., 2004, Bernauer et 
al., 1994, Kirzhner and Jakobiec, 2011).  Therefore, in cases with multisite involvement 
a biopsy of another mucosal lesion is more likely to produce a positive result.  DIF 
studies of peri-lesional skin or mucosa demonstrate a linear, continuous band at the 
basement membrane zone (BMZ), more often with IgG (90%), C3 (90%), IgA (80%), 
and IgM (70%) (Bean et al., 1972, Griffith et al., 1974, Rogers et al., 1977, Fine et al., 
1984, Meyer et al., 1985) as demonstrated in (Fig 1-6).   
 
Figure 1-6 DIF from an MMP patient (buccal mucosal sample) showing a linear band of 
IgG, C3 and /or IgA along the basement membrane zone (BMZ) (roof or floor binding 
depicts the heterogeneity of targeted antigens) 
1.4.1.1.2 Pemphigus vulgaris 
The gold standard of diagnosis is DIF which provides greater sensitivity than IIF.  Any 
areas biopsied will generally result in a positive DIF.  Patients who are in remission 
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may also still show a positive DIF (Judd and Lever, 1979).  IgG and C3 bind to the 
keratinocyte cell surface throughout the epidermis (Sami, 2011, Jordan Re, 1971).    
Inter-cellular binding of IgG and/ or C3 is found in the epithelium (Schmidt and 
Zillikens, 2010, Korman, 1988) as demonstrated in (Fig 1-7).   
 
 
Figure 1-7 DIF from a PV patient (buccal mucosal sample) showing intercellular 
deposition of IgG and/or C3 in a characteristic ‘chicken wire’ pattern 
1.4.1.2 Indirect immunofluorescence (IIF) 
In order to quantify the autoantibody titre present in the patient’s serum, indirect 
immunofluorescence is used.  The technique involves serially diluting the patient’s 
serum which is then reacted with a tissue substrate using a labelled anti-human 
immunoglobulin.  Unlike the DIF technique, which only utilises a primary conjugated 
antibody, IIF reaction depends on using both a primary and a secondary antibody.  First 
a non-conjugated primary antibody (serum sample) is applied which binds specifically 
to the target antigen.  Subsequently, a secondary antibody linked to a fluorophore, binds 
to the primary antibody after recognising it (Sciubba, 2011).  
1.4.1.2.1 Mucous membrane pemphigoid 
Circulating IgG autoantibodies were first reported by Dantzig with a titre of 1:40 
(Dantzig, 1973).  Early IIF studies used animal tissues including monkey oesophagus or 
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guinea pig lip and these infrequently showed circulating antibodies (0-36%) (Bean et 
al., 1972, Griffith et al., 1974).  By using salt-split skin (SSS) (0.1 mol/L salt split skin 
or mucosa) the sensitivity of IIF improved to 88-100% (Gammon et al., 1984, Kelly and 
Wojnarowska, 1988).  The binding patterns of circulating autoantibodies in patients 
with MMP may occur on the epithelial side of the split, dermal, or combined reflecting 
the variation in autoantigens detection by autoantibodies (Chan et al., 2002).  IgG4 and 
IgG1 are the predominant subclasses in MMP (Bernard et al., 1991).  Some studies 
report 20-30% circulating autoantibodies (Leonard et al., 1984, Ahmed et al., 1991, 
Leonard et al., 1988), while others have up to 90% positivity for both IgG and IgA 
(Setterfield J. et al., 1998, Setterfield  et al., 1999, Murakami H. et al., 1998). 
1.4.1.2.2 Pemphigus vulgaris 
Unlike MMP, guinea pig or monkey oesophagus substrates are successful in PV and are 
used for IIF testing in PV (Harman et al., 2000b, Yeh et al., 2003).  Circulating IgG 
autoantibodies to Dsg3 and 1 show a characteristic “chicken wire” pattern 
predominantly on the lower most epithelial cell layers (Fig 1.7).  It is considered to be a 
less sensitive technique for PV than DIF but provides a prognostic value as titres of 
circulating antibodies correlate with disease activity (challacombe S. J. et al., 2001).   
IgG is detected in 80-90% of the patients and correlates with disease activity (Sami, 
2011).  Tissue bound and circulating antibodies mainly fall into the IgG1 (T helper 1 
regulated) and IgG4 (T helper 2 regulated) subclasses (Hertl et al., 2006).  It has also 
been reported, that both IgG4 and IgG1 are present in high titres in the acute phase of 
the disease, while IgG1 is found in remission and healthy individuals (Bhol et al., 
1994).  
 
1.4.2 Enzyme-linked immunosorbent assay (ELISA) 
Engvall and Perlmann in 1972 reported a sensitive and simple method for the 
quantitative determination of autoantibodies (Engvall and Perlmann, 1972).  The 
indirect ELISA technique involves the binding of an antigen by incubation to a micro-
titre plate.  This antigen solid phase is used to bind specific antibodies of a test sample.  
Unbound material is removed by washing and antibody is detected using an enzyme 
labelled anti-immunoglobulin.  This is the type of ELISA used in detecting 
autoantibodies targeted against specific antigens in MMP and PV.  ELISA’s are now 
arguably more sensitive than IIF as they are less technique sensitive (Ishii et al., 1997). 
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1.4.2.1 Mucous membrane pemphigoid 
Since the introduction of ELISA in the early 1990’s, this technique has been used 
frequently to aid in the diagnosis of immunobullous diseases.  ELISA is now being 
more commonly utilized to detect BMZ components, which are identified by the 
patients’ sera (Hayakawa et al., 2014).  Pre-coated commercial ELISA plates are now 
available using recombinant BP180 (Calabresi et al., 2007, Sciubba, 2011). There is 
much debate about the pathogenesis of MMP in relation to autoantibodies to BP180 in 
MMP. However it has been shown to be the main target antigen in a large study of 
MMP patients (Oyama et al., 2006).     
The use of ELISA for serum studies in MMP is well described. However, only one 
study thus far has used saliva as a fluid for autoantibody detection in MMP (Andreadis 
D, 2006).  The authors reported that saliva testing for MMP was unhelpful.  They 
argued that their use of pre-coated plates with the recombinant NC16a domain of BP180 
was the reason for the negative results (Andreadis D, 2006).  However numerous studies 
have described IgG reactivity with this epitope of BP180 in serum (Balding et al., 1996, 
Calabresi et al., 2007, Chan et al., 2002, Csorba et al., 2011).  
Research into the pathogenesis of BP has paved the way for a better understanding of 
the pathogenesis of MMP.  Notably a recent study has been published testing for 
salivary antibodies to BP180-NC16a in BP patients.  Esmaili et al reported that in 50 
new patients tested for reactivity to both BP180-NC16a and BP230 ELISAs using both 
serum and saliva were both specific and sensitive for diagnosis.  In addition, salivary 
anti-BP180-NC16a antibodies were associated with disease severity.  They also 
reported that serum and salivary IgG anti-BP230 antibodies were associated with 
mucosal severity (Esmaili et al., 2015).  This is surprising as mucosal involvement in 
BP is usually mild and transient.  This raises the possibility that these patients may have 
been MMP with skin lesions.  Further studies are therefore needed. 
 
1.4.2.2 Pemphigus vulgaris 
ELISA is a well-established method of measuring serum autoantibody titres to Dsg3 
and Dsg1, which directly correlate with mucosal involvement and skin involvement 
respectively in PV (Harman et al., 2000a).  ELISA is also used to monitor sequential 
serum antibody levels over the course of the disease (Schmidt and Zillikens, 2010).    
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There are only three published studies using saliva.  Andreadis et al found that salivary 
anti-Dsg1 and 3 IgG ELISA are both sensitive and specific, thus suitable for the 
diagnosis of pemphigus (Andreadis D, 2006).  In addition, Hallaji et al similarly 
reported salivary Dsg1 and 3 ELISA could be used for the diagnosis of PV (Hallaji et 
al., 2010).  More recently, Mortazavi et al published a 90% specificity and 70% 
sensitivity of saliva anti-Dsg antibody detection (Hosseein Mortazavi, 2015).  However, 
further studies are now indicated to study paired salivary and serum titres and their 
potential use in disease monitoring.   
 
 Target Antigens 
The basement membrane links epithelial cells to the underlying connective tissue and is 
fundamental to maintaining the structural integrity of the skin or mucous membranes.  
Target antigens to which autoantibodies are produced, lie within the hemidesmosomal 
region of the basement membrane zone in MMP.  In PV the target antigens, are found 






Figure 1-8 Structure of desmosome and hemidesmosome.  The figure displays the basal cell 
and underlying connective tissue.  The desmosome and hemidesmosome are home to antigens 





(keratin 5 & 14) 
α6β4 
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1.5.1 Mucous membrane pemphgoid 
Hemidesmosomes are specialized junctional complexes that provide attachment 
between epithelial cells and the underlying basement membrane.  They maintain cell 
polarization, organization and tissue architecture (Borradori and Sonnenberg, 1999).  
They are small electron dense domains (< 0.5 µm) located at the surface of basal 
keratinocytes.  Hemidesmosomal plaque, anchoring filaments and anchoring fibrils 
form the functional unit known as the hemidesmosomal adhesion complex.  This 
provides a stable attachment of keratinocytes to the underlying basement membrane 
(Zillikens, 1999).  Any interference that occurs to this complex results in disruption of 
the tissue architecture and causes split formation at the level of the dermal-epidermal 
junction (Zillikens, 1999, Borradori and Sonnenberg, 1999).     
A number of hemidesmosomal antigens have been implicated in the pathogenesis of 
MMP.  These include BP180 (75%), BP230 (25%), laminin 332 (25%), α6β4 integrin, 
and type VII collagen (Schmidt and Zillikens, 2013).  The major target antigen is 
BP180.  While specific clinical subtypes have been associated with specific target 
antigens, e.g. ocular MMP and the β4 integrin (Tyagi et al., 1996) and oral MMP with 
the α6 integrin (Chan, 2012), others have found conflicting results.  Some multi-site 
disease patients have been reported to show IgG antibody reactivity to the β4 integrin 
(Leverkus et al., 2001).  In addition, in the pure ocular sub-group, antibody reactivity 
was reported with both β4 and the C-terminal domain of BP180 (Solano-López et al., 
2014).   However, in cases of oral MMP, the target antigen is still unclear; Rashid et al 
in 2006 studied 30 patients whom 15 had oral involvement alone and showed that all 
reacted with the α6 integrin (Rashid et al., 2006a).  Moreover, Bhol et al found that 16 
of 20 cases of oral pemphigoid reacted with the α6 integrin (Bhol et al., 2001).   
Contrary to those findings, Calabresi et al studied 20 cases limited to the oral cavity in 
whom 75% of the cases reacted with BP180 (Calabresi et al., 2007).  Carrozzo et al in 
the 28 cases studied showed 46% reacting with BP180 (Carrozzo et al., 2004).  Schmidt 
et al in 2001 reported that autoantibodies target different epitopes of BP180 in the 26 
cases studied (Schmidt et al., 2001b).  This shows the controversy surrounding target 
antigens and specific phenotypes. Further research is needed in this area. 
Since the majority of cases target BP180, this will be the main antigen to be studied in 
this project together with the α6β4 integrin. As the α6 and β4 fragments’ associations 
may be linked to specific clinical phenotypes.  These two antigens are described in 
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further detail below.  BP230 and laminin 332 are also considered major antigens of 
MMP and are described below.  Collagen VII on the other hand, has not been described 
because of the overlap with epidermolysis bullosa acquisita (EBA) as it is considered 
the major antigen for that disease.  The table below shows the heterogeneity of MMP 
and the different antigens targeted (Table 1-1). 
 
 
Table 1-1 Summary of main Clinical and Immunological features of mucous membrane 
pemphigoid 
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(Bhol et al., 
2001) 
n=20 Oral IgG α6 16/20 80% Immunoblot 
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332 
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terminal 
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   IgA BP180-
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terminal 
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(Egan et al., 
2003) 
n=35 Multisite IgG Laminin 
332 
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(Carrozzo et n=28 Oral(+/- IgG BP180 13/28 46% Immunoblot 
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al., 2004) mucosal) 
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   IgA BP180 3/28 11%  
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length 
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A-Bullous Pemphigoid antigen 2 (Collagen XVII) (BP180) 
BP180 is a transmembrane glycoprotein with a type II orientation; the carboxyl 
(COOH) terminal portion is extracellular (1007 amino acid (aa)) shown in (Fig 1-9).  
The amino (-NH2) terminal is the intracellular segment (466 aa).  The extracellular 
portion consists of 15 collagenous domains of various sizes which are separated by 
short non-collagenous sequences of 500 residues.  
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There are two main epitopes identified in the literature; the NC16a domain and 4575-
segment (C-terminal domain). NC16a is the first non-collagenous segment in the 
extracellular part of BP180.  It is a 72 amino acid stretch (490-562) and it contains the 
NC16a domain (490-534).  The 4575 epitope, is a 48 aa segment further down BP180, 
adjacent to the carboxyl terminal (1365-1413) (Zone et al., 1998, Powell et al., 2005).  
The extracellular ligand of BP180 attaches to the α6 integrin, while the intracellular 
portion is associated with the β4 integrin (Powell et al., 2005).  The majority of patients 
show circulating IgG antibodies specific to BP180.  Some sera contain IgA antibodies 
which are reactive with a 97/120 Kda protein, the linear IgA bullous dermatosis 
(LABD) antigen 1 which is homologous to the extracellular portion of BP180 
confirming heterogeneity of MMP (Christophoridis et al., 2000, Parisi et al., 2003, Zone 
et al., 1998, Murakami H. et al., 1998). 
 
 
Figure 1-9 Structure of BP180 The figure depicts the intracellular domain, transmembrane 
domain and the extracellular region of BP180 highlighting the epitopes which are considered 
the most antigenic (NC16a and 4575).  Modified from (Zone et al., 1998) 
 
B-Alpha 6 Beta 4 Integrin (α6β4) 
The α6β4 integrin is a cell surface glycoprotein complex.  As a member of the integrin 
superfamily, it mediates cell-cell and cell-matrix interactions.  Integrins are 
heterodimers of non-covalently linked alpha and beta transmembrane glycoproteins 
(Tamura et al., 1990).  Most strongly expressed in stratified squamous epithelium, alpha 
6 is present in the entire surface of basal cells although strongly localized to the basal 
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region.  Βeta 4 is found mainly in the basal region.  As this integrin is localized to the 
hemidesmosome, it provides an important role in binding epidermal cells to the 
basement membrane (Sonnenberg et al., 1991).  Furthermore, it shows specific roles in 
cell signal transduction pathways in both the central and peripheral nervous systems, it 
is associated with cytoskeletal and signalling molecules and is considered a potential 
target for cancer molecule therapy (Su et al., 2008). 
The α6 subunit contains 1073 aa residues and is very similar to various alpha subunits 
cloned.  The β4 subunit however, has a unique cytoplasmic domain, which consists of 
1778 aa (683 aa extracellular domain, 23 aa transmembrane domain and 1072 
intracellular cytoplasmic domain) (Tamura et al., 1990).  Specific interactions of the β4 
subunit and cytoplasmic proteins have been documented (Suzuki and Naitoh, 1990).  
The extracellular domain of α6β4 binds laminin 332 while the carboxy terminus binds 
BP180 (Giancotti, 1996). 
 
C- Bullous Pemphigoid antigen 1 (BP230) 
The plakin family of proteins are involved in the organisation of the cytoskeletal 
architecture and include BP230 and plectin (Borradori and Sonnenberg, 1999).  BP230 
was first recognized as a target antigen for bullous pemphigoid (BP) in 1981 (Stanley et 
al., 1988).  It is an intracellular component of the hemidesdmosomal plaque (Desai et 
al., 2008).  The COOH terminal is associated with intermediate filaments indicating a 
role of BP230 in the attachment between the intermediate filaments and 
hemidesmosomal plaque.  The NH2 terminal of BP230 has been reported to interact 
with the cytoplasmic domain of BP180 (Borradori and Sonnenberg, 1999).  It is targeted 
in MMP in about 25% of the cases and usually with BP180 reactivity (Schmidt and 
Zillikens, 2013).  BP230 pre-coated ELISA kits are available for testing sera (Lee et al., 
2012). 
D- Laminin 332 
Laminin 332 is a heterodimeric glycoprotein which consists of 3 subunits α3 (200-165 
Kda), β3 (140 Kda) and γ2 (155-105 Kda).  These subunits are covalently linked with 
disulphide bonds.  It plays an important role in the attachment of basal cells to the 
underlying connective tissue (Bekou et al., 2005).  It is estimated at 460 Kda and has 
previously been known as nicein, kalinin, epiligrin and laminin 5 (Domloge-Hultsch et 
al., 1994).  It is produced by epithelial and mesenchymal cells and is found in the skin, 
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trachea, cornea and oesophagus for example.  Gene defects are known to cause Herlitz 
and non-Herlitz junctional epidermolysis bullosa acquisita (Vailly et al., 1995).   
Passive transfer of the IgG fraction containing anti-laminin 332 antibodies from sera of 
MMP patients has been shown to cause subepidermal separation and blister formation 
(Lazarova et al., 1996).  All three subunits have been shown to react with MMP sera 
however the most common reactivity is with the α3 subunit (Bekou et al., 2005, 
Schmidt and Zillikens, 2013).  ELISA tests should be conducted for dermal binding sera 
in light of the association between an underlying malignancy and anti-laminin 332 
MMP (Bekou et al., 2005, Bernard et al., 2013). 
 
1.5.2 Pemphigus vulgaris 
Desmosomes are multiprotein complexes.  They form the intercellular attachment 
structures that are linked to the intercellular intermediate filament network.  They are 
expressed mainly by epithelial cells and are most commonly present in tissue 
undergoing mechanical stresses such as the skin, heart and bladder (Payne et al., 2004).  
They maintain cell cohesion.  They are disc-shaped organelles of 0.1-0.5 µm diameter.  
Heterophilic interactions between transmembrane glycoprotein desmocollins and 
desmogleins (Dsc and Dsg) are thought to form the basis of cell-cell adhesion (Schmidt 
A. and Koch, 2007).  
Cadherins (calcium dependent cell adhesion molecules) are transmembrane components 
of the desmosome.  They are responsible for intercellular adhesion and interact with 
intermediate filaments.  There are two main groups identified; Dsg and Dsc which 
contain an extracellular portion.  They bind to the desmosomal plaque through the 
intracellular fragments.  Anti-desmoglein pathogenic antibodies are usually the culprit 
of cell-tissue attachment disturbances which clinically result in mucocutaneous lesions 
(Tchernev and Orfanos, 2006). 
Dsg3 has been identified as the PV antigen (Amagai et al., 1991, Eyre and Stanley, 
1988).  Dsg3, 130 KDa, is a transmembrane protein belonging to the cadherin family.  It 
comprises of five extracellular domains, a transmembrane domain, and an intracellular 
portion.  The major antigenic regions of Dsg3 are EC1, EC2, and EC4 (Gniadecki, 
2006).  Dsg3 and Dsc1 are implicated in the IgA subtype of pemphigus.  Other antigens 
may be targeted such as cholinergic keratinocyte receptor, desmoplakin, endoplakin, 
periplakin and plectin (Tchernev and Orfanos, 2006). 
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Dsg1 is a 160 KDa transmembrane molecule and is part of the cadherin family.  The 
mature form consists of five extracellular domains EC1-EC4 and an extracellular anchor 
domain attached to the transmembrane region.  The intracellular domain is made up of 
five domains.  It is abundantly found in stratified epithelium of the epidermis, tongue 
and oesophagus.  Dsg1 is considered the PF antigen (Gniadecki, 2006, Eyre and 
Stanley, 1988).   
 
 Mucosal immunity 
Mucosal immunity represents the portion of the immune system which provides 
protection within the mucous membranes.  It protects the mucosa from infection, 
prevents the uptake of microbes and moderates the immune response.  The discovery of 
a distinct immunoglobulin (IgA) and later the epithelial glycoprotein, which is known 
today as secretory component (SC) that acts as a membrane receptor, were the starting 
points of understanding mucosal immunology.  A difference was constantly shown 
between humoral response at mucosal surfaces and that of serum.  Therefore the notion 
that a local mucosal immune system which is structurally and functionally separate 
from the systemic counterpart was evidenced by the characteristic mucosal immune 
response at mucosal surfaces, and by the  distinct immunoglobulin isotype serving as 
the major mucosal antibody (Tomasi, 1972).   
The mucosal immune system is commonly described as mucosa-associated lymphoid 
tissue (MALT).  It is also classified according to the type of mucosa, i.e. gut-associated 
lymphoid tissue (GALT) and nasal-associated lymphoid tissue (NALT).  Mucosal 
surfaces in the body include the respiratory mucosa, the gut, oral and ocular mucosa as 
well as the vagina (Janeway CA Jr, 2001). 
One of the main characteristics of the mucosal immune system is that IgA induced at 
one mucosal site can be detected at another mucosal site with IgA secreting B cells.  
The term “common mucosal immune system” is therefore an apt description. This is 
also supported by the fact that the mucosal system is divided into inductive and effector 
sites.  Common induction sites include tonsils, adenoids and Peyer’s patches (Mantis et 
al., 2011).  Effector sites are represented by the lymphocytes and plasma cells scattered 
within the lamina propria at the mucosal sites (Janeway CA Jr, 2001).  It is noteworthy 
to mention that some studies have reported germinal centre reactions in non-lymphoid 
target tissue such as salivary glands in Sjögren Syndrome (Stott et al., 1998, Szodoray et 
al., 2005).  Secretory IgA (SIgA) is the most dominant immunoglobulin in the mucosal 
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immune system.  In serum, monomeric IgA is most commonly found while dimeric IgA 
is most abundant in mucosa (Mestecky, 1987).  Monomeric IgA is 150 Kda.  SIgA 
contains the J chain (15 Kda) which links two IgA molecules in addition to the SC (70 
Kda) resulting in a molecular weight of 385 Kda. 
The role of mucosal immunology has been extensively studied especially with regards 
to the gut and vaccines (MacPherson et al., 2008, Holmgren and Czerkinsky, 2005).  
Since MMP is mainly a mucosal disease where mucosal surfaces are involved; the 
presence of SIgA may be very relevant.  Mucosal antibodies have not been studied 
before in MMP.  Oral MMP, although a milder form of the disease, tends to take a long 
time to heal.  Thus the potential presence of mucosal antibodies may have particular 
relevance to the pathophysiology of the disease.  Similarly in PV, the oral mucosa is one 
of the main sites affected and therefore the presence of mucosal antibodies would also 




Saliva in humans is a dynamic fluid.  It possesses several important functions for 
maintaining oral health and homeostasis.  Oral fluid originates from three major salivary 
glands (parotid 23%, sublingual 4%, and submandibular 65%) as well as from a large 
number of minor salivary glands (8%) (Chiappin et al., 2007).   
In addition, saliva contains a non-glandular component.  It encompasses fluids 
originating from oro-pharyngeal mucosa, gingival crevicular fluid (GCF) derived from 
the epithelium of the gingival crevice and produced at 2-3 µl/h per tooth, food debris, 
and blood-derived compounds.  The normal adult produces 500-1500 ml of saliva per 
day, approximately 0.5 ml/min.  This can be affected by physiological and pathological 
conditions.  Saliva consists mainly of 98% water and 2% comprising mucous, enzymes, 
electrolytes, proteins, and antibacterial components.   
The salivary immunoglubulins are mainly SIgA which make up >85% of the total 
immunoglobulin in saliva.  They are produced directly by B lymphocytes located near 
salivary glands and 35% of SIgA is produced by minor salivary glands.  The remaining 
5-15% of immunoglobulin comprise of mainly IgG and IgM which are, to some extent, 
derived from gingival crevicular fluid (GCF) or from plasma leakage (Van Nieuw 
Amerongen et al., 2004).  However, >70% of IgG in saliva is thought to be of local 
origin; produced by palatine, parotid, lingual, adenoids, and tonsillar plasma cells 
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(Butler et al., 1990).  It has been estimated that crevicular fluid washings (CFW) 
contributes 1-2 ml/day into saliva and that the IgG concentration approaches that of 
serum (Challacombe et al., 1978).  In terms of monomeric IgA 77% is derived from 
serum (Mestecky, 1987).   
Salivary components are not only important for oral cavity functions; they also provide 
clues to systemic conditions.  Importantly salivary IgA was shown to be stable under 
storage conditions (Ng et al., 2003). 
1.7.2 Potential use of biomarkers in saliva 
The term biomarker is used to refer to a specific substance or molecule which is 
considered a measurable indicator to a certain condition.  Because serum components of 
saliva are derived primarily from the local vasculature; saliva offers a fluid source that 
provides many, if not most, of the same molecules found in the systemic circulation, 
thus having potential in clinical and research applications.  It has been used to test for 
antibodies to bacteria and viruses, hormones (oestrogen, testosterone), environmental 
toxins, alcohol, tobacco, and certain drugs (ethanol, cocaine, marijuana, and lithium).  It 
is used to diagnose human immunodeficiency virus (HIV), various viral infections, 
breast and ovarian cancer, oral squamous cell carcinoma, and preterm labour 
(Lawrence, 2002, Ng et al., 2003) (Table 1-2).  Recently published studies suggest that 
salivary biomarkers may be a practical alternative to serum to diagnose Sjögren’s 
syndrome (SS) (Ching et al., 2011, Hu et al., 2011).  Furthermore, saliva testing for 
Helicobacter pylori has been proven reliable to screen dyspeptic patients (Sonmezoglu 
et al., 2005).  Saliva is also used as a mean for caries risk assessment as well as 
periodontal inflammatory markers (Wang et al., 2015).   
One of the main drawbacks of salivary diagnostics is the low concentrations of analytes 
found in saliva compared to blood.  Despite that fact, Streckfus et al documented human 
epidermal growth factor receptor 2 (HER2, c-erbB-2) and cancer antigen 15-3 in saliva 
as the most reliable markers for breast cancer  prognosis (Streckfus et al., 2000).  Oral 
cancer patients in comparison to healthy controls, differentially expressed tumour 
necrosis factor-α (TNFα), interleukin-1 (IL-1), IL-6, IL-8, tissue poly peptide antigen, 
and cancer antigen 125 which could be potentially useful for early detection (Streckfus 
et al., 2000).  Pancreatic cancer is one of the most lethal malignancies.  Zhang et al 
reported the possibility of salivary biomarkers mRNA (KRAS, CDKL3) to be used for 
early detection of pancreatic cancer.  This however, needs further study due to the 
modest sample size (n=42)  (Zhang et al., 2010).   
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C-reactive protein (CRP), as reported by Floriano et al, provides an opportunity for non-
invasive assessment of cardio-vascular disease (CVD) risk.  It needs sensitive detection 
technologies due to the low concentration in saliva.  Further investigations of reference 
ranges and their correlation with serum concentrations is required (Floriano et al., 




 Table 1-2 Salivary biomarkers in disease diagnosis 
Reference Marker Disease 
(Krishna Prasad 
et al., 2013) 
p53, mRNA Oral squamous cell carcinoma (SCC) 
(Kaufman and 
Lamster, 2002) 





(Streckfus et al., 
2000) 
C-erb-2, 15-3 antigen Breast cancer 
(Wang et al., 
2015) 
CRP,IL-1β, IL-6 Periodontitis (inflammatory biomarkers) 
(Miller et al., 
2010, Floriano et 
al., 2009) 
MYO,CRP,TNFα  Acute myocardial infarction (AMI) 
HIV (Human immunodeficiency virus), HBV (Hepatitis B virus), HAV (hepatitis A virus), HCV 
(Hepatitis C virus), EBV (Epstein-Barr virus), CMV (Cytomegalovirus), CRP (C reactive protein), TNF 
(Tumour necrosis factor), MYO (Myoglobin), IL (Interleukin) 
 
Saliva has become a more attractive medium due to its minimal potential for cross 
infection.  The collection requires a less invasive procedure, and is also cost-effective.  
As technology progresses, saliva has the potential to become a first-line diagnostic 
medium.  There is a potential value for it in the diagnosis and management of MMP and 
PV as investigated to date by, Andreadis et al (27 PV, 12 MMP), Hallaji et al (50 PV) 
and Mortazavi et al (86 PV) (Andreadis D, 2006, Hallaji et al., 2010, Hosseein 
Mortazavi, 2015) but these studies need to be confirmed and extended. 
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 Aims of the Study 
This study was designed to look at the clinical and immunpathological findings in MMP 
and PV in order to address the aims listed below. Patients were drawn from Guy’s 
Hospital Oral Medicine and Dermatology departments as well as Moorfields Eye 
Hospital to include a broad spectrum of clinical phenotypes. 
These aims were intended to relate phenotype to antibody isotypes and target antigens 
to try to further the understanding of the clinical spectrum and disease severity.   
 
1.8.1 Main aims of the study 
 
1. To investigate the potential of saliva for diagnosis and disease-monitoring in both 
MMP and PV. 
2. To utilize serum and salivary biomarkers in the analysis of disease activity and 
therapeutic response in both MMP and PV. 
3. To investigate whether distinct clinical phenotypes are associated with specific target 
antigens and epitopes in MMP.  
 
1.8.2 Specific aims of the study 
 
 Chapter 3 
1) To identify whether serum and saliva IgG and/or IgA autoantibodies to BP180-
NC16a were present in our cohort of MMP patients 
2) To identify whether there was an association with carefully defined clinical 
subgroups 
3) To utilize serum and salivary biomarkers in the analysis of disease activity and 
therapeutic responses 
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 Chapter 4 
1) To identify the whether serum and saliva IgG and/or IgA autoantibodies to α6β4 
were present in our cohort of MMP patients 
2) To identify whether there was an association between autoantibodies against 
α6β4 integrin and carefully defined clinical subgroups 
3) To determine antibody avidity using BIAcore technology 
 Chapter 5 
1) To establish whether whole saliva might provide a suitable alternative to serum 
for diagnosing and monitoring PV   
2) To investigate whether anti-Dsg3 IgA antibodies could be detected in serum and 
saliva  
3) To establish whether there was an association between serum or saliva anti-Dsg3 
antibodies and disease severity 
4)  To utilize serum and salivary biomarkers in the analysis of disease activity and 
therapeutic response
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2 Materials and Methods 
 
 Clinical  
2.1.1 Ethical approval 
Ethical approval was obtained from the Health research authority REC reference 
09/H0721/54 and REC reference 12/LO/1350 (Appendix 1, 2). 
2.1.2 Patients 
The series consisted of 100 MMP patients, 45 males and 55 females with a ratio of 1:1.2 
and a mean age of 65.3 ± (13.0) ranging from (26-89) years.  Ninety five of the patients 
were Caucasians while 5 were either Asian (n=3), African (n=1) or Algerian (n=1).  
Patients included multisite disease patients (n=51), pure oral (n=33) and pure ocular 
(n=16).  The demographics of the 100 MMP patients are summarised in Appendix 3, as 
well as details of individual site involvement, oral and ocular severity score, DIF, IIF as 
well as specific autoantibody titres (IgG, IgA) against BP180-NC16a and α6β4 integrin 
in serum, whole saliva as well as parotid saliva.  In addition, results from our 
collaborators in Germany, Prof Zillikens, regarding BP180-4575 and Laminin 332 
western blot results were obtained. 
For PV, the series consisted of 23 PV patients analysed in the PV study plus 3 patients 
included in the controls for the MMP study.  The PV cohort included 10 males and 16 
females with a ratio of 1:1.6 and a mean age of 52.1 ± (19.5) ranging from (16-95) 
years.  Fifteen of the PV patients were Caucasians while 10 were Asian and 1 was 
African.  Patients had either mucosal lesions (n=18) or had mucocutaneous lesions 
(n=8).  The demographics of the 23 PV patients as well as site involvement, oral 
severity score, DIF, IIF, Dsg1 ELISA and specific autoantibody titres (IgG, IgA) 
against Dsg3 are summarised in Appendix 4.  
Patients admitted to the studies were drawn from those attending clinics at Guy’s and 
St. Thomas’s Hospital Oral Medicine department (GSTT NHS Foundation Trust), 
Dermatology department and Moorfields Eye Hospital.  Patients were diagnosed with 
either MMP or PV on the basis of their clinical presentation, direct immunofluorescence 
(DIF), indirect immunofluorescence (IIF) and classical histopathology.  A total of 100 
MMP patients, 26 PV patients, 50 healthy controls (HC) and 16 diseases controls (DC) 
with lichen planus (LP) were recruited.  LP patients were included based on the clinical 
presentation, histology and negative DIF and IIF. 
2 MATERIALS AND METHODS 
52 | P a g e  
 
Three studies were conducted to investigate IgG and IgA autoantibody in serum and 
saliva reactivity to specific autoantigens in MMP and PV patients: Table 2-1 
summarises the distribution of patients between the different studies described in this 
thesis. 
Table 2-1 Summary of the distribution of patients between the different studies described 
in this thesis 
MMP= mucous membrane pemphigoid, PV= pemphigus vulgaris, LP= lichen planus, 























100 21 15 
(36) 
40 
PV study  PV MMP LP  

















100 26 16 50 
2 MATERIALS AND METHODS 




 Studies include: 
 1) Study 1: Serum and salivary antibodies to BP180-NC16a in patients with 
Mucous Membrane Pemphigoid 
a) Study 1(a) in relation to clinical phenotype and disease activity (Cross-sectional 
study): Use of ELISA to test serum and whole saliva activity against BP180-NC16a in 
a cross-sectional study.  This study included MMP patients (n=78), HC (n=50) and DC 
(n=16) comprising patients with PV (n=6) and LP (n=10).  MMP patients included 37 
males and 41 females with a 1:1.1 ratio and a mean (± standard deviation) age of 65.5 
(± 11.6) years with a range (26-87 years).  Twenty randomly selected MMP patients 
(20/78) provided parotid saliva as well as 6/50 of the HC.  All PV and LP patients 
provided parotid samples.  DIF was positive in 59/77 (77%) of the patients excluding 
one patient with missing DIF, and 23/65 (35%) having a positive IIF excluding patients 
with missing IIF results (13/78) so only 8 patients had both DIF and IIF negative 
results.  The majority of patients were on systemic immunosuppressive and immune-
modulating treatment that included prednisolone, dapsone, sulfamethoxypyridazine, 
azathioprine or mycophenolate mofetil.  Some were on topical treatment such as 
corticosteroid eye drops or betamethasone mouthwashes (0.5 mg) in 10 mL water.  
Patients had been on treatment for an average of 9.2 ± 4.5 years range (2-20) years prior 
to inclusion in the study.  Disease controls included 4 males and 12 females with a ratio 
of 1:3 and a mean age of 47.0 (±12.1) years.  Healthy controls consisted of 24 males and 
26 females with a ratio of 1:1.1 and a mean age of 60.5 (±12.9) years.   
 
b) Study 1(b) in relation to therapeutic response (Longitudinal study): Use of 
ELISA to test serum and whole saliva activity against BP180-NC16a in a longitudinal 
study.  This study included a total of 22 MMP patients in addition to HC (n=18) and DC 
(8 PV, 10 LP).  Samples were collected at 3-month intervals for 9 months.  The mean 
age of MMP patients was 65.7 (±15.3) with a range of (29-89) years.  Ten males and 12 
females were included with a ratio of 1:1.2.  DIF was positive in 21/22 (95%) patients.  
IIF was positive in 11/22 (50%) of the patients with only one patient having a negative 
DIF and IIF result.  Patients were on treatment for an average of 5.9 (±0.9) years with a 
range of (2-18) years at the start of the study.  Disease controls included 6 males and 12 
females with a ratio of 1:2 and a mean age of 49.7 (±18.3).  Healthy controls included 6 
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males and 12 females with a ratio of 1:2 and a mean age of 59.4 (±10.4) years.  Parotid 
saliva was provided by all MMP and DC.  Six HC provided parotid saliva. 
2) Study 2: Serum and salivary antibodies to alpha 6 beta 4 Integrin in relation to 
clinical phenotype and disease activity (Cross-sectional study) 
 MMP ELISA testing serum, whole and parotid saliva against α6β4 integrin (cross-
sectional) included MMP patients (n=100), HC (n=40) and DC (n=36) (PV=21 and LP= 
15).  MMP patients consisted of 45 males and 55 females with a ratio of 1:1.2 and a 
mean age of 65.3 (±13.03) ranging from (26-89).  DIF was positive in 76/94 (81%) and 
IIF was positive in 36/87 (40%) of the patients excluding those with missing IIF results 
(13/100).  Nine patients had a negative result on both DIF and IIF.  Disease controls 
involved 12 males and 24 females with a ratio of 1:2 and a mean age of 49.6 (±17.9).  
Healthy controls included 19 males and 21 females with a ratio of 1:1.1 and a mean age 
of 61.3 (±11.4).  Parotid saliva was provided by 40/100 MMP patients, 6/40 HC and all 
DC. 
3) PV study: Serum and salivary antibodies to Dsg3 in relation to disease activity 
(Cross-sectional) and Sequential antibody titres in PV patients to Dsg 3 in relation 
to therapeutic response (Longitudinal study) 
Activity of serum as well as whole and parotid saliva against Dsg3 was determined by 
ELISA.  This study included PV patients (n=23), HC (n=17) and DC (n=19) (8 MMP 
and 11 LP).  PV patients comprised 10 males and 13 females with a ratio of 1:1.3 and a 
mean age of 51.1 (±19.2) ranging from (16-95).   Inclusion criteria were that patients 
had predominantly mucosal involvement and at least one of either positive direct 
immunofluorescence (DIF) (23/23 100%), positive indirect immunofluorescence (IIF) 
(17/23 74%) and / or a positive ELISA with commercially available plates for Dsg 
3(17/23 74%).  All patients were on a combination of prednisolone and azathioprine or 
mycophenolate mofetil as well as a betamethasone mouthwash.  Patients were on 
treatment for an average of 5.4 (±4.3) years (range 2-22 years).  Disease controls were 6 
males and 13 females with a ratio of 1:2.2 and a mean age of 55.3(±15.8) years.  
Healthy controls included 6 males and 11 females with a ratio of 1:1.8 and a mean age 
of 58.9 (±10.4) years.  Both PV and DC provided parotid saliva.  Six of the HC 
provided parotid saliva.  Samples were collected at 3-month intervals for 9 months.   
 
2.1.3 Sample Collection 
Matched serum and whole saliva samples were collected from all participants including 
MMP, PV, LP and HC.  In addition, parotid saliva was obtained from 40 of the MMP 
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patients (n = 40/100), all PV (n = 26) and LP (n = 16) patients and 6 of the HC (n = 
6/50). 
2.1.3.1 Serum  
Blood samples were collected in 5 ml tubes in the clinic by a member of the trained 
clinical staff.  Specimens were then taken to the lab with a name and study ID.  A 
tracker sheet indicating date, time and volume was completed.  Serum was obtained by 
centrifugation at 5000 g for 10 minutes (Mistral 3000 MSE Ltd, London, UK).  Serum 
was stored as aliquots (0.5 mL) at -80°C for long term storage.  Samples for immediate 
testing were kept at -20° C. 
2.1.3.2 Saliva 
Whole un-stimulated saliva was collected in 20 mL universal tubes and patients were 
asked to spit saliva in the tube for a 10 minute period as previously described (Percival 
et al., 1994).  Parotid saliva was first stimulated with a few drops of 2% citric acid just 
at the beginning of the collection and the saliva was then collected into a universal 
container as previously described (Challacombe, 1976).  The collection was done by a 
commercially available Lashley cup which is routinely used for the collection of parotid 
saliva in the clinic.  It is a small plastic cup of two concentric rings with a tube out of 
each, one to be able to apply mild suction to hold the cup in place, and the other allows 
the parotid saliva to flow directly to a collection bottle.   Whole saliva was centrifuged 
at 3000 g for 5 minutes.  All samples were aliquoted (0.5 ml) and stored at -80° C.  The 
aliquots subsequently used in this study were then all stored at -20° C. 
2.1.4 Clinicopathological associations 
Patients with MMP were examined by specialists in each area (Dermatology, Oral 
Medicine, Otolaryngology, Ophthalmology) carefully to determine the presence and 
extent of disease in each potentially affected site (mouth, nasopharynx, larynx, 
conjunctiva, skin).  A previously described Oral diseases scoring methodology for use 
in lichen planus and modified from a published methodology for MMP was used 
(Escudier et al., 2007) (Appendix 5).  
Patients with PV were also assessed for severity of oral disease using the same 
methodology.  For the longitudinal studies, serial oral severity scores were undertaken 
at each visit.  Clinicopathological associations could then be analysed for these studies. 
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 Laboratory Techniques 
List of antibodies and dilutions used: Dilutions of antibodies used in ELISA were 
derived from previous work in our lab (data not shown) while those for Western Blots 
were used as per manufacturer’s instructions. (List of Buffers and reagents is described 
in Appendix 6) 
 Alkaline phosphatase conjugated goat polyclonal anti-human IgA antibody 
(A3400, SIGMA-ALDRICH) (1:500 / 1:1000) 
 Mouse monoclonal anti-human secretory component antibody (I6635, SIGMA-
ALDRICH) (1:1000) 
 Rabbit polyclonal anti-mouse IgG antibody alkaline phosphatase linked (A1902,  
SIGMA-ALDRICH) (1:1000) 
 Rabbit polyclonal anti-human IgA (Dakopatts A0262) (1:10000) 
 Goat anti-human-IgA (2010-04 SouthernBiotech) (1:1000) 
 Rabbit polyclonal anti-goat IgG alkaline phosphatase linked (A4062, SIGMA-
ALDRICH) (1:1000) 
 Goat polyclonal anti-human IgG (A8542, SIGMA-ALDRICH) (1:500) 
 Goat polyclonal anti-human IgM (A3437, SIGMA-ALDRICH) (1:500) 
 Mouse monoclonal anti-human IgA antibody (SkyBio M26012) (1:1000) 
 Rabbit polyclonal anti-mouse IgG peroxidase antibody (A9044 SIGMA-
ALDRICH) (1:2500) 
 Goat polyclonal anti-human IgG human integrin alpha 6/CD49f  antibody 
(AF1350, R&D systems) (1:500) 
 Sheep polyclonal anti-human IgG human integrin beta 4/CD104 antibody 
(AF4060 R&D systems) (1:1000) 
 Donkey polyclonal anti-sheep IgG alkaline phosphatase (A5187, SIGMA-
ALDRICH) (1:1000) 
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2.2.1.1 Analyses of antibody binding activity to the NC16a domain of BP180 
Commercially available pre-coated plates with the NC16a domain of BP180 
(MESACUP BP180 ELISA Kit, Medical and Biological laboratories Nagoya, Japan. 
Woburn, MA 01801) were used to test for both specific IgG and IgA antibody in serum 
as well as in whole and parotid saliva (Fig 2-1). 
 
Figure 2-1 BP18-NC16a ELISA plates. ELISA wells describing the different layers used.  
a) Testing Human serum or whole saliva samples for IgG antibody to BP180-NC16a. b) Testing 
Human serum or whole saliva samples for IgA antibody to BP180-NC16a.  c) Testing Human 
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2.2.1.1.1 Analysis of IgG antibody against BP180-NC16a 
The plates were optimized for serum IgG antibody testing and the manufacturer’s 
instructions were followed.  All incubations were carried out at 37° C in the 
(Mini/4/SS/VS scientific supplies, Nottingham UK).  Calibrators (a positive and a 
negative control were provided with the kit) and patient sera (10 fold dilution) were 
added to these plates allowing anti-BP180 antibodies to react with the antigen for 1 
hour.  After washing with PBS/Tween 20 (3 times) using the LT-3500 microplate 
washer (Labtech East Sussex UK) to remove unbound serum proteins, horseradish 
peroxidase conjugated anti-human IgG antibody was added and plates were incubated 
for 1 hour (Conjugate incubation).  After further washing with PBS/Tween 20, the 
peroxidase substrate, tetramethylbenzidine dihydrochloride/hydrogen peroxide 
(TMB/H2O2) (supplied with the kit), was added and plates were incubated for 30 
minutes (substrate incubation) as shown in (Fig 2-1).    1.0N sulphuric acid was then 
added to terminate the reaction and stabilize colour development.  Bound antibody was 
determined by measurement of OD450nm.  This was quantified by measuring the reaction 
photo-metrically.  All materials were supplied with the kit.  This has been described 
previously (Sakuma-Oyama et al., 2004). 
In order to test for reactivity for IgG antibody in whole saliva, samples were incubated 
for 1 hr and the manufacturer’s conjugate and substrate were used.  The sensitivity of 
detection of specific IgG antibody in saliva was determined separately.  Using the pre-
coated BP180-NC16a plates, the positive pooled sera standard was spiked with PBS (50 
µl), whole saliva containing IgG-/IgA+ antibody against BP180-NC16a or whole saliva 
negative for both IgG and IgA antibody against BP180-NC16a.  The samples were 
tested in duplicates in 7 doubling dilutions (1:100, 200, 400, 800, 1000, 3200 and 6400).  
Otherwise, conditions were those recommended by the manufacturer, as above. 
2.2.1.1.2 Analysis of IgA antibody against BP180-NC16a 
Incubation times for anti-human IgA antibody were previously optimized in this 
laboratory (Coogan et al., 1994).  Alkaline phosphatase conjugated goat polyclonal anti-
human IgA antibody was used to detect bound antibody (A3400, SIGMA-ALDRICH). 
Phosphatase substrate (4-nitrophenyl phosphate disodium salt hexa-hydrate) in tablet 
form was dissolved in 1M diethanolamine pH 9.8, and 3M NAOH (50 µl) was used to 
stop the reaction.  Both the sample and conjugate incubation times were 2 hours at 37° 
C and the assay diluent (PBS/ Tween 20 and 0.09% sodium azide) provided with the kit 
was used.   
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To determine whether IgA in parotid saliva samples that bound to the NC16a domain, 
was secretory form, bound antibody was probed with mouse monoclonal anti-human 
secretory component antibody (I6635, SIGMA-ALDRICH) using rabbit polyclonal anti-
mouse IgG antibody alkaline phosphatase linked for detection (A1902,  SIGMA-
ALDRICH).  In parallel, plates were also probed with the conjugated goat anti-human 
IgA as above.  Incubations with saliva and the anti-secretory component antibody were 
both for 2 hours at 37° C.  Incubation with the alkaline phosphatase-conjugated 
antibody was for 1 hour at 37° C as shown in (Fig 2-1).  Phosphatase substrate was 
added and the reaction was stopped with 3M NaOH.   For parotid samples, the results 
were expressed as OD405nm values since antibody levels and background were much 
lower and fell below values derived from a standard curve from serum, they could not 
be quantified using the serum derived standard curve.   
The specificity of the monoclonal anti-secretory component antibody, used above, was 
confirmed by ELISA 
A) - A 96-well-plate (Immulon 2HB  Thermo lab systems), divided into three 
sections each coated with a Rabbit polyclonal anti-human IgA at different 
dilutions; 1:5000, 1:10000, 1:20000 in Phosphate buffered saline (PBS) for a 
checkerboard optimization of coating.  The optimal coating concentration was 
found to be 1:10000.  The plate was then blocked with PBS/ BSA (Bovine 
serum albumin)/ Tween20 (P1379 TWEEN (R) 20 SIGMA-ALDRICH) for 1 
hour at 37° C.  All dilutions were done in PBS/ BSA/ Tween 20 and all 
remaining incubations were at 37° C.  Three serum samples were tested in 
duplicate at 6 doubling dilutions (1:100, 200, 400, 800, 1600, and 3200) and 
incubated for 2 hours.  The secondary antibodies added were goat anti-human-
IgA (A3400, SIGMA-ALDRICH) and another using the mouse anti-human 
monoclonal anti-secretory component antibody for 2 hours.  The conjugates 
used were anti-mouse IgG alkaline phosphatase linked (A1902, SIGMA-
ALDRICH) and an anti-goat IgG alkaline phosphatase (A4062, SIGMA-
ALDRICH) linked incubated for 1 hour.  The phosphatase substrate and stop 
solution were used and results were reported in OD405 nm. 
 
B) - Parotid saliva samples were tested using the same pre-coated BP180-NC16a 
plates and the mouse monoclonal anti-secretory component (IgA) antibody with 
different conjugates.  In this experiment, a goat polyclonal anti-human IgG 
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(A8542, SIGMA-ALDRICH) and a goat polyclonal anti-human IgM (A3437, 
SIGMA-ALDRICH) were used under the same conditions described for the 
parotid saliva testing.   
2.2.1.1.3 Quantitation of anti-NC16a antibody 
Optical density (OD) was measured at 450 nm for IgG and 405 nm for IgA using an 
ELISA plate reader (LT4000 Labtech microplate reader).  All samples were screened 
for both IgG and IgA specific antibody and a standard was developed using a range of 
pooled antibody (both IgG and IgA) positive serum samples.  The standard was given 
an arbitrary value of 100,000 units and standard curves constructed using 6 doubling 
dilutions starting at 1:100 as previously described (Challacombe, 1976).  Serum IgG, 
IgA, whole saliva IgG and IgA antibody titres were expressed in units by calculating the 
mean of values of four doubling dilutions falling on the reference curve.  The starting 
dilution for serum samples was 100 fold dilution while a 10 fold dilution was used for 
whole saliva.  The 1:10 dilution was found to offer a better sensitivity than 1:50 shown 
in Appendix 7.  
The reproducibility of the ELISA was measured by the coefficient of variance value.  A 
positive control sample used in each plate for all variables; a positive serum sample for 
serum IgG and serum IgA and a positive saliva sample for saliva IgG and saliva IgA, as 
well as a positive parotid sample for parotid IgA and SIgA.  The samples were used in 
each plate to calculate the reproducibility of each plate (Intra and inter-plate variation).  
A total of 20 plates were calculated.  ELISA mean coefficient of variation for intra-plate 
variation of serum IgG antibodies was 9.6% and for IgA antibodies was 10.4%.  Inter-
plate variation for serum antibodies for IgG was 11.4% while it was 12% for IgA.  
Assay of whole salivary antibodies was more variable with a coefficient of variation up 






Our collaborators D. Zillikens and E. Schmidt from Germany were kind enough to share 
some of their results.  They tested 39 samples from our MMP cohort for IgG and IgA 
antibody reactivity to the 4575 epitope of BP180 and to laminin 332.  These results are 
shown in Appendix 3. 
 
 
2 MATERIALS AND METHODS 
61 | P a g e  
 






















11.4% 12% 16.4% 18.2% 15.6% 16.02% 
 
Size-exclusion chromatography of whole saliva 
Five whole saliva samples positive (n = 4) or negative (n = 1) for anti- BP180-NC16a 
IgA antibody, as determined by ELISA using the anti-secretory monoclonal antibody 
for detection, were fractionated by size exclusion chromatography.  The aim of this 
experiment was to determine whether anti-BP180-NC16a binding activity was 
associated with high molecular weight SIgA.  Saliva (125 µl 1:2 dilution in 100mM (tris 
(hydroxymethyl) aminomethane, THAM)-HCL pH 8.0) was loaded on a Sephacryl S-
200 column (10/300, GE Healthcare) and chromatography was performed using the 
ÄKTAbasic system (GE Healthcare).  The elution buffer was 10 mM ammonium 
bicarbonate.  Absorbance was monitored at 280 nm and 0.5 ml fractions were collected 
at a flow rate of 0.5 ml/min.  Fractions were lyophilized (Edwards freeze dryer) and re-
suspended in 400 µl of PBS.  Fractions of defined molecular weight were analysed by 
Western Blotting (as described below) for the presence of secretory component and 
IgA.  Fractions that included secretory component and IgA were further tested for 
binding activity against BP180-NC16a using the pre-coated ELISA plates as above.   
The Sephacryl S-200 column was calibrated by chromatography of molecular weight 
standards: apoferritin (480 Kda), gamma globulin (120 Kda), ovalbumin (45 Kda) and 
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Denaturing Polyacrylamide Gel Electrophoresis 
1) - NuPAGE® Novex® 4-12% Bis-Tris Protein Gels, 1.0 mm, with either 15 wells 
(NP0323 Life Technologies) or 10 wells (NP0321 Life Technologies) were used to 
separate proteins according to molecular weight.  ColorBurst (TM) Electrophoresis 
Marker, mol wt 8,000-220,000 Da (C1992-1VL Sigma-Aldrich) was loaded.  Samples 
were prepared as recommended by addition of NuPAGE® LDS (lithium dodecyl 
sulphate) sample buffer (4X concentrated) followed by heating at 100C for two 
minutes.  Electrophoresis was at 120 V 150 mA (EPS00 Pharmacia) for 50 minutes 
using the NuPAGE® MOPS SDS Running Buffer (for Bis-Tris Gels only) (20X) 
(NP0001 Invitrogen).  For electrophoresis under reducing conditions, samples were 
heated in the presence of 0.1M DTT (dithiothreitol).  
Proteins were visualised by incubating gels in 0.25% (w/v) Comassie brilliant blue 
R250 in 25% (v/v) methanol, 10% (v/v) acetic acid in distilled H2O followed by 
destaining of background with 25% methanol, 10% acetic acid in distilled H2O.   
Western blotting 
For Western blotting, proteins were transferred to nitrocellulose membranes using the 
wet transfer protocol (Power pack basic, Bio-rad, Hertfordshire UK) with 1XTransfer 
buffer at constant current (400 mA) with maximum of 90 V for 90 minutes.  After the 
transfer was complete the gel was stained with Coomassie blue as above to confirm 
protein transfer. 
Membranes were blocked by incubation in 5% milk (dry milk powder) in PBS for 1 
hour at room temperature on a shaker (SSM3 mini gyro-rocker, BioCote Coventry UK ) 
and were washed with PBS/ Tween 20, 3 times (3x) 10 minutes each.  Primary antibody 
in 2% milk in PBS was then added and membranes were incubated with gentle shaking 
overnight at 4° C (SSM1 mini orbital shaker, BioCote Coventry UK).  Membranes were 
then washed 3x 10 minutes with PBS/ Tween 20.  The secondary antibody (horse radish 
peroxidase conjugate) in 2% milk in PBS was then added and membranes were 
incubated for 1 hr at room temperature with gentle shaking. Membranes were again 
washed 3x times with PBS/Tween 20 and peroxidase substrate (Luminata Crescendo 
Western HRP Substrate WBLUR0500 Millipore) was then added.  Membranes were 
incubated for 90 seconds following the manufacturer’s instructions.  The film (47410 
19236 Fuji medical x-ray film) was then developed using an automated x-ray film 
processor (Model JP-33 Jpi) at different time exposures for optimal image. 
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2.2.1.2 α6β4 Integrin Coated Plates 
Recombinant human integrin alpha 6 beta 4 (α6β4) 50 µg (5497-A6-050 R&D systems) 
was reconstituted as per manufacturer’s instructions.  This was used to coat a 96-well 
ELISA plate at different concentrations to obtain the optimal coating concentration for 
testing the samples.  A checkerboard test was designed; 0.1, 0.5 and 1 µg/ml α6β4 in 
carbonate/ bicarbonate 9.6 pH buffer was used to coat the plate which was then left 
incubating at 4°C overnight.  All incubations thereafter were at 37° C.  The plate was 
then allowed to reach room temperature and blocked for 1 hr with PBS/BSA/T20 which 
was then used as a diluent for the assay.  Anti-sera, both α6 and β4 (1:250, 500 and 
1000) at different concentrations were added and incubated for 2 hours.  These were 
Goat anti-human polyclonal IgG human integrin alpha 6/CD49f antibody (AF1350 
R&D systems) and sheep anti-human polyclonal IgG human integrin beta 4/CD104 
antibody (AF4060 R&D systems).  The secondary antibodies were alkaline phosphatase 
conjugated at a 1:1000 dilution and incubated for 1 hr.  Donkey anti-sheep polyclonal 
IgG alkaline phosphatase (A5187 SIGMA-ALDRICH) and rabbit anti-goat polyclonal 
IgG alkaline phosphatase (A4187 SIGMA-ALDRICH) were used respectively.  The 
previously mentioned alkaline phosphatase substrate was used to develop the plate 
which was incubated for 20 minutes stopped with 3M NaOH and OD405 nm. 
The optimal concentration was found to be 0.1 µg/ml and all subsequent plates were 
coated with that concentration (Appendix 8).  Serum and saliva samples were screened 
at 1:50 and 1:10 respectively to obtain a positive sample used as the positive control for 
all plates.  All samples were tested in duplicates.  Antibody IgG and IgA against α6β4 
integrin was then tested for in serum and saliva using an anti-human polyclonal IgG 
alkaline phosphatase linked (A8542 SIGMA-ALDRICH) and an anti-human polyclonal 
IgA alkaline phosphatase linked (A3400 SIGMA-ALDRICH) at a 1:500 dilution.  
Incubations were at 37° C for 2 hrs.  In between steps, the plates were washed with 
PBS/ T 20.  A positive sample was used repeatedly in order to establish the mean 
coefficient of variation for serum and saliva plates (a total of 10 plates used); IgG 
antibody in serum (Intra-plate) was 10% while inter-plate variation was 13%.  IgG 
antibody saliva intra-plate variation was 13.5% while inter-plate variation 15%. 
2.2.1.3 Dsg3 Pre-coated Plates 
Commercially available pre-coated plates with the desmoglein 3 antigen (Dsg3) 
MESACUP Dsg3 test (Medical and Biological laboratories Nagoya, Japan) were used 
to test for both IgG and IgA antibody to Dsg3 in serum, whole and parotid saliva.  All 
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samples were screened for both IgG and IgA anti-Dsg3 antibody and a standard was 
developed using a range of pooled antibody (both IgG and IgA) positive serum samples.  
The standard was given an arbitrary value of 100,000 units and standard curves 
constructed using 6 doubling dilutions starting at 1:100 as previously described 
(Challacombe, 1976).  Serum IgG, IgA, whole saliva IgG and IgA antibody titres were 
expressed in units by calculating the mean of values of four doubling dilutions falling 
on the reference curve reported at OD450 nm.  The starting dilution for serum samples 
was 100 fold dilution while a 10 fold dilution was used for whole saliva.  Measurement 
of serum IgG antibody against Dsg3 was performed according to the manufacturer’s 
instructions using reagents provided with the kit.  This has been previously described 
(Ishii et al., 1997).  Optimal conditions were established by screening all samples in 
duplicates (serum 1:50 and saliva 1:10) with different conjugate concentrations and 
incubation times for anti-Dsg3 IgG antibody in saliva and anti-Dsg3 IgA antibody in 
serum and saliva. Serum and saliva samples (1:100 dilution for serum and 1:10 for 
saliva) were tested for IgA antibody against Dsg3 as described for BP180-NC16a 
except that the anti-IgA antibody was used at a dilution of 1:1000 and incubations were 
for 1 hour instead of 2 hours at OD405nm (Appendix 9).  The mean coefficient of 
variation was calculated by using a positive sample repeatedly in each plate.  The mean 
coefficient of variance (intra-plate) for IgG antibody in serum was 9.4% and inter-plate 
variation was 10%.  The mean coefficient of variance (intra-plate) for IgA antibody in 
serum was 10.6% and inter-plate variation was 12.1%.  The mean coefficient of 
variance for IgG antibody in saliva (intra-plate) was 11.2% while inter-plate was 13%. 
 
Dsg1 results: 
The Dsg1 results used in this thesis were completed by Mr.Bhogal at the St John’s 
Institute of Dermatology, Guy’s and St Thomas’s NHS Foundation Trust, London, 
United Kingdom. 
2.2.2 Expression and purification of recombinant BP180 
Plasmids: 
pGEX2T was from GE Healthcare Life Sciences Buckinghamshire UK. 
E.coli BL21strains harbouring recombinant pGEX2T encoding fusion proteins with the 
NC16a epitope (residues 490-562 of BP180) and the 4575 epitope (residues 1365-1413 
of BP180) were kindly provided by D. Zillikens and E. Schmidt (University of 
Luebeck, Germany)  
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pET15b was from MerkMillipore Hertfordshire UK (Cat. No 6966-13). 
 
Bacterial cells: 
E. coli XL1 Blue: genotype {recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZΔM15 Tn10 (Tetr)], used for DNA production, was from Stratagen Santa 
Clara, CA United states (Cat. n. 200249). 
E. coli BL21 (DE3): genotype [F–ompT hsdS (rB–mB–) dcm+ Tetr gal λ (DE3); used 
for protein expression Stratagene], used for protein production was from Stratagene 
(Cat. no. 230280). 
Bacterial Media: 
LB (Lysogeny Broth) medium: 10g/L Tryptone (Oxoid, Cambridge, UK); 5g/L Yeast 
extract (Oxoid, Cambridge, UK); 10g/L NaCl (Sigma-Aldrich, Dorset, UK). 
LB Agar: 15g/L Agar Bacteriological (Oxoid, Cambridge, UK) dissolved in LB 
medium. 
SOC medium: 20g/L Tryptone (Oxoid, Cambridge, UK); 5g/L Yeast extract (Oxoid, 
Cambridge, UK); 0.5 g/L NaCl; 4.8 g/L MgSO4 (Sigma-Aldrich, Dorset, UK). 
2.2.2.1 Purification of plasmid DNA 
Plasmid DNA was purified from 1 - 5 ml cultures, grown overnight in LB supplemented 
with carbenicillin (50µg/ml) using the QIAprep Spin Miniprep Kit (QIAGEN, West 
Sussex, UK) according to the manufacturer’s instructions.  The system is based on 
alkaline lysis of bacterial cells.  E.coli cells were harvested by centrifugation and re-
suspended in 10 mM EDTA, 100 μg/ml RNase A in 50 mM Tris-HCl (pH 8.0).  Lysis 
buffer (200mM NaOH, 1% SDS) was added followed by 3M KAcetate.  Precipitated 
cell debris and denatured chromosomal DNA were removed by centrifugation and the 
supernatant was applied to silica resin.  Following washing with ethanol for further 
removal of RNA, proteins and salts, plasmid DNA was eluted in 50 µl of deionized 
water or TE buffer. 
The concentration of purified DNA was determined using the Nanodrop 2000 (Labtech 
International Ltd, East Sussex, UK).  DNA preparations with an OD260 nm/OD280 nm ratio 
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Digestion of DNA with restriction enzymes: 
Restriction enzymes were all from New England Biolabs and were used according to 
the manufacturer’s instructions.  Generally 10-20 U of restriction enzyme were used to 
digest 1 µg of plasmid DNA in the presence of the buffer supplied.  Mixtures were 
incubated at 37°C for a minimum of 60 minutes.  Enzyme inactivation, when necessary, 
was carried out after digestion by heating the reaction for the time and temperature 
required for each enzyme according to the manufacturer’s instructions.  DNA digestion 
was verified by agarose gel electrophoresis. 
Ligation of DNA: 
Purified plasmids (approximately 100 ng), linearised by restriction enzyme digestion, 
were combined with a 3-fold molar excess of insert DNA in the presence of the supplied 
ATP-containing ligase buffer (30mM TRIS-HCl pH 7.8, 10mM MgCl2, 10mM DTT 
and 1mM ATP) and 10 U (1 µl) of T4 DNA ligase.  The reaction was incubated for 2 
hours at 25 °C, temperature at which the enzyme has optimal activity.  Control reactions 
with no insert or no polymerase were included to indicate the level of non-recombinant 
transformants (see below). 
Polymerase Chain Reaction (PCR): 
DNA amplification was performed by PCR with plasmid DNA (10ng) as template.  The 
reaction mixture (total volume l) also contained dNTPs (deoxyribonucleotides: 
dATP, dCTP, dGTP and dTTP) each at 0.2 mM, 2.5 mM MgCl2 (Promega, 
Southampton, UK), 10 mM (NH4)2SO4, 10 mM KCl, 0.1% (v/v) Triton X-100, 0.1 
mg/ml BSA in 200 mM Tris-HCl (pH 8.8 at 25°C) with 2.5U PfuUltra™ HF DNA 
polymerase (Stratagene, La Jolla, CA, USA); 10pmol each of forward (sense) and 
reverse (antisense) oligonucleotides were included as primers (Sigma-Aldrich, Dorset, 
UK).  Following initial template denaturation (2 min at 95°C), DNA was amplified by 
30 denaturation-annealing-extension cycles.  Finally, reactions were incubated for 1 min 
at the annealing temperature and for 5 min at 72°C for final annealing and extension. 
Extension time was evaluated according to the size (BP) of the target DNA.  Annealing 
conditions were optimized based on the oligonucleotide sequences. 
2.2.2.2 Preparation of electrocompetent E.Coli 
LB medium (5 ml) was inoculated with E. coli (single colony from agar plate) and 
incubated for 16h at 37°C with shaking at 250 rpm.  The culture was then used to 
inoculate 500ml of LB medium in a 2 l-conical flask.  Incubation was at 37°C with 
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shaking at 250 rpm until the OD600nm of the culture was 0.5.  The culture was then 
cooled on ice for 30 min with swirling of the flask every 5-10 min.  Bacterial cells were 
harvested by centrifugation at 150 x g for 20 min at 4°.  The cell pellet was re-
suspended in sterile ice-cold distilled water and cells were again recovered by 
centrifugation at 150 x g for 20 min at 4°C.  The cell pellet was gently re-suspended in 
50 ml of sterile ice-cold distilled water and transferred to 50-ml polypropylene tubes. 
Cells were again recovered by centrifugation (720g, 20min, and 4°C) and re-suspended 
in 20ml ice-cold 10% glycerol (in H2O).  Following further centrifugation (720g, 
20min, 4°C), cells were re-suspended in 2 ml of 10% glycerol and aliquoted (100 µl). 
Aliquoted electrocompetent cells were frozen in liquid nitrogen and stored at -80°C. 
Transformation of E.coli by electroporation: 
DNA (either purified plasmids or ligation reaction mixture) was desalted to reduce the 
likelihood of sample arcing using the QIAquick PCR purification Kit (QIAGEN) 
according to the manufacturer’s instructions and was eluted in deionized water. 
Electrocompetent E.coli were thawed on ice 15 min before transformation. Cells (45 µl) 
were transferred to an ice-cold electroporation cuvette (gap width 0.1 cm) (Biorad CA, 
USA) and gently mixed with the desalted DNA (1-10 ng in a maximum of 10 µl). 
Electroporation was carried using the Gene-Pulser (Biorad) set to discharge a 25 uF 
capacitor, charged to 2.5kV in parallel with a 200 Ω resistor giving time constants 
ranging between 4.5 and 5 m/s.  SOC medium (950 µl) was added immediately after 
electroporation.  The cell suspension was then incubated for 60 min at 37°C with 
shaking at 250 rpm to allow for expression of the antibiotic resistance gene.  Cells were 
then plated on LB agarose plates supplemented with carbenicillin (50 µg/ml). 
 
Screening of transformants: 
LB (3 – 5ml) supplemented with carbenicillin (50 µg/ml) was inoculated with selected 
transformants and cultures were incubated at 37˚ C for 16 hours.  For some cultures, 
isopropyl β-D-1-thiogalactopyranoside (IPTG, 1mM) was added to induce expression of 
recombinant protein.  Aliquots (1 ml) of cultures were frozen in 20% (w/v) glycerol and 
stored at -80C.  Cells were recovered by centrifugation and resuspended for plasmid 
purification.  Purified plasmids were screened for the presence of inserted DNA by 
restriction enzyme digestion or polymerase chain reaction (PCR) followed by agarose 
gel electrophoresis. 
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For analysis of protein expression, cells were lysed.  Lysates were resolved by SDS-
PAGE and expression of recombinant GST-fusion protein was determined by western 
blotting using anti-GST antibody. 
DNA agarose gel electrophoresis: 
DNA plasmids or fragments were analysed by agarose gel electrophoresis.  Gels were 
prepared by dissolving electrophoresis grade agarose [(0.8-2% w/v) Sigma-Aldrich, 
Dorset, UK] in TAE buffer (0.04M Tris-acetate, pH 8.0; 1 mM EDTA).  The 
intercalating nucleic acid stain GelRed (Biotium, Hayward, CA, USA) was added (1 in 
104 dilution) to the solution after it was cooled to 55-60 °C.  The gel solution was 
poured into a cast with the sample well comb inserted.  DNA samples were mixed with 
loading buffer [0.04% (w/v) bromophenol blue; 0.04% (w/v) xylene cyanol; 5% 
glycerol] and loaded into wells at the end of the gel closer to the anode.  A voltage of 
80-120 V was applied allowing for DNA migration to the positive terminal (cathode). 
Bromophenol blue and xylene cyanol served as tracking dyes migrating at about the 
same rate as a 500 or 4000 base pair DNA fragment, respectively.  DNA molecular 
weight markers (1 kb DNA ladder, 100bp DNA ladder; New England Biolabs, Ispwich, 
MA, USA) were run in parallel with the DNA samples.  DNA fragments were 
visualised by UV light exposure.  Pictures were taken by using a gel documentation 
system (Syngene). 
Preparative agarose gel electrophoresis for purification of DNA fragments: 
For sub-cloning, digested plasmid and inserts were resolved on agarose gels and 
recovered from excised gel slices.  Agarose gels were prepared as described above with 
autoclaved TAE buffer.  With the exception of the chamber lid, all the equipment used 
for electrophoresis (chamber, gel cast and combs) was pre-washed with 10% SDS and 
rinsed with autoclaved distilled water in order to minimise nuclease activity.  DNA (1-5 
µg) in 20-60 µl was applied to the gel wells.  Electrophoresis was at 80 volts for 4-5 
hours for optimal separation.  DNA was visualised by brief (5 – 10s) exposure to long 
wavelength UV to reduce the likelihood of phosphodiester bond cleavage (DNA 
nicking).  DNA bands corresponding to inserts and linearized vectors were excised with 
sterile blades and purified using the QIAquick Gel Extraction Kit (QIAGEN) following 
the manufacturer’s instructions.  This system is based on DNA selective absorption by a 
silica membrane.  Agarose gel slices were solubilized using a guanidine thiocyanate-
containing buffer which also provided the high-salt concentration conditions required 
for DNA binding to the silica membrane.  Following adsorption to silica and washing 
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with 70% ethanol, DNA was eluted in 15-30 µl of deionized water or TE buffer (10 mM 
Tris pH 8.0, 1mM EDTA). 
2.2.2.3 Sub-cloning of NC16a-GST and 4575-GST in pET15b   
DNA fragments encoding the NC61a and 4575 epitopes fused with GST as well as GST 
(wild type) were amplified by PCR using the recombinant pGEX2T plasmids and non-
recombinant pGEX2T, respectively, as templates.  Primers used for PCR were: 
NC61a-GST :   
Forward ,5’CGCTCAGCATATGATGTCCCCTATACTAGGTTATTG 3’, 
Reverse, 5’GAGGAAGAAGCTAATGATGGAACAGGAATAAGGATCCATCTT 3’ 
4575-GST: 
Forward, 5’ CGCTCAGCATATGATGTCCCCTATACYAGGTTATTG 3’  
Reverse, 5’GGCCACAGGGGCCACCCGGCATCAGCTAGGGATCCATCTG 3’  
GST: 
Forward, 5’ ATTCGCATATGATGTCCCCTATACTAGGTTATTG 3’ 
Reverse, 5’ GCGACCATCCTCCAAAATAAGGATCCATCT T 3’. 
NdeI and BamHI sites in the forward and reverse primers, respectively, are shown in 
bold, the stop codons in the reverse primers are underlined. 
PCR products were analysed by agarose gel electrophoresis to confirm correct 
amplification and were digested with NdeI and BamHI. In parallel, pET15b was 
digested with the same restriction enzymes.  Digestion products were purified by 
preparative agarose gel electrophoresis as above.  Digested amplification products were 
ligated into linearised pET15b with T4 ligase and electrocompetent E. coli was 
transformed with ligation reaction products as above.  Transformants were screened by 
PCR and recombinant plasmids were confirmed by DNA sequence analyses. 
 
2.2.2.4 Expression of recombinant proteins 
Scale-up expression for recombinant protein purification was carried out in 1 L of LB 
supplemented with carbenicillin (50g/ml) which was inoculated with 5ml of culture 
(LB/carbenicillin) grown for 16 hours from a single colony.  Bacterial cultures were 
split in 2L-conical flasks (500 ml each) and grown at 37°C with shaking at 250 rpm to 
mid-exponential phase (OD600nm = 0.7), when IPTG (1 mM final concentration) was 
added. Cells were harvested after 3 hours of -induction by centrifugation at 5000 x g for 
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20 min in a refrigerated centrifuge (4°C).  Cell pellets were either processed 
immediately or were stored at -20 °C. 
2.2.2.5 Purification of proteins 
Cell pellets (from 1L cultures) were resuspended in 40 ml of 100mM Tris-HCl (pH 8.0) 
or PBS.  An equal volume of Ballotini glass beads, size 12 (Jencons) was added and 
cells were lysed by homogenisation (3 bursts of 30 s duration at 6 m/s) using the Fast-
prep 24 (MP Biomedicals, Santa Ana, California, USA).  The glass beads were removed 
by centrifugation for 1 min at 1000 x g and the supernatant was transferred to centrifuge 
tubes (Nalgene, Rochester, NY, USA).  Insoluble material was removed by 
centrifugation at 20,000 x g for 30 min at 4°C   (Sorvall RC 5C PLUS) and recombinant 
proteins were purified from the supernatant as in the following sections. 
2.2.2.5.1 Affinity chromatography using glutathione-Sepharose 
Affinity chromatography was performed using 1 -2 ml Glutathione Sepharose 4B (GE 
Healthcare) in 10 cm or 5 cm x 1 cm diameter glass chromatography columns (Econo-
Column; Biorad) at 4C.   Resin was washed with at least 10 column volumes (CVs) of 
PBS before loading of cleared lysates.  Following loading of the lysates, columns were 
washed again with PBS (at least 10CVs until OD280nm reached a base-line).  Retarded 
components were eluted with 10mM glutathione in PBS and collected in 1 ml fractions. 
OD280nm of each fraction was determined using the Nanodrop 2000.  Aliquots of each 
fraction were analysed by SDS-PAGE. 
2.2.2.5.2 Affinity chromatography using Ni 2+- resin 
GST and GST-fusion proteins that were sub-cloned and expressed in pET15b express 
an additional (His) 6 affinity tag.  Following purification using glutathione-Sepharose, 
these proteins were further purified by affinity chromatography with Ni2+ resin. 
Approximately 2 ml of chelating sepharose (GE Healthcare) was used for each 
recombinant protein. Columns were washed with 30 column volume (CV) of HPLC-
grade water, then charged with Ni2+ by addition of 5 CV 50 mM NiSO4.   Excess 
NiSO4 was removed by washing with 10 CV of HPLC-grade water.  Resin was 
equilibrated with 10 CV of 5mM imidazole buffer (100mM Tris-HCl pH 8.0; 0.5 M 
NaCl; 5mM imidazole).  GST and GST-fusion proteins eluted from glutathione-
Sepharose columns were loaded directly.  Columns were then washed with 5mM 
imidazole buffer to remove non-retarded components.  Retarded fusion proteins were 
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eluted with 200mM imidazole, 0.5M NaCl in 100mM Tris-HCl (pH8.0).  As before, 
fractions (1 ml) were collected, absorbance was measured and fractions were analysed 
by SDS-PAGE. 
Mass spectroscopy analyses 
Following SDS-PAGE electrophoresis of recombinant proteins, bands corresponding to 
GST, NC16a and 4575 were excised.  Subsequently, at the Proteomics Facility, 
University of Bristol excised bands were digested with trypsin using the ProGest 
automated digestion unit (Perkin Elmer).  Peptides were analysed using a 4700 MALDI-
Tof/Tof mass spectrometer (Applied Biosystems, Foster City, CA) to give a peptide 
mass fingerprint and peptide sequence information.  
 
2.2.2.6 ELISA  
A 96-well plate was coated with GST, NC16a and 4575 at different concentrations; 2, 5 
and 10 µg/ml in 100mM carbonate bicarbonate pH 9.6 incubated overnight at 4° C.  It 
was then allowed to reach room temperature and washed with PBS/ T 20 3 times.  The 
plate was blocked with PBS/ BSA/ Tween 20 which was the solution used as the assay 
diluent and was left at 37° C for one hr.  After washing, 6 serum samples were added in 
duplicates in 6 doubling dilutions (1:100, 200, 400, 800, 1600 and 3200) and left 
incubating for 1 hr at 37° C.  Subsequent to washing, the conjugate was added, an anti-
human polyclonal IgG alkaline phosphatase linked antibody (1:1000) (A8542 SIGMA-
ALDRICH) for 1 hr at 37° C.  The reaction was stopped and the plate read as described 
above. 
 To reduce GST background reactivity, serum samples were incubated with GST lysate 
in order to reduce GST reactivity.  Three sera samples were incubated with lysate at 
different concentrations; 2.5 and 10 fold of lysate with a 1:1 ratio of protease inhibitor 
(S8830 SIGMAFAST(TM) Protease Inhibitor Cocktail Tablets, EDTA-Free SIGMA-
ALDRICH) prepared as per manufacturer’s recommendations.  In addition, different 
temperatures (4° C and room temperature), as well as incubation times of 1 hour and 
overnight were incorporated.  Plates were blocked with PBS/ BSA/ Tween 20 for an 
hour at 37° C and washed 3x with PBS/ Tween 20 as previously described.  Sera were 
incubated for 1 hr at 37° C and the anti-human polyclonal IgG conjugate was added 
(1:1000) (A8542 SIGMA-ALDRICH)   
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2.2.3 Surface Plasmon analyses of antibody binding to α6β4 integrin 
The amine coupling procedure was used for immobilisation of α6β4 integrin.  The 
surface of a CM5 sensor chip (GE Healthcare Lifesciences) was activated by injection 
of 0.2M EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) together with 0.05M 
NHS (N-hydroxysuccinimide) followed by injection of α6β4 integrin (5μg/ml in 
10mM NaAcetate, pH4.0) over the surface of flowcell 2 (Fc2). No ligand was 
immobilised in Fc2 which served as a reference cell.  Non-substituted groups on the 
dextran surface were blocked by injection of 1M ethanolamine-HCl, pH8.5.  
Approximately 2,000 RU were immobilised.  Anti- α6 or anti- β4 antibodies (AF1350 
and AF4060 R&D systems, respectively) were injected over both flow cells at a 
concentration of 1μM in HBS-P to confirm immobilisation of the integrin.  Injection 
volume was 40μl, buffer was HBS-P and flow rate was 10μl/min.  The sensorchip 
surface was regenerated by injection of 100mM diethylamine.  The same conditions 
were used to investigate binding of sera (diluted in HBS-P) to the immobilised 
integrin. 
 
 Statistical analyses 
Statistical analyses were undertaken using the GraphPad Prism 5.02.  One-way 
analysis of variance (ANOVA) was used to compare the mean of the different 
subgroups tested i.e.; MMP, PV, HC and DC.  Positivity for either MMP or PV for 
any of the variables tested (IgG serum and saliva, IgA serum and saliva or IgA and 
SIgA parotid) was defined as above the mean +2SD of the healthy controls.  
Bonferroni and Newman-Keuls corrections for all post-anova comparison tests were 
used.  Associations between antibody titres and disease severity and 
clinicopathological associations were conducted by Chi square and Spearman Rank 
correlation for non-parametric data.  Sequential results’ analyses were conducted by 
taking the difference between the first and final time point in sample collection and 
performing Spearman correlation between the change in antibody titre and the oral 
disease severity score for MMP analysis.  Logistic regression was used for the analysis 
of the sequential data in PV.  The mean of the coefficient of variance was used to 
establish reproducibility of the ELISA tests based on a positive sample used repeatedly 
on the plates. Intra-and inter-plate variations were both calculated. 
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3 Results MMP Study 1 (a&b) 
Serum and salivary antibodies to BP180-NC16a 
in patients with mucous membrane pemphigoid 
(a)- Serum and salivary antibodies to BP180-NC16a in 
relation to clinical phenotype and disease activity (Cross-
sectional) 
(b)- Serum and salivary antibodies to BP18-NC16a in relation 
to therapeutic response (Longitudinal) 
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3 Serum and salivary antibodies to BP180-NC16a in patients with 
mucous membrane pemphigoid (MMP study 1 a&b) 
 
 Introduction 
The main target antigens lie within the hemidesmosome; these include bullous 
pemphigoid antigen 2 (BP180), laminin 332, alpha 6 beta 4 (α6β4) integrin and less 
commonly collagen VII (Schmidt and Zillikens, 2013).  There is still much controversy 
regarding specific target antigens and clinical phenotype.  The beta 4 integrin has been 
implicated in ocular MMP (Tyagi et al., 1996) while the alpha 6 integrin has been 
mentioned with oral MMP (Rashid et al., 2006b, Bhol et al., 2001).  However, other 
studies state that BP180 is the main antigen targeted in oral or multisite MMP (Schmidt 
et al., 2001b, Carrozzo et al., 2004, Calabresi et al., 2007).   
 Indirect immunofluorescence (IIF) on salt-split skin (SSS) can be used to monitor 
serum titres of IgG and IgA for the assessment of disease activity whereas enzyme-
linked immunosorbent assays (ELISA) are not yet used routinely for monitoring disease 
activity.  Dual serum antibodies (IgG and IgA) have been shown to be associated with a 
more severe disease (Setterfield J. et al., 1998).   
Testing serum for antibodies to basement membrane zone (BMZ) antigens by ELISA to 
diagnose MMP has been well documented (Calabresi et al., 2007, Sciubba, 2011, Chen 
et al., 1997, Bekou et al., 2005).  Specific target antigens, such as the NC16a domain of 
BP180, BP230 or laminin 332 have been used for serum testing and are documented 
(Bekou et al., 2005, Wieland C. N. et al., 2010).  In contrast, the use of saliva as a test 
fluid has been reported only once to our knowledge and  reported negative results 
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The aims of this study were: 
1) To identify the whether serum and salivary IgG and/or IgA autoantibodies to 
BP180-NC16a were present in our cohort of MMP 
2) To utilize serum and salivary biomarkers in the analysis of disease activity and 
therapeutic responses 
3) To identify whether there was an association with carefully defined clinical 
subgroups 
 
In this study both whole and parotid saliva were tested for the presence of antibodies to 
BP180-NC16a.  Saliva is a potentially valuable substrate as it reflects many components 
of the systemic circulation such as antibodies and cytokines (Mandel, 1990).  
Additionally parotid saliva was tested in order to differentiate between IgA in whole 
saliva as a serum transudate and/ or as mucosally derived antibody (i.e. whether it was 
monomeric or dimeric SIgA).  Antibodies in either fluid were related to disease activity 
to determine if a relationship between antibody titre and disease severity could be 
established.  Sequential samples were also analysed in order to deduce whether a 
relationship existed between changes in clinical severity (therapeutic responses) and any 
changes in antibody titre.   
Furthermore, in an attempt to ascribe a relationship between specific clinical phenotypes 
and definite target antigens, the cohort was sub-grouped into pure oral, pure ocular and 
multisite MMP.  Recombinant protein was expressed and purified to optimize ELISA 
testing for the C-terminal domain BP180-4575 (see methods). 
 
 A) Serum and salivary antibodies to BP180-NC16a in relation to 
clinical phenotype and disease activity (Cross-sectional study 1a) 
3.2.1 Serum and whole saliva 
In this study (Study 1 a), serum and whole saliva samples from MMP patients (n=78), 
healthy controls (n=50) and disease controls (PV n=6, LP n=16) were tested for 
antibodies against BP180-NC16a by ELISA.  The standard curves against which all 
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a) 
   
 
Figure 3-1 Standard curve for serum and whole saliva IgG/IgA antibody testing against 
BP180-NC16a by ELISA a) Standard curve for serum and whole saliva IgG antibody testing 
against BP180-NC16a by ELISA. b) Standard curve for serum and whole saliva IgA antibody 
testing against BP180-NC16a by ELISA. Both figures show a Y-axis which represents blank-
corrected optical density values and an x-axis representing arbitrary units (0-1000) (100,000 by 
multiplying by dilution factor 100).  The standard curve was constructed using 6 doubling 
dilutions of a range of pooled antibody positive serum samples. Serum and whole saliva 
IgG/IgA antibody titres were read in units by calculating the mean of values of four doubling 
dilutions falling on the reference curve 
A summary of patients’ demographics, clinical data, immunofluorescence and ELISA 
results are shown in Appendix 3.  The mean titres for both IgG antibodies (19062 ± 
34710) and IgA antibodies (13514±16639) in serum and saliva (740.9±2243)/ 
(1701±2273) from MMP patients, were significantly different from those of the controls 
(both healthy and disease) in all tested parameters using one-way ANOVA (p<0.0001).  
Values greater than the mean +2 SD of the healthy controls were considered positive.  
Healthy and disease control samples were all negative using these criteria.  The negative 
predictive values were 65% for IgG serum, 59% for IgA serum, 62% for IgA saliva and 
56% for IgG saliva.  Serum IgG antibodies against the NC16a domain of BP180 were 
detected in 28/78 (36%) of MMP patients (Fig 3-3).  Serum IgA antibodies were found 
b) 
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in 22/78 (28%) (Fig 3-4).  Combined serum IgG and/or IgA antibodies were positive in 
38/78 (48%) patients (Fig 3-2 b).  
In whole saliva, IgA antibodies were detected in 30/78 (38%) of MMP patients (Fig 3-
5).  IgG antibodies were detected in 11/78 (14%) of MMP whole saliva samples (Fig 3-
6), all of whom were also positive in serum for IgG antibodies and all eleven had active 
oral disease with oral scores indicating inflammation  (The Oral Disease Severity Score 
ranged between 5-35 in the positive samples).  Combined whole saliva IgG and/or IgA 
antibodies were positive in 34/78 (44%) (Fig 3-2 c).  Results are listed in Table 3-1.  
IgG antibody in serum and saliva to BP180-NC16a was detected in 28/78 (36%) MMP 
patients (Fig 3-2 d).  IgA antibody in serum and/or IgA antibody in saliva to BP180-
NC16a were detected in 41/78 (52%) patients (Fig 3-2 e).   Overall, 52/78 (67%) were 
positive for IgG and/or IgA antibodies to BP180-NC16a in serum and saliva or both 
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Figure 3-2 Venn diagram showing relation between antibodies (IgG/IgA) to BP180-NC16a 
detected in serum and whole saliva 
a) IgG and/or IgA antibody in serum and saliva (whole and/or parotid) was detected in 52/78 
(67%) b) IgG and/or IgA antibody in serum detected in 38/78 (48%) MMP patients. c) IgA 
antibody in saliva and/or IgG antibody in saliva was detected in 34/78 (44%) MMP patients d) 
IgG antibody in serum and saliva was detected in 28/78 (36%) MMP patients e) IgA antibody in 





Table 3-1 Study 1a ELISA results for IgG and IgA antibodies against BP180-NC16a in 
serum and whole saliva.  
Study 1 (a) 
MMP (n=78) 
IgG Serum IgG Whole 
Saliva 






Combined IgG and 
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Figure 3-3 Serum IgG antibodies against BP180-NC16a in MMP paients healthy and 
disease controls using ELISA (Mean +/- SD) The Y-axis represents the antibody titre in units 
while the X-axis shows the sample groups tested.  Horizontal I bar indicates cut-off level (mean 
+ 2SD of healthy controls).  Controls were negative in all.  MMP positive in 28/78 (36%) 














































Figure 3-4 Serum IgA antibodies to BP180-NC16a ELISA in MMP patients, Healthy and 
Disease controls using ELISA (Mean +/- SD) The Y-axis represents the antibody titre in units 
while the X-axis shows the sample groups tested.  Horizontal I bar indicates cut-off level (mean 
+ 2 SD of the HC).  Controls were negative in all.  Serum IgA antibody units against BP180-
NC16a in MMP were positive in 22/78 (28%) 
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 Whole saliva IgA antibody units against BP180-NC16a in






































Figure 3-5 IgA antibodies to BP180-NC16a ELISA in whole saliva in MMP patients, 
Healthy and Disease controls using ELISA (Mean +/- SD) The Y-axis represents the 
antibody titre in units while the X-axis shows the sample groups tested. Horizontal I bar 
indicates cut-off level (mean + 2 SD of the HC).  Controls were negative in all. Whole saliva 
IgA antibody units against BP180-NC16a in MMP were positive in 30/78 (38%) 














































Figure 3-6 IgG antibodies to BP180-NC16a ELISA in whole saliva in MMP patients, 
Healthy and Disease controls using ELISA (Mean +/- SD) The Y-axis represents the 
antibody titre in units while the X-axis shows the sample groups tested. Horizontal I bar 
indicates cut-off level (mean + 2 SD of the HC).  Controls were negative in all. Whole saliva 
IgG antibody units against BP 180-NC16a in MMP were positive in 11/78 (14%) 
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Additional immunoblotting results from the collaborators in Germany 
(Schmidt/Zillikens) on MMP samples from this study 
Immunoblotting studies to detect serum IgG or IgA antibodies to BP180-4575 (C-
terminal domain) and Laminin 332, were performed and provided by our collaborators.   
They tested serum from 39 patients we provided from this study for IgG and IgA 
antibodies to BP180-4575 domain as well as IgG antibody to Laminin 332 by western 
blot.  Serum IgG antibodies to BP180-4575 were positive in 7/39 (18%) patients.  Eight 
of 39 (21%) were positive for serum IgA antibodies to BP180-4575.  Finally, 6/39 
(15%) were positive for serum IgG antibodies to laminin 332.   
The results are summarised in (Table 3-2).  A comparison of results for antibodies to 
BP180-4575 from our collaborators and antibodies to BP18-NC16a in our ELISA 
results showed that all samples tested were positive for both except 4 samples which 
were positive for IgG and/or IgA against BP180-4575 but were negative with our 
ELISA tests (BP180-NC16a and/or α6β4 integrin).  These 4 negative samples were 
categorised as 3 of the pure oral subgroup and 1 of the pure ocular.  Similarly, three of 
the 6 samples positive to laminin 332 were positive with our ELISA tests while 3 were 
negative with our ELISA tests (BP180-NC16a and/or α6β4 integrin).  Of these 3 
negative samples, two were multisite disease subgroup and 1 was pure oral. 
 
 
Table 3-2 Summary of MMP serum samples tested against BP180-NC16a and 4575, α6β4, 
































*Indicates collaborators’ results 
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Relationship between serum and saliva antibodies to NC16a (data from study 1 a) 
and clinical phenotype 
When data were analysed for an association with clinical phenotype, there was a 
positive association between the presence of serum IgG antibodies to BP180-NC16a 
and multisite disease lesions (X2 = 11.9 p =0.003).  A significant relation was also found 
between the presence of IgA antibodies against BP180-NC16a in whole saliva and the 
presence of both oral and ocular disease (X2 = 6.23 p =0.016).  There was no apparent 
association with other clinical subgroups (pure oral or pure ocular) or disease severity 
(Table 3-3). 
There was a positive correlation between IgG antibodies to BP180-NC16a in serum and 
saliva (Spearman r =0.244 p =0.003) (Fig 3-7 a).  A positive association was also found 
between IgG and IgA antibodies to BP180-NC16a in serum (Spearman r =0.303 p 
=0.0002) (Fig 3-7 b).  No statistically significant correlation was found between IgA 
antibodies to BP180-NC16a in serum and saliva.  No statistically significant correlation 
was found between IgA antibodies to BP180-NC16a in whole saliva and the oral 
disease severity score (Spearman r=-0.099 p=0.385).  However, a positive association 
was found between IgG antibody to BP180-NC16a secretory rate in whole saliva and 
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Table 3-3 Statistical analysis of data according to clinical subgroups. Antibodies to BP180-
NC16a (IgG and IgA) in serum and whole saliva and direct and indirect immunofluorescence 
results in relation to clinical phenotypes of pure oral, pure ocular, multisite disease.  









Overall Chi square  
p value 
IgG Serum 8/23 (35%) 0/16 20/50 (50%) 28/78 (36%) 11.9 p=0.003 
** 
IgA Serum 3/23 (13%) 5/16 (33%) 14/50 (35%) 22/78 (28%) 3.7 p=0.16  
IgG Whole 
saliva 
3/23 (13%) 0/16 (0%) 8/50 (20%) 11/78 (14%) 3.6 p=0.16  
IgA Whole 
saliva 
10/23 (44%) 7/16 (47%) 13/50 (33%) 30/78 (38%) 1.3 p=0.53 
(combined 
oral and/or 
ocular  6.23 
p=0.016*) 
DIF 21/22 (96%) 5/16 (39%) 31/39 (80%) 57/74 (77%) 15.3 p=0.000 
** 
IIF 7/18 (39%) 0/16 10/21 (48%) 23/65 (35%) 1.1 p=0.59  
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Correlation between IgG antibody units in serum and whole saliva against
BP180-NC16a













































Correlation between IgG and IgA antibody units in serum against BP180-NC16a













































Figure 3-7 Correlations (Spearman rank correlation for non-parametric data) between:  a) 
IgG antibodies to BP180-NC16a in serum and whole saliva (Spearman r =0.244 p=0.003) and 
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Correlation between anti-BP180-NC16a IgG antibody secretory rate in whole
saliva and the oral disease severity score




























Figure 3-8 Spearman rank correlations of anti-BP180-NC16a antibody secretion rate in 
whole saliva and the oral disease severity score Correlation of anti-BP10-NC16a IgG 
antibody secretion rate in whole saliva and the oral disease severity score (Spearman r=0.225 
p=0.048)  
Sensitivity of assays 
The sensitivity of detecting IgG antibody against BP180-NC16a in whole saliva was 
tested by the spiked ELISA described (see chapter 2).  The standard was spiked to test 
whether IgA or salivary components such as mucins were inhibiting IgG detection.  The 
results showed that the technique was sensitive as there was no difference between the 
standards (all three lines representing the various conditions overlap) (Fig 3-9). 
 
Antibodies in relation to clinical phenotype 
The MMP samples tested in both cross-sectional and longitudinal studies (n=91) were 
further analysed by subgrouping the patients based on clinical phenotype; pure oral 
(n=25), pure ocular (n=16) and multisite (n=50) (Fig 3-10 and 3-11) (results 
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Figure 3-9 Three spiked standards were used to establish the sensitivity of IgG antibody 
detection against BP180-NC16a using the commercially available pre-coated ELISA plates  
(blue on graph) standard spiked with PBS, (red on graph) standard spiked with a whole saliva 
sample positive for IgA antibody against BP180-NC16a but negative IgG antibody, (green on 
graph) standard was spiked with a whole saliva sample negative for both IgG and IgA 
antibodies against BP180-NC16a. Y-axis in the OD and X-axis represents units of IgG antibody 
to BP180-NC16a 
 
Serum antibodies in relation to clinical phenotype 
The pure ocular MMP subgroup was found to be negative for IgG antibody against 
BP180-NC16a (0/16).  In the pure oral subgroup, 36% (9/25) were positive for serum 
IgG antibody against BP180-NC16a, while in the multisite group 46% (23/50) were 
positive for IgG antibody against BP180-NC16a.  With regard to IgA antibody in serum 
against BP180-NC16a, 38% (6/16) were positive in the pure ocular group (the highest 
percentage), 16% (4/25) were positive in the pure oral group and 28% (14/50) were 
positive in the multisite group.  Thus, in the pure ocular group, serum antibodies to 
NC16a were of the IgA isotype and not IgG.  
 
Salivary antibodies in relation to clinical phenotype 
In whole saliva, IgG antibody against BP180-NC16a was positive in 16% (4/25) in the 
pure oral group and 18% (9/50) in the multisite groups with none being positive in the 
pure ocular subgroup.  IgA antibody in whole saliva against BP180-NC16a was positive 
in 44% (7/16) in the pure ocular subgroup in 40% (10/25) of the pure oral subgroup and 
in 30% (15/50) of the multisite group (Table 3-4).  Thus overall, a higher percentage of 
patients showed salivary IgA antibodies to NC16a than serum IgA antibodies (32 of 91 
(35%) versus 24 of 91 (26%). 
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Table 3-4  Results of IgG and IgA antibodies in serum and whole saliva against BP180-
NC16a ELISA by clinical phenotype distribution.  
 

























Study by clinical 
phenotype 
 MMP (n=91) 
against BP180-
NC16a 
Pure Oral  
(n=25) 
Pure Ocular (n=16) Multi-site 
 (n=50) 
IgG Serum 9/25 (36%) 0 23/50 (46%)* 
IgG Whole Saliva 4/25 (16%) 0 9/50 (18%)* 
IgA Serum 4/25 (16%) 6/16 (38%)* 14/50 (28%) 
IgA Whole Saliva 10/25 (40%) 7/16 (44%)* 15/50 (30%) 
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IgG Antibodies in Serum Against BP180-NC16a in MMP subgroups
(Pure Oral, Pure Ocular and Multisite)











































IgG Antibodies in  Whole Saliva Against BP180-NC16a in MMP
subgroups (Pure Oral, Pure Ocular and Multisite)












































Figure 3-10 MMP patients subgrouped according to clinical phenotype and tested for IgG 
antibodies against BP180-NC16a in serum and whole saliva (Mean +/- SD)  
Subgroups include MMP cohort (study a+b) (n=91), pure oral (n=25), pure ocular (n=16) and 
multisite (n=50).  The Y-axis represents the units of each specific antibody in the medium 
tested.  The X-axis corresponds to the sample groups tested.  Positivity was established at the 
mean + 2SD of the HC group (see methods).  Controls were negative (See Fig 3.2-3.5). 
Comparisons were drawn between the MMP subgroups only. a) IgG antibody units in serum 
against BP180-NC16a 32/91 (35%) positive in MMP(all), pure oral 9/25 (36%), pure ocular 
(0/16) and multisite group 23/50 (46%) b) IgG antibody units in whole saliva against BP180-
NC16a 13/91 (14%) positive in MMP (all), pure oral 4/25 (16%), pure ocular (0/16) and the 
multisite group 9/50 (18%)  
a) 
b) 
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IgA Antibodies in Serum Against BP180-NC16a in MMP subgroups
(Pure Oral, Pure Ocular and Multisite)












































IgA Antibodies in Whole Saliva Against BP180-NC16a in
MMP subgroups (Pure Oral, Pure Ocular and Multisite)










































Figure 3-11  MMP patients subgrouped according to clinical phenotype and tested for IgA 
antibodies against BP180-NC16a in serum and whole saliva (Mean +/-SD) 
Subgroups include MMP cohort (study a+b) (n=91), pure oral (n=25), pure ocular (n=16) and 
multisite (n=50).  The Y-axis represents the units of each specific antibody in the medium 
tested.  The X-axis corresponds to the sample groups tested.  Positivity was established at the 
mean + 2SD of the HC group (see methods).  Controls were negative (see Fig. 3.2-3.5) 
Comparisons were drawn between the MMP subgroups only. a) IgA antibody units in serum 
against BP180-NC16a 24/91 (26%) positive in MMP (all), pure oral 4/25 (16%), pure ocular 
showed 6/16 positivity (38%) and the multisite group 14/50 (28%). b) IgA antibody units in 
whole saliva against BP180-NC16a were positive 33/91 (36%) of MMP (all), pure oral 10/25 
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b) Relationship between antibodies to BP180-NC16a and Disease severity 
There was a positive relation between the units of IgG antibody in whole saliva against 
BP180-NC16a and the oral disease severity score in the multisite subgroup (Spearman r 
=0.323 p =0.022) (Fig 3-12), and also a positive correlation between the units of IgG 
antibody in serum and in saliva against BP180-NC16a and the number of sites involved 
(Spearman r =0.335 p =0.017 and Spearman r =0.329 p =0.019, respectively) (Fig 3-13 
a-b).  A positive association was also found between IgG antibody units against BP180-
NC16a in serum and saliva in both the pure oral and multisite groups (Spearman r 
=0.483 p =0.015 and Spearman r =0.569 p <0.0001, respectively) (Fig 3-14 a-b).  
Similarly, a positive relation was found between IgG and IgA antibody units against 
BP180-NC16a in serum in both the pure oral and the multisite groups (Spearman r 
=0.495 p =0.012 and Spearman r =0.454 p =0.0009, respectively) (Fig 3-15 a-b).  




Correlation between IgG antibody units in saliva in multisite MMP and oral
disease severity score



























Figure 3-12 The correlation between IgG antibodies in whole saliva against BP180-NC16a 
in the multisite subgroup of MMP and the oral disease severity scores (Spearman r =0.323 p 
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Correlation between IgG antibodies in serum in multisite MMP and
the number of sites involved



























Correlation beween IgG antibodies in saliva in multisite MMP and
the number of sites involved



























Figure 3-13 The correlation between IgG antibodies to BP180-NC16a in both serum and 
whole saliva and number of sites involved in the multisite subgroup a) The correlation 
between IgG antibodies to BP180-NC16a in serum and number of sites involved in the multisite 
subgroup (Spearman r =0.335 p =0.017). b) The correlation between IgG antibodies to BP180-
NC16a in whole saliva and number of sites involved in the multisite subgroup (Spearman r 
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Correlation between  IgG antibodies against BP180-NC16a in serum and
saliva in pure oral subgroup












































Correlation between IgG antibodies against BP180-NC16a in serum and
saliva in multisite subgroup












































Figure 3-14 The correlation between IgG antibodies toBP180-NC16a in both serum and 
whole saliva in the pure oral and multisite subgroups a) The correlation between IgG 
antibodies to BP180-NC16a in serum and saliva in the pure oral subgroup (Spearman r = 0.483 
p =0.015). b) The correlation between IgG antibodies to BP180-NC16a in serum and saliva in 
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Correlation between IgG and IgA antibodies in serum against
BP180-NC16a in the pure oral subgroup












































correlation between IgG and IgA antibodies against BP180-NC16a
in the multisite subgroups












































Figure 3-15 The correlation between IgG and IgA antibodies to BP180-NC16a in serum in 
the pure oral and multisite subgroups a) The correlation between IgG and IgA antibodies to 
BP180-NC16a in serum in the pure oral subgroup (Spearman r =0.495 p =0.012). b) The 
correlation between IgG and IgA antibodies to BP180-NC16a in serum in the multisite subgroup 
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Table 3-5 Summary of correlations between serum and salivary antibodies to BP180-
NC16a and the disease severity in different clinical phenotypes 
Variables Clinical phenotype P Value  
IgG antibodies to BP180-
NC16a in serum and whole 
saliva 
Pure oral Spearman r=0.4826   p= 0.015 
IgG antibodies to BP180-
NC16a in serum and whole 
saliva 
Multi-site disease Spearman r=0.5688 p<0.0001 
IgG and IgA antibodies to 
BP180-NC16a in serum  
Pure oral Spearman r= 0.4953 p= 0.012  
IgG and IgA antibodies to 
BP180-NC16a in serum 
Multi-site disease Spearman r= 0.4535 p= 0.0009 
IgG antibodies to BP180-
NC16a in serum and 
number of sites involved in 
multi-site disease patients 
Multi-site disease Spearman r= 0.3351 p= 0.017 
IgG antibodies to BP180-
NC16a in whole saliva and 
number of sites involved in 
multi-site disease patients 
Multi-site disease Spearman r= 3286 p= 0.019 
IgG antibodies to BP180-
NC16a in whole saliva and 
the oral disease severity 
score 
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3.2.2 Detection of secretory IgA antibodies to NC16a in Parotid Saliva 
Antibodies in whole saliva may be derived from serum as transudate, locally produced 
antibodies within the mucosal system or a combination of both.  Antibodies in parotid 
are predominantly secretory IgA.  Thus whole and parotid saliva were evaluated for 
both IgA and SIgA antibodies to BP180-NC16a.  Antibodies against BP180-NC16a 
were detected in parotid saliva in 9/20 (45%) patients and were positive for secretory 
component in all nine (Fig 3-16 a).  In addition, the antibodies detected by anti-IgA and 
by anti-secretory component were strongly correlated (Spearman r=0.9141) (Fig 3-16 
b).  Amongst the 9 positive for SIgA antibodies in parotid samples, all were also 
positive for IgA antibodies in whole saliva (annotated as * in Appendix 3) but 7/9 were 
negative in serum.  Conversely, three samples positive for IgA antibody to BP180-
NC16a in serum and whole saliva were negative in parotid. 
A description of the whole saliva results incorporating parotid saliva results are 
summarized (Table 3-6) and detailed here.  Of the 30 whole saliva samples which were 
positive for IgA antibodies to BP180-NC16a (30/78), 12 had parotid saliva samples 
(12/30) while the rest did not (18/30) as parotid samples were randomly collected at the 
onset of the study.  Of these 12, seven were positive in parotid and whole saliva 
(marked * in Appendix 3).  Three were positive in serum and whole saliva (marked ^ in 
Appendix 3).  One was positive in whole saliva alone (underlined in Appendix 3) and 
finally, one was positive in serum, whole and parotid saliva (marked + in Appendix 3).  
The remaining 18 samples which did not have parotid saliva samples analysed showed 
that 11 were positive in whole saliva alone (underlined in Appendix 3) while seven 
were positive in serum and whole saliva (marked ˅ in Appendix 3).    No link was found 
between parotid saliva and clinical subgroups (pure oral, pure ocular or multisite 
disease) or with disease severity.  Whole saliva was also tested using the anti-secretory 
component antibody and the results showed that 6/20 (30%) samples were positive, 
however, two were positive for SIgA in parotid saliva while the remaining four were 
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Detection of parotid secretory IgA antibody to BP180-NC16a















   
































Figure 3-16 IgA and SIgA antibodies to BP180-NC16a in parotid saliva a) The figure 
represents the OD of SIgA antibody against BP180-NC16a in parotid saliva using an anti-
secretory component antibody. The Y-axis represents OD while the X-axis shows the sample 
groups tested.  Horizontal I bar indicates cut-off level (mean +2SD of the HC).  Nine of twenty 
MMP patients (45%) were positive for SIgA tested by an anti-secretory component antibody 
which was also positive for IgA. b) Positive correlation between SIgA and IgA antibody in 


















o relation between SIgA and IgA antibodie  against BP180-NC16a in parotid saliva 
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Table 3-6 Summary of IgA antibodies to BP180-NC16a in parotid and whole saliva 
Summary of IgA antibodies to BP180-NC16a positivity in parotid and whole saliva 
Parotid saliva  
9/20 +ve 
 
7 +ve P&WS (marked * Appendix 3) 
1+ve P&S (marked × Appendix 3) 
1+ve P&ws&S (marked + Appendix 3) 
11/20 -ve 6 –ve in all P&WS&S 
3 –ve P but +ve WS&S (marked ^ Appendix 
3) 
1 –ve P but +ve WS (underlined Appendix 3) 
1 –ve P but +ve S (marked ° Appendix 3) 
Whole saliva 30/78 +ve (38%) 
12/30 +ve (had parotid samples analysed) 
7 +ve P&WS (marked * Appendix 3) 
3 +ve WS&S (marked ^ Appendix 3) 
1+ve P&ws&S (marked + Appendix 3) 
1 +ve WS (underlined Appendix 3) 
 
 
18/30 +ve (No parotid saliva analysed) 11 +ve WS (underlined Appendix 3) 
7 +ve WS&S (marked ˅  Appendix 3) 
 
+ve (Positive), -ve (Negative), P (Parotid saliva), WS (Whole saliva) and S (Serum) 
 
 
Whole saliva samples (from 4 patients) which were positive for SIgA antibody against 
BP180-NC16a by ELISA (Fig 3-17 a, c-e) and 1 whole saliva sample which was 
negative were fractionated by size exclusion chromatography (Fig 3-17 b).  Secretory 
component and IgA were identified by Western blotting in fractions 14-17 (for all 
patients) corresponding to molecular weight ≥ 250 Kda and in one patient, additionally, 
fraction 20 corresponding to a molecular weight of approximately 170 Kda (Fig 3-17 a).  
Since secretory component has a molecular weight of approximately 80 Kda, these data 
indicate that secretory component is associated with a high molecular weight complex, 
presumably dimeric SIgA.  The fraction with the molecular weight of 170 Kda could be 
as a result of some degradation which may correspond to monomeric IgA.  Fractions in 
which secretory component and SIgA were detected by blots and control fractions (none 
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detected) were further tested on the BP180-NC16a pre-coated ELISA plates to 
investigate antibody activity against BP180-NC16a.   As shown in (Fig 3-18), SIgA 
antibody to BP180-NC16a binding activity was associated with the presence of the high 
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Figure 3-17 Anti-BP180 NC16a activity is associated with SIgA in parotid saliva 
Following size exclusion chromatography of whole saliva, fractions were tested for binding to 
BP180-NC16a by ELISA (a,c-e) (b is a negative sample on ELISA) Chromatogram of whole 
saliva samples from patients with MMP.  Absorbance shown in red (left axis) and reactivity of 
SIgA against BP180-NC16a in individual fractions shown in blue (right axis).  The positions of 
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Figure 3-18 Western blotting of fractions from size exclusion chromatography showing 
results of probing with anti-secretory component antibody and probing with anti-IgA 
antibody 
 
Sample 1 (a) 
Sample 2 (b) 
Sample 3 (c) 
Sample 4 (d) 
Sample 5 (e) 
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Parotid saliva samples were also tested for IgG and IgM antibodies to BP180-NC16a 
(n=20) and all were negative, confirming that the antibodies tested were of the IgA 




Figure 3-19 Parotid saliva samples in MMP, HC and DC tested for IgG and IgM 
antibodies to BP180-NC16a using pre-coated ELISA plates  
The Y-axis represents optical density while the X-axis shows samples tested.  Results show that 
both IgG and IgM antibodies were negative against the BP180-NC16a epitope using the anti-
secretory component antibody further confirming the detection of SIgA.  MMP samples (1-19), 
HC (20-21) and DC (22-23).  HC (healthy control), DC (disease control), SIgA (secretory IgA). 
Finally, the specificity of the anti-secretory component antibody used was tested using 
ELISA.  Among serum samples positive for IgA antibodies to NC16a, (n=6) no 
reactivity was found using the anti-secretory component antibody while there were 
positive reactions with the anti-IgA antibody. This result confirmed that the anti-
secretory component antibody was specific to secretory component only and not IgA 
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Figure 3-20 IgA antibody positive serum samples to NC16a showed no reactivity with anti-
secretory component antibody A 96-well-plate was coated with anti-human IgA, serum 
sample starting 1:100 in 6 doubling dilution tested in duplicate and probed with anti-IgA 
antibody and anti-secretory antibody.  Antibody activity using detection with anti IgA (red 
squares) and using anti secretory component (blue diamonds) in same samples 
 
 B) Sequential antibody titres in MMP patients to BP180-NC16a in 
relation to therapeutic response (Longitudinal Study 1b) 
Samples of serum, whole and parotid saliva from MMP patients were collected 
sequentially.   A total of four samples of each fluid were collected from 22 patients who 
were seen at 3 monthly intervals.  The samples were tested against the commercially 
available BP180-NC16a pre-coated plates for IgG and IgA antibodies in both serum and 
saliva (whole and parotid).  Oral disease severity scores were performed at each visit. 
Changes in antibody titre were seen in the majority of patients over nine months in 
serum (Fig 3-21 a-b) and whole saliva (Fig 3-22 a-b).  Statistical analysis of the 
sequential samples showed that the change in serum IgG and IgA antibodies had a 
significant relationship with the change in severity scores (Spearman r=0.426 p=0.048) 
and (Spearman r=0.455 p=0.033) respectively (Fig 3-23 a-b).  This indicates that the 
change in antibody level (titre), for both IgG and IgA in serum against BP180-NC16a, 
was significantly correlated with the change in oral severity score i.e. disease activity.  
The change in salivary antibodies (IgG and IgA), however, did not correlate 
significantly with the change in severity score.   Notably, in the selected samples the 
titre dropped before the disease activity.  Two representative graphs were plotted as an 
example of serum concentrations of antibodies to BP180-NC16a following therapeutic 
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IgG Antibodies in Serum Against BP180-NC16a in MMP at different
time points












































IgA Antibodies in Serum Against BP180-NC16a in MMP at different
time points











































Figure 3-21 Levels of IgG and IgA antibodies to BP180-NC16a in serum in MMP patients 
at 3-monthly time-points. a) Anti-BP180-Nc16a IgG antibody level in serum at the different 
collected time points b) Anti-BP180-Nc16a IgA antibody level in serum at the different 
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IgG Antibodies in  Whole Saliva Against BP180-NC16a in MMP at
different time points











































IgA Antibodies in Whole Saliva Against BP180-NC16a in MMP at different
time points









































Figure 3-22 Levels of IgG and IgA antibodies to BP180-NC16a in whole saliva in MMP 
patients at 3-monthly time-points. a) Anti-BP180-Nc16a IgG antibody level in whole saliva at 
the different collected time points b) Anti-BP180-Nc16a IgA antibody level in whole saliva at 
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Correlation between change in serum IgG antibodies to BP180-NC16a and
change in ODSS
-2











































Correlation between change in serum IgA antibodies to BP180-NC16a and
change in ODSS
-2










































Figure 3-23 Correlation between the change in anti-BP180-NC16a antibody levels in 
serum (IgG/IgA) and the change in ODSS a) The change in anti-BP180-NC16a IgG antibody 
levels in serum and the change in oral disease severity score (ODSS) (Spearman r=0.426 
p=0.048) b) The change in anti-BP180-NC16a IgA antibody levels in serum and the change in 
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Figure 3-24 Graph showing serial MMP samples (2 representative samples) IgG and IgA 
units to BP180-NC16a in serum and whole saliva (ELISA) as well as oral disase severity 
score   
The X-axis represents 4 serum or saliva samples which were collected at three monthly 
intervals.  BP180-NC16a ELISA results for serum and whole saliva IgG and IgA antibodies, the 
left Y-axis (antibody units).  The oral disease severity score, the right Y-axis (Oral disease 
severity score). Red (IgG antibody to BP180-NC16a in serum), Blue (anti-BP180-NC16a IgA 
antibody in serum), Green (IgG antibody to BP180-NC16a in whole saliva), Purple (anti-
BP180-NC16a IgA antibody in whole saliva) and Turquoise (oral disease severity score) 
 Expression and purification of recombinant BP180-NC16a&BP180-
4575 
With the aim of developing ELISA procedures for analyses of autoantibodies directed 
against the 4575 epitope (residues1365 -1413) of BP180 (Zone et al., 1998) as well as 
NC16a, recombinant proteins fused to GST were expressed in E. coli and purified. 
 
3.4.1 Sub-cloning and expression of GST-fusion proteins using pET15b 
Plasmids pGEX-2TNC16a, pGEX-2T4575 and non-recombinant pGEX-2T were 
purified from cultures of transformed E. coli.  DNA sequence analyses of the plasmids 
confirmed the presence of inserts encoding NC16a and 4575 epitopes (data not shown).  
a) 
b) 
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Recombinant fusion proteins as well as non-recombinant GST were expressed and 
purified by affinity chromatography using glutathione-Sepharose. Yields of proteins 
were consistently low at <500 µg/l culture.  Use of an alternative expression vector was 
therefore investigated and DNA fragments (encoding GST, GST-NC16a and GST-
4575) were sub-cloned into pET15b.     
DNA fragments encoding GST-NC16a, GST-4575 and GST were amplified by PCR 
using the pGEX2T plasmids as templates.  PCR-amplified products were analysed by 
agarose gel electrophoresis and bands corresponding to the expected sizes were evident 
(Fig 3-25). 
 
Figure 3-25 PCR-amplified DNA fragments of GST and GST-fusion proteins pGEX2T 
plasmids were used as templates for PCR-amplification of DNA fragments encoding GST and 
fusion proteins and aliquots of the reaction mixture were analysed by agarose gel 
electrophoresis and bands were visualised by staining with GelRed (0.1%). The composite 
figure shows amplification products: lane a. GST (expected size 778bp); b. GST-4575 (909bp); 
c. GST-NC16a (972bp). Marker (1Kb ladder) was loaded in lane M and the positions of the 0.5 
and 1 kb bands are indicated 
PCR amplified products were digested with NdeI and BamHI ligated into pET15b 
(digested with the same restriction enzymes) and ligation products were used to 
transform E. coli XL-1 blue.  DNA sequence analyses of purified plasmids from 
selected transformants confirmed sub-cloning of the respective inserts.  Expression of 
GST and recombinant fusion proteins using pET15b as expression vector results in the 
insertion of a (His)6 affinity tag at the N-terminus which allows purification by Ni
2+-
affinity chromatography.  Proteins were therefore purified by a 2-step procedure 
involving affinity chromatography with glutathione-Sepharose followed by affinity 
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Figure 3-26 SDS-PAGE analysis of GST and GST-fusion proteins expressed using pET15b 
Purified proteins were analysed by SDS-PAGE and visualised by staining with Coomassie blue. 
The composite figure shows: lane 1, GST-NC16a; lane 2, GST-4575; lane 3, GST. The 
positions of the molecular weight markers (x10-3) are shown on the left 
Purified proteins were analysed by SDS-PAGE as shown in (Fig 3-26).  Bands of the 
expected molecular weights (36.8 kDa, GST-NC16a; 33.6 kDa, GST-4575; 29.2kDa, 
GST) were observed together with some bands of both higher and lower molecular 
weights.  Western blotting with an anti-GST antibody confirmed that all bands were 
recombinant proteins (Fig 3-27).  Some degradation resulting in lower molecular weight 
forms is evident while bands of higher molecular weight may represent dimeric forms. 
The identity of the recombinant proteins was further confirmed by mass spectrometric 
analyses of tryptic digests of excised bands which identified GST peptides as well as 
peptides from NC16a and 4575 epitopes.  Use of the pET expression system resulted in 
levels of protein expression that were much higher than previously (in the range of 10 – 
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Figure 3-27 Western blotting of purified recombinant proteins Purified proteins (loaded as 
in the previous figure) were separated by SDS-PAGE and transferred to nitrocellulose filters for 
probing with anti-GST antibody (panel A). In the control filter (panel B), anti-GST antibody 
was omitted 
3.4.2 Use of recombinant proteins in ELISA 
Optimization of coating with the GST fusion proteins for use in ELISA was investigated 
by testing different concentrations and measuring binding of a positive (from previous 
ELISA determinations) MMP serum sample as shown in (Fig 3-28).  A concentration of 
1.5 µg/ml appeared to be optimal coating concentration.  This was repeated for all 3 
proteins (GST, NC16a and 4575).  Results shown are for GST-NC16a.  
 
Figure 3-28 GST-BP180-NC16a ELISA plate coating optimization Different protein 
concentrations were tested against a positive serum sample and results were reported by optical 
density read at 405 nm 
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In further testing, serum binding to wells coated with GST-NC16a was compared with 
binding to GST.  As shown in (Fig 3-29), a high level of serum binding to GST (with no 
fusion partner) was observed.  Binding of antibody to the GST moiety of the NC16a 
fusion protein may therefore contribute to the OD values shown in (Fig 3-28).  Pre-
absorption of the patient’s serum with lysate of E. coli BL21 expressing GST was 
investigated as a means of reducing the “background” binding to GST.  The absorbed 
serum shows some decrease in binding (approximately 27%) to GST compared with 




Figure 3-29 Serum binding to GST A high level of serum binding to GST (with no fusion 
partner) was observed 
Although the recombinant proteins were purified by a double affinity chromatography 
procedure, it is possible that some E. coli-derived material may be present in the 
preparations and that this could contribute to apparent serum reactivity.  The 
preparations were therefore further purified by size exclusion chromatography and 
tested again as coating antigens in ELISA.  A decrease of 50% in serum binding to GST 
was noted with these preparations.  Subsequently, a positive MMP sample and a 
negative MMP sample (as determined by ELISA using the commercially available pre-
coated NC16a ELISA plates) together with healthy and disease controls were used to 
test an ELISA plate coated with the further purified peptides.  There was no difference 
in the reactivity against NC16a-GST or 4575-GST between any of the MMP samples, 
whether they were positive or negative, and between the controls, both healthy and 
disease controls (Fig 3-31 a-c).   
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Figure 3-30 Reduced optical density of serum reactivity to GST after pre-absorbing the 
MMP serum sample with GST lysate   
a) A positive MMP serum sample was tested against a coating of GST and NC16a without 
lysate pre-absorption b) A positive sample was tested after pre-absorbing the sera with the GST 
lysate and a reduction in optical density can be seen. GST (blue), NC16a (red) and corrected 
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Figure 3-31 Testing MMP, healthy and disease control serum samples by ELISA against 
purified recombinant proteins ELISA plate coated with GST, GST-NC16a and GST-4575 
after further purification by size exclusion chromatography. a) Positive MMP sample b) 
negative MMP sample both resulting in similar OD (tested in 4 doubling dilutions 1:100, 1:200, 
1:400 and 1:800). c) Healthy control (HC) and disease controls; LP (Lichen planus) PV 
(Pemphigus vulgaris) resulting in OD as high as MMP samples (tested in duplicates 1:100). 
There was no discrimination by ELISA testing between the different samples; positive MMP, 
negative MMP, healthy control and disease control (LP and PV).  All samples were pre-
adsorbed with GST lysate. OD (optical density) 
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In this study, whether IgG and IgA antibodies to the NC16a domain of BP180 could be 
detected by ELISA in both the serum and saliva of  MMP patients and whether these 
biomarkers could be used in the analysis of disease severity and therapeutic response 
was explored.  Moreover, whether there was an association with carefully defined 
clinical subgroups was investigated.  This novel data has shown that whole saliva 
samples were reactive to the NC16a domain of BP180 with IgG antibodies in 14% of 
patients , IgA antibodies in 38% and either overall in 44% of the patients.  In addition, 
locally produced secretory IgA antibodies (SIgA) to BP180-NC16a have also been 
demonstrated for the first time in saliva of these patients.   
 
MMP antibodies in serum 
In this study ELISA assays have been used to detect levels of IgG and IgA antibodies in 
both saliva and serum to the NC16a domain of BP180.  The data has shown that MMP 
sera were reactive to the NC16a domain of BP180, with IgG antibodies in 36%, IgA 
antibodies in 28% or overall in 48% of the patients.  These results are comparable to 
previously published work where 8/18 (44%) of patients were positive to IgG antibodies 
against the NC16a domain of BP180 on ELISA (Calabresi et al., 2007, Murakami H. et 
al., 1998).  Similarly, data from collaborators has shown that the reactivity to the C-
terminal domain (BP180-4575) on Western blot in which 7/39 (18%) MMP patients 
were positive for IgG antibody to BP180-4575, and 8/39 (21%) MMP patients were 
positive for IgA antibody to BP180-4575 was similar to those reported by Murakami 
where 30 % were positive (Murakami H. et al., 1998).   
The results however, showed a lower percentage of reactivity with IgG antibody to the 
C-terminal domain of BP180 (4575) than previous studies positive in about 50% 
(Schmidt and Zillikens, 2013, Hayakawa et al., 2014).   
Furthermore, 6/39 (15%) showed IgG antibody reactivity against laminin 332 (work 
undertaken by collaborators) which corresponds to previous literature and our 
collaborators own published results (Schmidt and Zillikens, 2013, Hayakawa et al., 
2014).   
When the cohort was subdivided into clinical phenotypes i.e. pure oral, pure ocular and 
multisite disease, results showed that IgG antibody to BP180-NC16a was highest in 
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both the serum (46% 23/50) and whole saliva (18% 8/50) of multisite disease patients.  
This was supported by finding a positive correlation between the number of sites in the 
multisite disease group and the IgG antibody titre in serum (p =0.0174) and whole 
saliva (p =0.0198) to BP180-NC16a.  This suggests either that antibodies reflect the 
greater degree of antigen challenge found in multisite patients or that antibodies of a 
certain titre and avidity may result in multisite disease. 
 Interestingly, IgG antibody reactivity to BP180-NC16a was not detected in the pure 
ocular group.  Contrarily, this group of patients had the highest IgA reactivity to BP180-
NC16a in both serum 6/16 (38%) and whole saliva 7/16 (44%) when compared with the 
pure oral and multisite disease subgroups.  In the literature, a link between the pure 
ocular subgroup and β4 integrin reactivity has been proposed (Chan, 2012).  These 
results suggest a connection between pure ocular MMP and IgA reactivity against 
BP180-NC16a.  A recent finding of IgA antibody to the C-terminal domain of BP180 
has been reported (Solano-López et al., 2014).  In this cohort one pure ocular patient 
was associated with IgA antibodies to the 4575 domain of BP180.  Pure ocular 
pemphigoid patients generally have lower autoantibody levels detected, indeed DIF is 
reported as negative in 14-40% patients (Thorne et al., 2004, Bernauer et al., 1994, 
Kirzhner and Jakobiec, 2011). 
The relatively low positivity of circulating autoantibodies in the series (46%), in 
addition to low numbers showing circulating antibodies in the pure ocular group (38%), 
may in part be due to the majority of patients being on long-term treatment and thus 
having low levels of disease activity as has been shown elsewhere (Sami et al., 2002).   
It is also well recognised that MMP patient sera target one or more additional basement 
membrane zone (BMZ) antigens (Oyama et al., 2006).  Setterfield et al detected serum 
IgG and IgA antibodies in MMP patients by IIF on salt-split skin resulting in 83.6% and 
61.2% positivity respectively (Setterfield J. et al., 1998).  Since IIF corresponds to 
reactivity against any or many of the BMZ components, this may explain the higher 
positivity with their technique.  Nonetheless, IIF results for this study show a 35% 
positivity which is similar to our ELISA results.  Using a combination of ELISA plates 
including additional epitopes of BP180, laminin 332, α6 and β4 integrin may 
significantly increase the diagnostic sensitivity of serum.   
In this study, sequential samples have shown that the change in antibody levels of both 
IgG and IgA targeting BP180-NC16a in serum correlated significantly with an 
improved clinical severity (i.e. the therapeutic response to treatment) (Spearman 
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r=0.426 p=0.0482) and (Spearman r=0.455 p=0.0334) respectively.  This was also 
shown by Setterfield et al and confirmed in a recent study (Di Zenzo et al., 2014, 
Setterfield  et al., 1999). 
MMP Antibodies in saliva 
It has been proposed that in comparison to blood,  saliva may provide more sensitive 
and specific biomarkers for oral diseases (Wong, 2006).  Salivary diagnostics have been 
reported throughout the literature and have advanced dramatically as they are being 
used in the diagnosis of various conditions, including cancers (Arif et al., 2015, Cheng 
et al., 2014).   
Since MMP predominantly affects the oral cavity in many patients, saliva may be a 
more sensitive medium.  IgG antibodies are present in saliva as a serum transudate from 
gingival crevicular fluid, mucosal inflammation or via an ulcer and therefore the 
detection of these is likely to relate to the oral disease activity.  Furthermore, it is has 
been shown that the amount of IgG in saliva as a transudate from the gingival crevice, is 
related to the degree of inflammation in periodontal disease (Brandtzaeg, 2007).  In 
pemphigus vulgaris a high anti-Dsg3 IgG antibody level in whole saliva has been 
demonstrated in 94% of untreated patients (Hallaji et al., 2010, Hosseein Mortazavi, 
2015).  IgA antibodies, in addition to transudate from serum, may additionally appear in 
saliva as secretory IgA (SIgA) (i.e. produced from within the glands) either from major 
or minor salivary glands.  
To investigate whether SIgA antibodies were present, parotid samples were included in 
addition to whole saliva.  IgG antibodies to BP180-NC16a were detected in (11/78) 
(14%) of the MMP cohort in whole saliva.  As expected, IgG antibodies were not 
detected in parotid saliva.  The low percentage positivity in whole saliva may reflect the 
fact that the majority of patients had well-controlled disease at the time of sampling; 
only 68% of the patients had a positive oral disease score.  In addition, it is possible that 
factors such as the presence of mucins in saliva may reduce the sensitivity of the assay 
for antibody detection.  It would be interesting to compare the specific IgG positivity at 
presentation in MMP patients with very active disease and then to correlate the titre 
with a disease severity score.  As stated, patients with multisite disease had the highest 
amounts of IgG antibody to BP180-NC16a in both serum and whole saliva (46% and 
18%, respectively).  Therefore it was not surprising to find a positive relation between 
the amount of IgG antibody to BP180-NC16a in whole saliva and the oral disease 
severity score in this subgroup.    
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Detection of secretory IgA antibody 
IgA antibodies were also detected in both whole and parotid saliva.  In whole saliva 
IgA antibodies were found in 30/78 (38%) of MMP patients tested, which was higher 
than for serum 22/78 (28%).  Parotid samples were tested in an attempt to differentiate 
between IgA as a serum transudate (detected as a monomer and IgA positive) from local 
production (mucosally produced i.e. secretion from the gland) (dimeric IgA and 
secretory component positive).  Interestingly, antibodies in almost half of parotid 
samples were both IgA and secretory component positive.  Size exclusion 
chromatography showed activity with a high molecular weight complex in four patients 
who had tested positive on ELISA.  These results were also confirmed by testing for 
IgG and IgM antibody in parotid samples of these MMP patients and were not detected.  
In addition, IgA antibody positive serum showed reactivity to anti-IgA antibody alone 
but not with the anti-secretory component antibody. 
The precise mechanism of how these antibodies have been stimulated has not been 
ascertained.  However, BP180 is found in salivary gland basement membranes 
(Gonzalez et al., 2011).  Although patients do not present with symptoms of salivary 
gland involvement, it is possible to speculate that subclinical damage to the gland may 
subsequently result in exposure of BP180 within the basement membrane of the gland, 
leading to the production of local IgA autoantibodies directed specifically against 
epitopes of BP180.  Furthermore, germinal centres within salivary glands have been 
reported in Sjögrens disease patients, which may help explain where these mucosal 
antibodies are being produced (Stott et al., 1998, Szodoray et al., 2005, Le Pottier et al., 
2009).   Alternatively, there may be distant mucosal site stimulation; since MMP 
patients may have other mucosal sites affected e.g. conjunctiva, nasopharynx, genital or 
oesophagus (MacPherson et al., 2008).  
In this series, 4/9 of the patients producing specific IgA in their parotid glands had 
either multisite involvement including the oral cavity, conjunctiva, genital and/or 
nasopharynx, whilst 3/9 showed only oral involvement at the time of sampling and the 
remaining 2/9 were pure ocular patients.  A further possibility is that SIgA in whole 
saliva may be due to secretion from the other major salivary glands or perhaps more 
importantly, from minor salivary glands which are known to be the major source of 
SIgA in saliva as minor salivary glands would give rise to secretory component positive 
antibodies into whole saliva (Brandtzaeg, 2007).  Minor salivary glands are distributed 
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throughout the oral mucosa.  Injury to these sites may damage the minor salivary glands 
similarly exposing the target antigen and stimulating local antibody production thus 
inducing further lesions.  This might possibly help to explain the propensity for oral 
lesions on the soft palate where there are many minor salivary glands.  This maybe 
further supported by this data since 4/6 of whole saliva samples tested for SIgA were 
negative in parotid saliva.   
While oral involvement in MMP is sometimes considered to be a mild form of the 
disease, lesions often take several months to heal.  In addition, the detection of serum 
anti-BMZ antibodies is often low or absent in mild oral MMP (Carrozzo et al., 2004). 
Thus it is puzzling why the disease is sometimes so active.  It is possible that locally 
produced autoantibodies found in one secretion may also be found in others (Mestecky, 
1987).  So in a common mucosal system, the antibodies detected in parotid saliva may, 
in part at least, be stimulated by disease activity at sites other than oral.  Some of these 
patients have ocular involvement or genital involvement and so could be producing 
these secretory antibodies in other mucosal sites.   
 
MMP antibody avidity 
Indirect immunofluorescence results may be low in MMP (50-80%) (Schmidt and 
Zillikens, 2013).  Some patients may have very active disease even though the levels of 
detected antibodies are low or absent.  This might be explained by the avidity of 
antibodies to a certain target antigen.  Expression and purification of GST fusion 
proteins with the NC16a and 4575 epitopes was undertaken with the aim of developing 
ELISA procedures for the 4575 epitope.  Sub-cloning into the pET15b expression 
vector markedly improved the yield of recombinant proteins from approximately 0.5 
mg/l bacterial culture to 10-20 mg/l culture.  In initial experiments to establish ELISA 
procedures, recombinant proteins and GST (as control) were used as coating antigens to 
test sera previously identified as positive or negative for binding to NC16a (with the 
commercially available plates).  In contrast to the previous findings, both patient and 
control sera showed similar binding activity to the fusion proteins as well as significant 
binding to GST (absorbance values of approximately 50% of those of the fusion 
proteins).  The possibility that the presence of antibodies against GST in the sera was 
obscuring differences in binding to BP180 epitopes was investigated by pre-absorption 
of lysates of GST-expressing E.coli.  While this reduced binding to GST in control 
wells, it did not improve discrimination between binding of patient and control sera to 
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the NC16a and 4574 fusion proteins.  Thus it seems unlikely that recognition of the 
GST fusion proteins by both patient and control sera can be attributed to antibodies 
directed against GST. 
GST-fusion proteins have been used extensively to investigate antibody binding to 
autoantigen epitopes and few report significant binding to GST alone.  In analyses of 
serum immunoreactivity to an epitope of the human muscarinic acetylcholine receptor 
3, expressed as a GST fusion protein, ELISA absorbances of sera from 40 healthy 
control patients were all below 0.2 while values for 33/40 patients were 0.3 or higher 
(Marczinovits et al., 2005).  GST has been reported as an autoantigen in patients with 
glaucoma (Yang et al., 2001) where anti-GST antibodies were present sera of 52% of 
patients and 20% of age-matched control subjects.  In a preliminary study, GST has 
been suggested as an autoantigen in multiple sclerosis with anti-GST activity reported 
in cerebrospinal fluid of 27% of patients compared with 25% of normal controls 
(Laffitte et al., 2005).  Although this does not seem a strong case for identification of 
GST as an autoantigen, it does point to significant anti-GST activity in patients as well 
as in healthy controls.  In further work, it may be appropriate to investigate alternative 
fusion partners for the NC16a and 4574 epitopes as well as investigating further means 
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 Conclusion 
To my knowledge, this is the first study demonstrating both IgG and IgA antibodies to 
BP180-NC16a in saliva.  There has only been one previous study testing salivary anti-
BMZ antibodies in MMP patients.  Andreadis et al, tested 12 MMP serum and whole 
saliva samples for IgG reactivity, using commercially available BP180-NC16a  pre-
coated  ELISA plates (Andreadis D, 2006).  They were unable to show IgG reactivity in 
either serum or whole saliva and the authors proposed that MMP patients produced 
autoantibodies that were reactive against the C-terminal domain of BP180 and not the 
NC16a domain.  Although we and others have shown that both IgG and IgA 
autoantibodies may target the C-terminal domain of BP180, in this study the presence of 
autoantibodies in both serum and saliva against the NC16a epitope of BP180 has been 
demonstrated (Hayakawa et al., 2014, Lee et al., 2003, Murakami H. et al., 1998).  
Moreover, the results have also shown that ELISA testing of serum samples from MMP 
patients for IgG and IgA antibodies to BP18-NC16a can be related to oral disease 
activity and therapeutic response.  
These novel findings have shown that not only are NC16a specific salivary IgA 
antibodies present in MMP patients, but that this medium may have a greater sensitivity 
for detecting IgA.  Further investigation in a larger cohort including patients with 
untreated disease and using parallel mucosal secretions, e.g. tears, will be most 
informative.  To further increase the sensitivity of saliva as a diagnostic and disease 
monitoring medium, the additional testing for reactivity with laminin 332, α6 and β4 
integrin is likely to be most informative.  
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 Summary 
 Serum IgG antibodies against the NC16a domain of BP180 were detected in 
28/78 (36%) of MMP patients  
 Serum IgA antibodies were found in 22/78 (28%).  Combined serum IgG and/ or 
IgA antibodies were positive in 38/78 (48%) patients 
 IgG antibodies to BP180-NC16a were detected in 11/78 (14%) of MMP whole 
saliva samples shown for the first time 
 IgA antibodies to BP180-NC16a were detected in 30/78 (38%) of MMP patients 
in whole saliva.  Combined whole saliva specific IgG and/ or IgA was positive 
in 34/78 (44%).  Shown for the first time and as sensitive as serum IgA detection 
 Both SIgA and IgA antibody 9/20 (45%) were positive in parotid saliva samples 
which has not been reported previously 
 There was a positive association between the presence of serum IgG antibodies 
to BP180-NC16a with multisite disease lesions (X2 = 11.9 p =0.003) 
 A significant association was found between the presence of IgA antibody 
against BP180-NC16a in whole saliva and the presence of both oral and/or 
ocular disease (X2 = 6.23 p =0.016)   
 Pure ocular MMP patients showed no IgG antibody reactivity against BP180-
NC16a in either serum or saliva; however they were positive for IgA antibody to 
BP180-NC16a in serum and whole saliva (38% and 44%) respectively. 
 The higher the number of sites involved in multisite MMP, the higher the IgG 
antibody titre in serum and whole saliva against BP180-NC16a (p =0.017 and p 
=0.019, respectively) 
 Sequential samples showed that the change in serum antibodies (IgG and IgA) 
have a significant relation with the change in severity scores (p=0.048 and 
0.033) respectively, following therapeutic response 
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4 Results MMP Study 2 
Serum and salivary antibodies in MMP to alpha 6 beta 4 Integrin 
in relation to clinical phenotype and disease activity (Cross-
sectional study) 
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4 Serum and salivary antibodies in MMP to alpha 6 beta 4 Integrin 




MMP is a heterogeneous disease with various target antigens within the basement 
membrane zone.  BP180, which is considered the main target antigen, was studied in the 
previous chapter.  In this section, 64 is the antigen of interest.   It has been proposed 
that in oral and ocular pemphigoid, the target antigens are the α6 and β4 fragments 
respectively (Rashid et al., 2006a, Rashid et al., 2006b).  However, other antigens 
including BP180, have been shown to be the most prominent target antigens in both 
subgroups (Hayakawa et al., 2014, Solano-López et al., 2014, Calabresi et al., 2007).  
Consequently, no specific antigen has been definitively associated with a site-specific 
phenotype as yet.   
No study thus far has reported salivary antibodies against the α6β4 integrin.  Since pure 
oral pemphigoid patients have been reportedly linked with serum antibodies to α6 
integrin and since autoantibodies to BP180-NC16a domain could be detected in saliva 
as described in chapter 3, testing saliva samples from MMP patients for autoantibodies 
against α6β4 integrin was carried out.   
The aims were to:  
1) Identify the whether serum and saliva IgG and/or IgA autoantibodies to 64 
were present in our cohort of MMP patients 
2) Identify whether there was an association between autoantibodies against α6β4 
integrin and carefully defined clinical subgroups 
3) Determine antibody avidity using BIAcore technology 
The cohort of MMP patients was subdivided into ‘pure ocular’, ‘pure oral’ and multisite 
disease and the results were further analysed.  The presence of serum or saliva 
antibodies against α6β4 integrin was determined by ELISA using a soluble form 
(extracellular domains) of the integrin.  Western blotting was investigated as a means of 
differentiating between α6 and/or β4 reactivity in antibody positive patients.  Surface 
plasmon resonance (spr)-based assays were also investigated as a potential means to 
measure avidity of autoantibodies.   
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 Serum, whole and parotid saliva 
In this study, matched serum and whole saliva was tested using ELISA plates which 
were coated using a human recombinant 64 integrin (see Chapter 2: Materials and 
methods).  Samples from one hundred MMP patients, forty healthy controls (HC) and 
36 Disease controls (DC) (including 15 LP and 21 PV) were tested.  The mean IgG 
antibody values in serum (0.325±0.27) and in whole saliva (0.16±0.18) were 
significantly different than those of healthy controls in serum (0.07±0.11) and in whole 
saliva (0.08± 0.07) by using one-way ANOVA (p<0.0001).  Values greater than the 
mean +2 SD of the healthy controls were considered positive.   
The results using ELISA showed that 36/100 (36%) of MMP patients were positive for 
IgG antibody to 64 in serum and 18/100 (18%) of MMP patients were positive for 
IgG antibody to 64 integrin in whole saliva (Fig 4-1 a-b) (Table 4-1).  Oral disease 
was clinically present in 74/100 (74%) of patients, all of whom had active disease at the 
time of blood and saliva sampling with oral disease severity scores ranging from 5-43 
(see Appendix 3).  IgA antibody to 64 in serum, whole or parotid saliva was not 
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Serum IgG Antibody  Against a6b4 Integrin in MMP, Healthy and Disease
Controls



















Saliva IgG Antibody  Against a6b4 Integrin in MMP, Healthy  and Disease
Controls






















Figure 4-1 IgG antibody against α6β4 integrin in serum and whole saliva in MMP 
patients, healthy and disease controls using ELISA (mean +/- SD)  The Y-axis represents 
optical density values while the X-axis shows the sample groups tested.  Values greater than the 
mean + 2SD of the HC were considered positive.  The horizontal I bar represents the cut-off. a) 
Serum IgG antibody against α6β4 integrin showed 36/100 (36%) positivity.  b) Whole saliva 




Serum IgG Antibody Against α6β4 Integrin in MMP, Healthy and Disease 
Controls 
Saliva IgG Antibody Against α6β4 Integrin in MMP, Healthy and Disease Controls 
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Serum IgA Antibody Optical Density Against a6b4 Integrin in MMP,
Disease Controls and Healthy controls




















Saliva IgA Antibody Optical Density Against a6b4 Integrin in MMP,
Disease Controls and Healthy controls




















Figure 4-2 IgA antibody against α6β4 integrin in serum and whole saliva in MMP patients, 
healthy and disease controls using ELISA (mean +/- SD) The Y-axis represents optical 
density values while the X-axis shows the sample groups tested.  a) Serum (MMP n=50, HC 
n=5, DC n=8) b) Whole saliva (MMP n=100, HC n=22, DC n=26).  There was no significant 
difference between the Means of IgA antibody level in all three subgroups tested.  Therefore, 





Saliva IgA Antibody Against α6β4 Integrin in MMP, Healthy and Disease 
Controls 
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Table 4-1 Study 2 ELISA results for IgG antibodies to α6β4 integrin in serum and whole 
saliva 
Study 2 MMP 
(n=100) 









A positive correlation was found between IgG antibody in serum and whole saliva to 
α6β4 integrin (Spearman r =0.493 p <0.0001) (Fig 4-3).  There was also a positive 
relationship between IgG antibody in whole saliva against α6β4 integrin and oral 
disease severity score (Spearman r =0.276 p =0.0055) (Fig 4-4).   
Correlation between serum and whole saliva IgG




































Figure 4-3 Correlation between IgG antibodies to α6β4 integrin in serum and whole saliva 






Correlation between serum and whole saliva IgG antibodies against α6β4 integrin 
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Correlation between Saliva IgG Antibody  Against A6B4 and Oral Disease
Severity Score





















Figure 4-4  Correlation between IgG antibody in whole saliva against α6β4 integrin and 
the oral disease severity score of MMP patients (Spearman r =0.276 p = 0.0055) OD 
=optical density 
Relationship between antibodies and clinical phenotype 
When clinical subgroups were analysed, the results for serum showed that in pure oral 
MMP 14/33 (42%) were positive for IgG antibody to α6β4 integrin.  In the pure ocular 
subgroup, 4/16 (25%) were positive, while the multisite subgroup showed 18/51 (35%) 
positivity (Fig 4-5 a).  A positive correlation between IgG antibody in serum against 
α6β4 and the oral disease severity score in the pure oral subgroup was found (Spearman 
r =0.365 p =0.037) (Fig 4-6). 
For saliva, IgG antibody to α6β4 integrin was detected in 7/33 (21%) of pure oral 
patients, 11/51 (22%) of multisite disease and none of the pure ocular group (Fig 4-5 b) 
(Table 4-2).  The multisite subtype had the highest percentage of positivity of IgG 












Correlation between saliva IgG antibodies against α6β4 integrin and oral disease 
severity score 
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Clinical phenotype antibody distributions:  
 
Serum IgG Antibody  Against a6b4 Integrin in MMP
subgroups (Pure oral, pure ocular and multisite)



















Saliva IgG Antibody  Against a6b4 Integrin in
MMPsubgroups (Pure oral, pure ocular and multisite)





















Figure 4-5 MMP patients subgrouped according to clinical phenotype and tested for IgG 
antibody against α6β4 integrin in serum and whole saliva (Mean +/- SD) Subgroups include 
MMP cohort (n=100), pure oral (n=33), pure ocular (n=16) and multisite disease (n=51).  The 
Y-axis represents the OD values.  The X-axis shows the sample groups tested.  Positivity was 
established at values greater than the mean + 2SD of the HC group as previously stated. a) 
Serum IgG antibody against α6β4 was positive in 36/100 MMP (36%), pure oral 14/33 (42%), 
pure ocular 4/16 (25%) and 18/51 (35%) were positive in the multisite group. b) Whole saliva 
IgG antibody against α6β4 were positive in 18/100 MMP (18%), pure oral 7/33 (21%), pure 




Serum IgG Antibody Against α6β4 Integrin in MMP Subgroups (Pure oral, pure 
ocular and multisite) 
Saliva IgG Antibody Against α6β4 Integrin in MMP Subgroups (Pure oral, pure 
ocular and multisite) 
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Correlation between Serum IgG Antibody in Pure Oral MMP and Oral
Disease Severity Score




























Figure 4-6 Correlation of IgG antibody OD against α6β4 in serum in pure oral MMP 
subgroup and the oral disease severity score (Spearman r =0.365 p =0.037) OD =optical 
density 
 
Table 4-2 Summary of IgG antibodies in serum and whole saliva against α6β4 ELISA by 
clinical phenotype distribution 










IgG Serum  14/33 (42%)* 4/16 (25%) 18/51 (35%) 
IgG Whole Saliva 7/33 (21%) 0 11/51 (22%)* 













Correlation between Serum IgG antibodies against α6β4 integrin and oral disease 
severity score in Pure Oral MMP 
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 Investigation of surface plasmon resonance for measuring binding of 
serum autoantibodies to α6β4 integrin 
The α6β4 integrin (approximately 2,000 resonance unit -RU-) was covalently coupled to 
the surface of flowcell 2 (Fc2) of a sensorchip while Fc1 (no protein coupled) served as 
a reference cell.  Anti-α6 or anti-β4 polyclonal antibodies (see Chapter 2, used in 
western blotting below as well) were injected separately over the sensorchip surface to 
confirm immobilisation of the integrin and exposure of at least some epitopes.  As 
shown in Fig 4-7, both antibodies bound to the immobilised ligand.  The anti-β4 
antibody bound much more strongly with KD (equilibrium dissociation constant) of 
approximately 3x10-10 M compared with the anti-α6 antibody that bound with KD of 
approximately 1.6x10-7 M (Fig 4-7).  In contrast, no binding was evident when patients’ 
sera was injected over the sensorchip surface (Fig 4-8).  The decrease in the spr signal is 
the result of changes in the refractive index of the solution due to the presence of serum 
components.  
 
Figure 4-7 Binding of anti-α6 and anti-β4 antibodies to immobilised integrin Integrin 
(approximately 2,000 RU) was immobilised on the sensorchip surface of Fc2 while Fc1 served 
as a control surface. Superimposed difference sensorgrams show binding of each antibody. 
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Figure 4-8 Superimposed sensograms depicting binding activity of autoantibodies to α6β4 
integrin  The Y-axis shows the response (in resonance units) and the X-axis is the time in 
seconds.  α6β4 integrin was immobilized on the sensor chip of Fc2 while Fc1 was left blank. 
The resulting sensograms were calculated by subtracting the signal of Fc1 from Fc2.  Sheep 
anti-β4 antibody (1μM) was injected over the sensorchip surface as control for antibody binding 
(dark blue).  a) A serum sample (MMP JA055, positive on α6β4 ELISA) was loaded at four 
dilutions (1in 5, 1in 10, 1in 50 and 1in 100) b) A second serum sample (MMP MS049, positive 
on α6β4 ELISA) was loaded (1in10 dilution) and repeat sensorgrams are shown 
 Investigation of specificity of anti-integrin antibodies 
The molecular weights of the α6 and β4 extracellular domains in the complex, used 
above for ELISA, are 125-135 kDa and 100-110 kDa, respectively (R&D Systems: 
https://www.rndsystems.com/products/recombinant-human-integrin-alpha-6-x1-beta-4-
protein-cf_5497-a6).  The two polypeptides were therefore separated by SDS_PAGE 
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and transferred to nitrocellulose filters for Western blotting.  As shown in (Fig 4-9 a), 
identity of the separated polypeptides was confirmed by probing with anti-α6 or anti-β4 
polyclonal antibodies (see Chapter 2) (lanes 1and 2 respectively) and (Fig 4-9 b lane 2). 
Sera from nearly all patients as well as healthy controls appeared to react with the α6 
polypeptide while little or no reactivity towards the β4 polypeptide was evident (Fig 4-
9).  In controls where serum (or first antibody) was omitted, no bands were observed 









Figure 4-9 Western blots depicting reactivity of serum samples from MMP, disease and 
healthy controls against the α6β4 integrin α6β4 integrin on a reducing gel (α6 125 Kda β4 
100 Kda), M (marker, numbers on the side are the molecular weights), - (no primary antibody), 
a:1&2 b:1 (probing with anti-α6 / anti-β4 polyclonal antibodies to confirm identity of the 
separated polypeptides), +ve MMP (MMP serum samples positive to α6β4 on ELISA), -ve 
MMP (MMP serum samples negative to α6β4 on ELISA), DC (disease controls include PV, 
LP), HC (healthy control). MMP, DC and HC show bands corresponding to α6 molecular 
weight (125 Kda) with minimal β4 reactivity (100 Kda).  There was no demarcation between 
the sample groups tested a) A representative western blot showing nonspecific binding to α6 in 
all tested groups with minimal β4 reactivity b) A representative western blot showing 
nonspecific binding to α6 in all tested groups with minimal β4 reactivity as well as a negative 
control that shows no reactivity with the α6 fragment.  These representative Western Blots show 
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IgG antibodies to α6β4 integrin were detected in 18/100 (18%) of whole saliva samples 
of MMP patients.  This has not been shown before.  Together with the previously 
mentioned results of IgG and IgA antibody detection to BP180-NC16a in saliva (44%), 
these data help support the notion that saliva provides a suitable diagnostic medium for 
MMP patients.  The detection of salivary antibodies offers an easier medium to 
diagnose patients as it is painless and easier to acquire.  
 Serum IgG antibodies were also detected in 36/100 (36%) of samples from MMP 
patients.  The actual prevalence of autoantibodies to the α6β4 integrin in MMP is 
unclear (Leverkus et al., 2001).  Previous studies refer to serum IgG antibodies to α6 
integrin or the β4 integrin separately.  However, a case report describing the presence of 
IgG antibodies to both subunits of α6β4 separately in serum of a pure oral MMP patient 
was published recently (Miyamoto et al., 2014).  Therefore, the report possibly 
represents the first study to detect IgG antibodies directed to both fragments of the α6β4 
integrin.  Furthermore, the patient showed antibodies to the BP180-NC16a epitope with 
no reactivity against the C-terminal domain of BP180.  These findings further support 
the heterogeneity of MMP and lack of a clear association between the various clinical 
sub-types and target antigens.  Further studies testing both α6 and β4 integrin fragments 
separately should be conducted. 
The current MMP cohort was then subdivided into pure oral, pure ocular and multisite 
disease patients and the findings were analysed.  Interestingly, the pure oral subgroup 
showed the highest positivity of IgG antibodies to α6β4 in serum 14/33 (42%), and 7/33 
(21%) in whole saliva.  
It has been proposed that 100% of untreated oral pemphigoid patients bind exclusively 
to the α6 fragment on Western blot (Rashid et al., 2006a).  However, sera from oral 
pemphigoid patients’ have also been shown to react to both the C-terminal and the 
NC16a epitopes of BP180, the main target antigen in MMP (Calabresi et al., 2007, 
Oyama et al., 2006, Carrozzo et al., 2004).  More recently, Hayakawa et al reported that 
17/30 (57%) of pure oral pemphigoid patients showed IgG antibody to the C-terminal 
domain of BP180 and laminin 332 (Hayakawa et al., 2014).  Therefore, comparative 
results in the literature vary.   
In the multisite disease group, 18/51 (35%) showed IgG antibody reactivity to α6β4 in 
serum and 11/51 (22%) in whole saliva.  Contrary to these findings, it has been 
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proposed that anti-α6 IgG antibodies are not detected in multisite disease patients but 
are specific to oral pemphigoid patients (Di Zenzo et al., 2014).    However, other 
studies have reported that multisite disease patients have IgG antibodies directed 
towards the β4 integrin (Rabelo et al., 2014, Leverkus et al., 2001).  Thus there is 
conflicting data in the literature. 
In the pure ocular subgroup, IgG antibody to α6β4 was detected in a quarter of the 
serum samples from MMP patients but none were detected in whole saliva.  Since the 
results describe reactivity against the whole integrin (α6β4) and not to the separate 
subunits, a link between a specific target antigen and clinical phenotype has yet to be 
confirmed.  Patients with clinical features of ocular pemphigoid with other site 
involvement have been reported to show reactivity against BP180 antigen as well 
(Letko E. et al., 2000).  However, in the literature, the β4 integrin is considered by some 
as the ocular pemphigoid antigen (Tyagi et al., 1996).  Antibody titre to the β4 integrin 
in pure ocular patients has been reported to correlate with disease severity (Letko E. et 
al., 2000).  Leverkus et al described a case of MMP with severe multisite involvement 
(oral, ocular, laryngeal and genital mucosal involvement) where antibody reactivity was 
detected to both BP180 and the  β4 integrin (Leverkus et al., 2001).  Furthermore, he 
found that the antibody titre to both antigens correlated with disease severity.  In 
addition, it has been reported that a patient with pure ocular pemphigoid showed IgG 
antibody reactivity to the β4 integrin  as well as both IgG and IgA antibody to the C-
terminal domain of BP180 (Solano-López et al., 2014).  This highlights the ongoing 
challenge of associating clinical phenotypes with specific antigens.   
A possible association between serum and saliva IgG antibodies to α6β4 and oral 
disease severity scores was looked at.  A positive correlation was found between IgG 
antibody to α6β4 in serum and the oral disease severity score (Spearman r =0.365 p 
=0.037).  Similarly, a positive association was found between IgG antibody to α6β4 in 
whole saliva and oral disease severity score (Spearman r =0.276 p = 0.0055).   In 
addition, a positive correlation was found between IgG antibodies to α6β4 in both serum 
and saliva (Spearman r =0.493 p <0.0001) which supports the presence of IgG antibody 
in whole saliva to α6β4 as a transudate from serum.  The extent and severity of disease 
was correlated with antibody titre to α6β4 in other reports supporting our findings 
(Rabelo et al., 2014, Sami et al., 2002).   In a report about 2 sisters, one with mucosal 
lesions while the other had predominantly cutaneous involvement, levels of anti-β4 
antibodies in serum were detected in the active stage of MMP but not in remission by 
immunoblot (Rabelo et al., 2014).  In addition, Sami et al tested serum samples in 7 
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patients with severe oral pemphigoid by immunoblot using bovine gingival lysate as a 
substrate.  They found that in patients with active disease the anti-α6 antibody could be 
detected but not in patients in remission.  In this cohort, 39/100 (39%) of the MMP 
patients with oral disease severity scores < 10 did not show IgG antibodies to α6β4. 
 IgA antibodies to α6β4 integrin were not detected in sera or whole saliva samples of 
our MMP patients.  Consequently, IgA did not provide a suitable diagnostic biomarker 
in either serum or whole saliva.  There have been no reports of IgA antibody reactivity 
to α6β4 integrin in MMP patients in either serum or whole saliva in the literature.   
No binding was detected to the α6β4 integrin by using BIAcore technology.  The 
observation that anti-α6 and anti-β4 antibodies bound to the immobilised integrin 
indicates that at least some epitopes remain accessible to fluid-phase antibody following 
covalent attachment to the sensorchip surface.  The absence of any signal on injection of 
sera from patients over the sensorchip suggests that antibodies are either at very low 
concentrations or of low affinity.  
As the MMP cohort included both pure oral and pure ocular groups, it would have been 
informative to assess specific target antigen i.e. α6 and β4 separately.  However, the 
Western blot results were inconclusive due to apparent non-specific binding to α6 
polypeptide and minimal reactivity with the β4 polypeptide.  A commercially available 
recombinant human α6β4 protein was used, which may account for these unexpected 
results.  The most sensitive method for autoantibody detection against α6β4 suggested is 
by using α6β4 from bovine gingival lysate (Schmidt and Zillikens, 2013).   
Furthermore, α6 specific antibodies were detected when using extracts from human 
gingival lysate (Di Zenzo et al., 2014).  Immunoblotting of a hemi-desmosome-rich 
fraction has also been used to differentiate between the two subunits of the 64 
integrin (Miyamoto et al., 2014).  
With regard to the β4 integrin, previous studies have tested for reactivity to the whole 
length molecule (205 Kda) or the intracellular domain (140 Kda) but not to the 
extracellular domain (100 Kda) (Bhol et al., 2003, Bhol et al., 2000).  Since the protein 
used in this study comprises only the extra-cellular domain of each polypeptide, this 
might explain the minimal reactivity to β4 integrin on Western blots.  In contrast, 
binding to the α6 integrin on Western Blots was noted in all subgroups tested. 
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 Conclusion 
These results showed the presence of IgG antibody to the α6β4 integrin in whole saliva 
of MMP patients.  This has not been previously reported.  Furthermore, the IgG 
antibody levels to the α6β4 integrin in both serum and whole saliva have a significant 
association with disease severity.  Salivary  and serum IgG antibodies to the α6β4 
integrin were significantly correlated, strongly suggesting that the IgG antibodies in 
saliva were derived directly from serum, presumably via transudation across inflamed 
mucosa or via the gingival crevice.  These results indicate the suitability of whole saliva 
in the diagnosis of MMP patients.  Further testing, however, is still needed to establish 
reactivity to the separate integrins i.e. α6 and/or β4.   
Although published studies propose a link between β4 and the pure ocular subgroup as 
well as between α6 and pure oral MMP, the heterogeneity of MMP is clearly evident as 
numerous studies report autoantibody reactivity to BP180 which is also supported by 
our results.  It would be insightful to establish specific binding results to α6 and /or β4, 
especially with saliva samples, which may show either dual or single binding to the 
separate fragments thus providing further clarity to the associations between certain 
clinical phenotypes and specific target antigens.   
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 Summary  
 Serum IgG antibodies against the α6β4 integrin were detected in 36/100 (36%) 
of MMP patients 
 Salivary IgG antibodies against the α6β4 integrin were detected in 18/100 (18%) 
of MMP whole saliva samples which has not been previously reported  
 Salivary IgG antibody to α6β4 was detected in 21% of both the pure oral and 
multisite disease groups (7/33 and 11/51) respectively. 
 IgA antibodies against the α6β4 integrin were not detected in either serum or 
saliva 
 The highest IgG antibody level detected against α6β4 integrin in serum was in 
the pure oral subgroup 14/33 (42%), followed by the multisite group 18/51 
(35%) and lastly the pure ocular subgroup 4/16 (25%). 
 IgG antibodies to α6β4 in both serum and whole saliva were significantly 
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5 Results PV Study 
 Serum and salivary antibodies to Dsg3 in relation to 
disease activity (Cross-sectional study) 
 Sequential antibody titres in PV patients to Dsg3 in 
relation to therapeutic response (Longitudinal study) 
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5 Serum and salivary antibodies in PV to Dsg3 in relation to disease 
activity and therapeutic response 
 
 Introduction  
The target antigen for mucosal lesions is Dsg3 while Dsg1 is the cutaneous antigen 
(Ding et al., 1997).  The mucocutaneous subgroup usually shows IgG autoantibodies to 
both Dsg1 and 3 antigens.  Although a minority of patients have been reported in the 
literature do not follow the typical clinical phenotype (Jamora et al., 2003).   
 The antibody titre in serum is well described as reflecting disease activity and has been 
used to monitor therapeutic response (Daneshpazhooh et al., 2007, Mortazavi et al., 
2009).  The use of ELISA for testing serum samples for the diagnosis and monitoring of 
PV patients has been well documented for the past decade (Ishii et al., 1997, Schmidt et 
al., 2010).  ELISA testing is considered more sensitive than indirect 
immunofluorescence (Ishii et al., 1997).  
The presence of IgG antibody in saliva against Dsg3 has been reported in the literature 
in 3 studies thus far.  Anti-Dsg3 IgG antibody has been reported in whole saliva in up to 
94% of newly diagnosed PV patients while anti-Dsg1 IgG antibody has been detected in 
up to 70% of PV patients (Andreadis D, 2006, Hallaji et al., 2010, Hosseein Mortazavi, 
2015).  Saliva provides a non-invasive and sensitive medium for diagnosing and 
monitoring diseases.  Advances in technology, nanotechnology and proteomics and 
salivary diagnostics have proven to be highly sensitive in the diagnosis of systemic 
diseases (Cheng et al., 2014, Krishna Prasad et al., 2013, Hu et al., 2011, Wong, 2006).  
Salivary biomarkers are currently being used in oral and breast cancer diagnostics with 
much potential (Arif et al., 2015, Cheng et al., 2014).  In this study, the presence of 
salivary and serum anti-Dsg3 antibodies in PV was investigated. 
 
The aims of this study were to:  
1) Establish whether whole saliva might provide a suitable alternative to serum for 
diagnosing and monitoring PV   
2) Investigate whether anti-Dsg3 IgA antibodies could be detected in serum and saliva  
3) Establish whether there was an association between serum or saliva anti-Dsg3 
antibodies and disease severity 
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4)  Utilize serum and salivary biomarkers in the analysis of disease activity and 
therapeutic response 
 
 Serum and salivary antibodies in PV to Dsg3 in relation to disease 
activity (Cross-sectional study) 
In this study PV patients’ (n=23), healthy controls’ (n=17) and disease controls’ (MMP 
n=8, LP n=11) serum, whole and parotid saliva samples were tested against Dsg3 by 
ELISA.  The standard against which all serum and whole saliva samples tested against 
Dsg 3 is shown in (Fig 5-1 a-b).  A summary of patients’ demographics, clinical data, 
immunofluorescence and ELISA results are shown in (Appendix 4).   The mean titre of 
anti-Dsg3 IgG antibodies in both serum (14593 ±22411) and saliva (885 ±1972) from 
PV patients, was significantly different from those of the controls, both healthy (46.87 
±116.5) and disease (57.07 ±71.12) in all tested parameters using one-way ANOVA (p 
<0.0001).  In addition, the mean titre of serum anti-Dsg3 IgA antibodies (61922 
±56283) were significantly different between the tested subgroups (p <0.0003).  All 
results measured above the mean +2 SD of the healthy controls were considered 
positive.  Control samples were all negative.  There was no significant difference in the 
mean of IgA antibodies to Dsg3 in whole saliva (p=0.684) as well as SIgA antibodies to 
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Figure 5-1 Standard curve for serum and whole saliva IgG/IgA antibody testing against 
Dsg3 by ELISA  a) Standard curve for serum and whole saliva IgG antibody testing against 
Dsg3 by ELISA. b) Standard curve for serum and whole saliva IgA antibody testing against 
Dsg3 by ELISA. Both figures show a Y-axis which represents blank corrected optical density 
values and an X-axis representing arbitrary units (0-1000) (100,000 by multiplying by dilution 
factor 100).  The standard curve was constructed using 6 doubling dilutions of a range of pooled 
antibody positive serum samples. Serum and whole saliva IgG/IgA antibody titres were read in 
units by calculating the mean of values of four doubling dilutions falling on the reference curve
a) 
b) 
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Serum and saliva antibody results to Dsg3: 
Serum IgG antibody to Dsg3 was detected in 17/23 (74%) of PV patients.  IgA antibody 
against Dsg3 in serum was detected in 14/23 (61%) of PV patients with a combined 
positivity (IgG and/or IgA antibody) 18/23 (78%) (Fig 5-2 a-b).  Whole saliva IgG 
antibody to Dsg3 was detected in 14/23 (61%) of PV patients, all of whom were 
positive for anti-Dsg3 IgG antibody in serum and had active oral disease with an oral 
disease activity score ranging from (7-57) (Fig 5-2 c).  Data summarized in Appendix 4.  
We were not able to detect reproducible anti-Dsg3 IgA antibodies in whole or parotid 
saliva (Fig 5-2 d).   
 
Table 5-1 PV Study ELISA results for IgG antibodies against Dsg3 in serum and whole 























14/23 (61%) 14/23 (61%) 
Combined   
(IgG and/ or 
IgA) 18/23 
(78%) 
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Serum IgG antibody units  against Dsg 3 in PV patients, healthy and
disease controls (LP/MMP)





































Serum IgA antibody units  against Dsg 3 in PV patients,
healthy and disease controls (LP/MMP)






































Figure 5-2 IgG and IgA antibodies to Dsg3 ELISA in serum in PV patients, Healthy and 
Disease controls using ELISA (Mean +/- SD) The Y-axis represents the antibody titre in units 
while the X-axis shows the sample groups tested. Horizontal I bar indicates cut-of level (mean 
+2SD of HC). Controls were negative in all. a) Serum IgG antibody units against Dsg3 in PV 
17/23 (74%) positive. b) Serum IgA antibody units against Dsg3 in PV 14/23 (61%) positive 










5 RESULTS PV STUDY 




Whole saliva IgG antibody units against Dsg 3 in PV patients,
healthy and disease controls (LP/MMP)






































Whole saliva IgA antibody units against Dsg 3 in PV
patients, healthy and  disease controls (LP/MMP)






































Figure 5-3 IgG and IgA antibodies to Dsg3 ELISA in whole saliva in PV patients, Healthy 
and Disease controls using ELISA (Mean +/- SD) The Y-axis represents the antibody titre in 
units while the X-axis shows the sample groups tested. Horizontal I bar indicates cut-of level 
(mean +2SD of HC).  Controls were negative in all. (a) Whole saliva IgG antibody against Dsg3 
was positive in 14/23 (61%) PV patients. b) There was no significant difference between the 
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There was a positive correlation between IgG antibody to Dsg3 in serum and whole 
saliva of PV patients (Spearman r =0.88 p<0.0001) (Fig 5-4).  Patients positive for anti-
Dsg3 IgG antibody in saliva were also positive in serum.   






































Figure 5-4 Correlation between IgG antibody to Dsg3 in serum and whole saliva 
Spearman r =0.88 p<0.0001 
 
 
All 23 PV patients had mucosal lesions while only 8/23 had skin involvement.  The 
patients’ sera were also tested for reactivity against Dsg1.  Of the eight patients with 
skin lesions, 3/8 (38%) had positive IgG antibodies to Dsg1 while 5/8 and the remaining 
15 mucosal samples were negative.  Therefore Dsg1 specific antibodies were not looked 
at for saliva. 
 
 
 Sequential antibody titres in PV patients to Dsg3 in relation to 
therapeutic response (Longitudinal study) 
PV patients (n=23) serum and whole saliva, were collected sequentially.  Four samples 
were collected from patients on a 3 monthly basis.  The mean severity score was 13.6 
(95% c.i. 10.6 to 16.6) and the median was 9.5 (range 0 to 57).  The models were 
validated using the square root transformation of severity given the non-normality 
detected in this outcome.  A significant change in severity was found over time, with the 
mean severity score decreasing in 2.2 (95% c.i 0.67 to 3.7; p=0.01) for each 3-month 
block of time.  After adjusting for this time effect, only saliva IgG was found to have a 
P<0.0001 
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significant effect on severity (mean=0.0025; 95% c.i. 0.0008 to 0.0042; p=0.004).  
Neither serum IgG (p=0.25) or serum IgA (p=0.08) were found to have any significant 
effect.  A representative sample showing anti-Dsg3 IgG and IgA antibody levels in 
serum and whole saliva over the collection time period and the oral disease severity 
scores (Fig 5-5).  The anti-Dsg3 antibody titre (IgG serum and whole saliva as well as 




Figure 5-5 Graph showing serial PV sample (1 representative sample) IgG and IgA units 
to Dsg3 in serum and IgG antibody in whole saliva as well as oral disease severity score  
The X-axis represents 4 samples which were collected three monthly.  Results of Dsg3 ELISA 
were plotted: serum anti-Dsg3 IgG and IgA antibodies and whole saliva anti-Dsg3 IgG 
antibodies, the left Y-axis (antibody units).  The oral disease severity score, the right Y-axis 
(Oral disease severity score). Red (IgG antibody to Dsg3 in serum), Blue (anti-Dsg3 IgA 
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Anti-Dsg 3 IgG antibody titre in serum at different time points




































Anti-Dsg 3 IgA antibody titre in serum at different time points





































Anti-Dsg 3 IgG antibody titre in whole saliva at different time points







































Figure 5-6 Levels of IgG and IgA antibodies to Dsg3 in serum in PV patients at 3-monthly 
time-points a) anti-Dsg3 IgG antibody level in serum at the different collected time points b) 
anti-Dsg3 IgA antibody level in serum at the different collected time points c) anti-Dsg3 IgG 
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The results show that not only does saliva provide a suitable medium for detecting anti-
Dsg3 IgG antibodies and the diagnosis of PV, it is also useful in monitoring disease 
activity.  Furthermore, serum IgA antibodies to Dsg3 were detected in sera of PV 
patients.   
Salivary diagnostics have improved with the advancement of technology (Wong, 2006, 
Pfaffe et al., 2011).  Salivary biomarkers are currently being used in oral and breast 
cancer diagnostics with much potential (Arif et al., 2015, Cheng et al., 2014).  Salivary 
IgG and IgA antibodies to BP180-NC16a in MMP patients were also detected.  This 
further supports the interest in salivary diagnostics for PV. 
 
IgG Anti-Dsg3 autoantibodies: 
In this study, both serum and whole saliva samples were tested for autoantibodies 
targeting Dsg3 antigen.  The results showed that 74% (17/23) of the PV patients were 
positive for IgG antibody to Dsg3 in serum while 61% (14/23) were positive in whole 
saliva.  All patients positive in saliva were also positive in serum for the IgG antibody 
and a positive correlation between IgG antibodies to Dsg3 in serum and whole saliva 
was found (p<0.0001).  These findings concur with three previous reports in the 
literature describing detection of IgG antibodies to Dsg1 and 3 in whole saliva of PV 
patients (Hosseein Mortazavi, 2015, Hallaji et al., 2010, Andreadis D, 2006).   
In previously reported studies, IgG antibody to Dsg3 in serum has been detected in up 
to 96% of new PV patients (Andreadis D, 2006, Hallaji et al., 2010, Hosseein 
Mortazavi, 2015).  The patients recruited to these were either new patients or samples 
were collected during the active stage of the disease.  Andreadis tested 27 PV patients 
and found that 93% had both serum and saliva anti-Dsg3 antibodies while 45% were 
positive for anti-Dsg1 antibodies in serum and saliva (Andreadis D, 2006).  Hallaji et al 
reported 94% (n=50) positivity in both serum and saliva anti-Dsg3 antibodies.  Anti-
Dsg1 antibodies were detected in 70% of the PV patients in both serum and saliva 
(Hallaji et al., 2010).  Finally, Mortazavi et al tested 86 PV patients and reported anti-
Dsg3 antibodies in 96% of PV sera while 73% showed salivary specific antibodies.  
Anti-Dsg1 results were positive in 72% of PV patient sera and 36% of saliva (Hosseein 
Mortazavi, 2015).   
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The results for serum showed a lower positivity of detection (74%) of IgG antibodies to 
Dsg3 than these previous studies.  This may be explained by the fact that our patients 
were not new referrals and had been on long term treatment resulting in lower levels of 
disease activity.  This is supported by the observations of significant decreases in serum 
antibodies over 9 months in sequential samples.  The patient cohort was also mainly of 
the mucosal variant of PV.  Only 8/23 had skin involvement of which 3/8 were positive 
for IgG antibodies to Dsg1 in serum (38%).   In contrast, in the mucocutaneous subtype 
up to 72% had anti-Dsg1 IgG antibody in serum (Hosseein Mortazavi, 2015).  Since the 
majority of our patients had mucosal involvement only, the low positivity to Dsg1 was 
expected. 
Previous studies have reported an association between serum autoantibody to Dsg1 or 3 
and therapeutic response (Schmidt et al., 2010).  In this study, results did not show a 
relationship between serum anti-Dsg3 antibody levels and therapeutic response during 
the study period (in contrast to saliva).  This could be due to the small number of 
patients tested, the short follow up time and again the fact that patients had already been 
on long term systemic treatment and that the antibody titre had already fallen.   
Results for salivary antibodies showed that despite being on long term systemic therapy, 
IgG antibody to Dsg3 in whole saliva was detected in 61% (14/23) patients in this 
cohort.  This is compared to untreated patients, among whom a positivity of IgG 
antibodies to Dsg3 has been reported in 70% to 94% of PV patients (Hosseein 
Mortazavi, 2015, Hallaji et al., 2010).  Salivary Dsg1 was not tested for due to the low 
positivity in serum and lack of cutaneous lesions in this cohort.  
IgG antibodies found in whole saliva are predominantly derived from serum.  These 
autoantibodies are transported into saliva by diffusion via the gingival crevicular fluid 
and breaches in the epithelium.    The more inflammation present within the oral cavity, 
the more leakage of antibodies from serum into whole saliva (Sistig et al., 2002).  This 
forms the basis for testing for IgG antibodies to Dsg3 in whole saliva of PV patients.  
Since oral lesions are commonly encountered, it would be expected for IgG antibody to 
be present in saliva during active disease.   
The testing of sequential salivary samples has not been previously reported.  This study 
has revealed for the first time that IgG antibodies to Dsg3 in whole saliva are associated 
with a change in severity score (p=0.004).  These findings suggest a promising use for 
salivary anti-Dsg3 detection in whole saliva as part of the monitoring of PV patients.   It 
is interesting that while more patients were positive for IgG in serum overall, this 
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biomarker was less discriminatory for disease activity.  It is therefore important to 
undertake further studies with a larger cohort and including more patients at the onset of 
disease. 
 
IgA Anti-Dsg3 autoantibodies: 
While the main focus in the literature has been testing for IgG antibodies to Dsg1 and 3 
in serum and saliva, we have tested for IgA antibodies to Dsg3 in both serum and saliva.  
IgA antibody to Dsg3 was detected in serum in 14/23 (61%) of the patients with a 
combined IgA and/or IgG antibody positivity of 18/23 (78%) patients.   None had serum 
IgA antibodies alone.   
On the basis of the presence of Dsg3 IgA antibodies in serum, we would have expected 
to detect IgA antibodies in whole saliva.  However, saliva contains many high 
molecular weight mucins which sometimes give rise to non-specific binding. Our 
background activity for IgA antibody was higher than that of IgG antibody, which may 
have masked the detection of anti-Dsg3 IgA antibody in PV patients.  Further work is 
underway. 
IgA positivity alone in PV usually reflects a separate entity labelled as IgA pemphigus 
(Tajima et al., 2010).  However, others have reported that in IgG-driven PV, IgA 
antibodies to Dsg3 are sometimes detected (Porro et al., 2014).  Spaeth et al reported 
the detection in acute onset and chronic PV of IgA antibody to Dsg3 in 9/15 (60%) and 
13/18 (72%) respectively (Spaeth et al., 2001).  Similarly, Mentink et al showed  serum 
IgA anti-Dsg3 antibodies in 18/27 (67%)  of patients while serum IgA anti-Dsg1 
antibodies were  positive in 15% (Mentink et al., 2007).  Hashimoto et al reported 
detection of anti-Dsg3 or 1 IgA antibody in 4/22 (18%) of pemphigus  patients 
(Hashimoto et al., 2001).  Thus the detection of IgA antibody to Dsg3 in PV patients 
may be more common than previously assumed (Mentink et al., 2007).  It has been 
proposed that IgA antibody activity to Dsg3 rather than IgG may be associated with the 
presence of mucosal lesions in PV (Spaeth et al., 2001).  Our PV patient cohort showed 
predominantly mucosal involvement and a high proportion had IgA antibodies.   
It is not known whether IgG and IgA antibodies are directed at different epitopes on 
Dsg3 or whether IgA has a role in disease pathology or epitope spreading.  However,  
Mentink et al found that serum IgA antibody to Dsg3 was elevated before serum IgG 
antibody started to rise (Mentink et al., 2007).  Whether IgA antibodies to Dsg3 are 
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directly involved in the pathogenesis or reflects  epitope spreading remains to be 
elucidated (Tchernev and Orfanos, 2006).   
ELISA provides a more sensitive tool for autoantibody detection against the PV target 
antigens than immunofluorescence (Lenz et al., 1999, Harman et al., 2000c, Heymann, 
2009).  This also appears to be the case for detecting IgA antibodies in serum to Dsg 
(Mentink et al., 2007).  Whether IgG/IgA pemphigus is a separate entity or whether the 
typical IgG pemphigus vulgaris has a wider spectrum needs further clarification (Porro 
et al., 2014).  In addition, the detection of IgA antibodies to Dsg3 further supports the 
hypothesis that PV is a T helper 2 (Th2) autoimmune mediated disease  and may 
suggest a possible pathogenic role for IgA antibodies in PV (Spaeth et al., 2001). 
 
 Conclusion: 
This study supports previous reports indicating the value of whole saliva for diagnosis 
of PV by detecting IgG antibodies to Dsg3.  By closely monitoring disease severity and 
relating this to sequential saliva samples, these results also show that salivary anti-Dsg3 
antibodies maybe used in monitoring PV patients.  Further studies are needed to more 
fully explain the role of IgA antibodies to Dsg3 in the pathogenesis and progression of 
PV.   
 
 Summary: 
 Serum IgG antibodies to Dsg3 were positive in 17/23 (74%) of PV patients  
 Serum IgA antibodies to Dsg3 were positive in 14/23 (61%) of PV patients.  A 
combined positivity was found in 18/23 (78%) of PV patients.    
 Whole saliva IgG antibodies to Dsg3 were detected in 14/23 (61%) of PV 
patients  
 There was a positive correlation between IgG antibody to Dsg3 in serum and 
whole saliva (Spearman r =0.88 p <0.0001) 
 Sequential samples showed that the change in IgG antibodies to Dsg3 in whole 
saliva had a positive association with the change in oral disease severity scores 
(p=0.004) 
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6 General Summary 
                                                                                                                                                                                                                                                                                                                                 
The main findings of this thesis are: 
Study 1 (a & b): Serum and salivary antibodies to BP180-NC16a in patients with 
mucous membrane pemphigoid 
(a)- In relation to clinical phenotype and disease activity (Cross-sectional study) 
(b)- In relation to therapeutic response (Longitudinal study) 
 Serum IgG antibodies against the NC16a domain of BP180 were detected in 
28/78 (36%) of MMP patients  
 Serum IgA antibodies were found in 22/78 (28%).  Combined serum IgG and/ or 
IgA antibodies were positive in 38/78 (48%) patients 
 Whole saliva IgG antibodies were detected in 11/78 (14%) of MMP  
 Whole saliva IgA antibodies were detected in 30/78 (38%) of MMP patients.  
Combined results for IgG and/ or IgA antibodies in ws were positive in 34/78 
(44%).   
 In parotid saliva both secretory IgA and IgA were positive in 9/20 (45%) 
patients 
 There was a positive association between the presence of serum IgG antibodies 
to BP180-NC16a and multisite disease lesions (X2 = 11.9 p =0.003) 
 A positive  association  was found between the presence of IgA antibody to 
BP180-NC16a in whole saliva and the presence of combined oral and ocular 
disease  (X2 = 6.23 p =0.0156)   
 Pure ocular MMP patients showed no IgG antibody reactivity to BP180-NC16a 
in either serum or saliva but a higher level of IgA antibody to BP180-NC16a in 
serum and saliva (38% and 44% respectively) than other clinical subgroups  
 The greater the number of involved sites involved in multisite disease MMP, the 
higher the IgG antibody titre in serum and whole saliva against BP180-NC16a 
(p =0.017 and p =0.019, respectively) 
 Sequential samples showed that the change in serum antibodies (IgG and IgA) 
was associated with a change in oral disease severity scores (p =0.048 and 
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Study 2: Serum and salivary antibodies to alpha 6 beta 4 integrin in relation to 
clinical phenotype and disease activity (Cross-sectional study) 
 Serum IgG antibodies against the α6β4 integrin were detected in 36/100 (36%) 
of MMP patients 
 IgG antibodies to the α6β4 integrin were detected in 18/100 (18%) of MMP 
whole saliva samples  
 IgA antibodies against the α6β4 integrin were not detected in either serum or 
saliva  
 The highest IgG antibody level detected against the α6β4 integrin in serum was 
in the pure oral subgroup 14/33 (42%), followed by the multisite group 18/51 
(35%) and lastly the pure ocular subgroup 4/16 (25%) 
 IgG antibody to α6β4 in whole saliva, was detected in 21% and 22% of both the 
pure oral and multisite disease (7/33 and 11/51, respectively) 
 IgG antibodies to α6β4 in both serum and whole saliva were significantly 
correlated with the oral disease severity score was (p =0.037 and p =0.0055, 
respectively) 
PV study: Serum and salivary antibodies to Dsg3 in relation to disease activity 
(Cross-sectional) and sequential antibody titres in PV patients to Dsg3 in relation 
to therapeutic response (Longitudinal study) 
 Serum IgG antibodies to Dsg3 were positive in17/23  (74%) of PV patients  
 Serum IgA antibodies to Dsg3 were positive in 14/23 (61%) of PV patients.  A 
combined positivity (IgG and/or IgA) was found in 18/23 (78%) of PV patients  
 Whole saliva IgG antibodies to Dsg3 were detected in 14/23 (61%) of PV 
patients  
 There was a positive correlation between IgG antibody to Dsg3 in serum and 
whole saliva (Spearman r =0.88 p <0.0001) 
 Sequential samples show that the change in IgG antibodies in whole saliva had a 
significant association with the change in severity scores (p =0.004) 
In this thesis, whether IgG and IgA antibodies to two target antigens, the NC16a domain 
of BP180 and to α6β4 integrin, in MMP and to the Dsg3 antigen in PV could be 
detected by ELISA in both serum and saliva was investigated.  Moreover, whether these 
antibodies could be used in the assessment of disease severity and therapeutic response 
was looked at.  In addition, the thesis aimed to identify whether certain clinical 
phenotypes were related to specific target antigens in MMP.  
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Serum and salivary autoantibodies: 
-BP180-NC16a 
In this cohort, 36% had circulating IgG antibodies in serum directed against the NC16a 
domain of BP180.  Serum IgA antibodies to BP180-NC16a in serum were detected in 
28% of the patients with a combined positivity of 48%.  Similarly, immunofluorescence 
results from this study show that 35% of the patients were positive on IIF.  Although 
our results may seem to be comparatively low, this may in part be due to the majority of 
patients being on long-term treatment and thus having lower levels of disease activity as 
has been shown elsewhere (Sami et al., 2002).  In addition, the higher positivity with IIF 
reported in the literature corresponds to reactivity against any of the BMZ components 
not to a single antigen (Setterfield J. et al., 1998, Oyama et al., 2006).   
Of particular interest, the data has shown that whole saliva samples were reactive to the 
NC16a domain of BP180 with IgG antibodies in 14% of patients, IgA antibodies in 38% 
and overall in 44% of the patients.  Salivary antibodies to BMZ antigens have not been 
shown before in MMP.  There has been one previous study reporting that neither serum 
nor salivary autoantibodies were detected against BP18-NC16a in MMP patients 
(Andreadis D, 2006).  The low percentage positivity in whole saliva may reflect the fact 
that the majority of patients had well controlled disease at the time of sampling. Only 
50% of the patients had a positive clinical score for oral disease, most of whom were 
mildly erythematous rather than having active ulceration. 
Specific antibody reactivity to the C terminal domain of BP180 on ELISA was not 
shown due to the high reactivity of serum to GST on ELISA plates.  Therefore antibody 
reactivity to different epitopes of BP180 was not demonstrated. 
 
-α6β4: 
MMP serum and salivary samples were tested for reactivity with the α6β4 integrin.  The 
results have shown that 36% and 18% of MMP patients were positive for IgG 
antibodies to the α6β4 integrin in serum and whole saliva respectively.  Salivary 
antibodies to the α6β4 integrin in MMP have not been reported previously.  Western 
blot testing of the separate α6 and β4 integrins were not conclusive.  Non-specific 
binding in the western blots resulted in the inability to demarcate between the MMP 
positive or negative sera and between the control groups.  BIAcore results were also 
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inconclusive as reactivity to the reference cells could not be differentiated.  Therefore 
reactivity to the separate integrins was not shown. 
 
Mucosal antibodies: 
Parotid samples were tested to attempt to differentiate between IgA present as a serum 
transudate (detected as a monomer), from local production (secretion from the gland 
and detected as dimeric IgA and secretory component positive).  Interestingly, 45% of 
parotid samples were both IgA and secretory component positive.  These results have 
been demonstrated for the first time in saliva of these patients.  Size exclusion 
chromatography showed that secretory component (which has a molecular mass of 80 
Kda) is associated with a high molecular weight complex (>250 Kda), presumably 
dimeric SIgA thus confirming the presence of locally produced antibodies.   
Although the precise mechanism of how these antibodies are stimulated has not been 
ascertained.  It is possible to speculate about a mucosal immune response.  Whether 
these antibodies are produced due to damage occurring from a distant mucosal site 
involvement (e.g. ocular mucosa), or whether subclinical damage within the salivary 
gland occurs exposing BP180 in their basement membrane has yet to be confirmed 
(Gonzalez et al., 2011, MacPherson et al., 2008).  
  
Clinical phenotype (Pure oral, pure ocular and multisite disease): 
-BP180-NC16a: 
The MMP cohort was further divided into pure oral, pure ocular and multisite disease 
clinical subsets.  A positive correlation was found between the number of sites involved 
in multisite disease and the level of IgG antibodies to BP180-NC16a in both serum and 
saliva (p=0.017 and 0.019 respectively).  Interestingly, no IgG antibody was detected in 
the pure ocular phenotype in both serum and whole saliva.  They did however, have the 
highest levels of IgA antibody to BP180-NC16a in serum and saliva (38% and 44% 
respectively).  Our results suggest a possible link between pure ocular MMP and IgA 
reactivity to BP180-NC16a.  A recent study suggests an association between the ocular 
subgroup and IgA antibody in serum targeting the C-terminal domain of BP180 
(Solano-López et al., 2014). 
-α6β4: 
By analysing the reactivity in subsets in this cohort of patients to α6β4 integrin, the pure 
oral subgroup showed the highest level of IgG antibodies in serum to α6β4 at 42%.  On 
the other hand, the multisite subgroup had the highest level of anti- α6β4 IgG antibodies 
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in whole saliva at 22%.  The pure ocular group were positive for IgG antibody to α6β4 
in serum but not in saliva.  In order to better appreciate these results, testing the samples 
against the separate fragments α6 and β4 is essential.  Consequently, associations 
between distinct clinical phenotypes and specific target antigens and epitopes were 
speculated on but not confirmed. 
Disease severity and therapeutic response: 
 A positive correlation was found between the presence of serum IgG antibodies 
against BP180-NC16a and the presence of multisite disease lesions (p=0.003) 
 A positive association was found between the presence of salivary IgA 
antibodies to B180-NC16a and the presence of oral and ocular lesions in MMP 
patients (p<0.02) 
 The greater the number of sites involved, the higher the IgG antibody level to 
BP180-NC16a in serum and whole saliva detected (p<0.02 for both) 
 A positive correlation was found between IgG antibodies to BP180-NC16a in 
whole saliva and disease severity in multisite disease patients (p=0.022) 
 Serum and salivary IgG antibodies to α6β4 integrin had a positive correlation 
with oral disease severity score (p=0.0370 and p=0.0055 respectively) 
IIF titres are usually used to monitor disease severity in MMP patients.  Sequential 
samples showed a positive association between the change in serum antibodies to 
BP180-NC16a (both IgG and IgA) and the change in severity score (p=0.048 and 
p=0.033 respectively).  These results suggest the valuable use of ELISA in monitoring 
MMP patients clinically over the course of their treatment.  
 
B). PV 
Serum and salivary autoantibodies: 
-Anti-Dsg3 IgG antibody: 
Regarding PV, 74% of the cohort had IgG antibodies detected in serum against Dsg3 
and 61% in saliva.  A positive correlation was found between serum and salivary anti-
Dsg3 antibodies (p<0.0001).  Other publications have reported the detection of anti-
Dsg3 IgG antibody in whole saliva (Hosseein Mortazavi, 2015, Hallaji et al., 2010, 
Andreadis D, 2006).   
-Anti-Dsg 3 IgA autoantibody: 
Interestingly, 61% were positive for IgA antibody to Dsg3 in serum (yielding a 
combined positivity of IgG and/or IgA of 78%).  Generally, IgA positivity is considered 
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as a separate entity; IgA pemphigus.  However, there are publications in the literature in 
which IgA antibody was detected in serum of PV patients targeting Dsg3 (Spaeth et al., 
2001, Mentink et al., 2007, Hashimoto et al., 2001).  Whether IgG/IgA pemphigus is a 
separate entity or whether typical IgG pemphigus vulgaris has a wider spectrum needs 
further clarification (Porro et al., 2014). 
Disease severity and therapeutic response: 
The sequential results showed that IgG antibody to Dsg3 in saliva had a significant 
correlation with the change in severity score (p=0.004).  This has not been previously 
described as earlier reports only established the detection of anti-Dsg3 antibodies in 
saliva.  These results indicate the usefulness of saliva not only in diagnosing the disease, 
but monitoring it as well.  This was not shown for serum in this cohort which could be 
due to the   small number of samples tested and a shorter follow up time. 
 
The results confirm what has been previously shown regarding Dsg3 serum and saliva 
IgG antibodies being both sensitive and specific for diagnosing if PV.  In addition, it has 
been shown that salivary anti-Dsg3 antibodies are useful in monitoring PV patients.  
The level of Dsg3 salivary IgG antibodies has a significant relation with therapeutic 
response in PV.  Anti-Dsg3 IgA antibodies are detected in serum of PV patients.  
Further research is required to better understand the significance of this in the 
pathogenesis of the disease.    
 
BP180-NC16a serum IgG and IgA antibodies both had a positive correlation with 
therapeutic response in MMP.    Salivary biomarkers, IgG antibodies to BP180-NC16a 
and α6β4 may be useful in the diagnosis of MMP patients as well as salivary IgA 
antibodies to BP180-NC16a.  The novel finding of locally produced antibodies may 
provide further insight into the pathogenesis of the disease which may explain the 
propensity of oral lesions.  These new findings demonstrate the value of saliva as an 
alternative to serum in the diagnosis of MMP as well as a being a valuable medium for 
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7 Conclusions and Future Work 
 Conclusions  
The cohort of patients was recruited included predominantly mucosal PV and the full 
spectrum of MMP; i.e. pure oral, pure ocular and multi-site disease patients.  The 
assessment of disease severity and sequential activity was made using a previously 
published scoring methodology initially published for use in oral LP (Escudier et al., 
2007).  As both MMP and PV are rare, most patients recruited were already on long 
term treatment and follow up which may, in part, have resulted in the lower levels of 
disease activity and of serum and salivary antibody activity.  This was considered as an 
unavoidable limitation of the study.  
The main conclusions drawn regarding each aim were as follows: 
1. To develop a sensitive salivary assay to diagnose and monitor MMP and PV: 
a. MMP: Salivary antibodies (both IgG and IgA) to BP180-NC16a could be 
detected in both whole and parotid saliva of MMP patients.  In whole saliva, 
the combined positivity (both IgG and IgA) was 44% which was similar to 
that of serum at 48%.  Furthermore, the novel finding of SIgA antibodies to 
BP180-NC16a were detected in both whole and parotid saliva of MMP 
patients.  The fact that some patients were found to be a) antibody negative 
in serum but had positive parotid samples for SIgA anti-BP180-NC16a 
antibodies, b) that parotid antibodies detected by anti-SC or by anti-IgA 
showed a strong correlation and c) antibody migrated at a molecular weight 
of dimeric IgA in chromatography, strongly suggests that these antibodies 
were mucosally derived.  This finding may help explain the propensity for 
oral lesions in MMP.   
Salivary antibodies against the α6β4 integrin were detected and reported for the first 
time.  IgG antibodies targeting α6β4 were detected in whole saliva (18%) of MMP 
patients but no IgA reactivity was detected.  The results overall show the importance of 
saliva as a medium to be tested in the diagnosis and monitoring of MMP patients.  Since 
antibodies can be detected in serum (36%), whole saliva (18%) or both (36%), 
combined testing of serum and saliva to multiple antigens should therefore provide 
more sensitive results.  This is further supported by the lack of IgG reactivity to BP180 
in the pure ocular group.  This group is generally known to be more serum antibody 
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negative therefore combined testing may offer a more sensitive method for antibody 
detection especially for IgA.   
b. PV: IgG antibodies targeting Dsg3 were detected in whole saliva of PV 
patients and in serum.  A positive correlation was found between serum and 
salivary anti-Dsg3 antibodies (p<0.0001).  Although the percentage of 
antibody positive patients was not as high as those reported in the literature, 
the fact that the majority of patients were on long term treatment may be 
responsible for the low levels of disease activity.  Interestingly, serum IgA 
antibodies targeting Dsg3 were detected in 61% of PV patients with a 
combined positivity of 78%.  IgA antibody detection to Dsg3 in IgG driven 
PV has been reported previously.  How anti-Dsg3 IgA affects the 
pathogenesis has yet to be elucidated.   
Therefore, in both MMP and PV, a sensitive salivary assay was developed to help 
diagnose and monitor both diseases.  This can be very helpful for patients with severe 
blistering in which obtaining a serum sample could be difficult.  It would be economic 
as training is not required for the sample collection and collection of saliva samples is 
pain free, less time consuming and better accepted by the patients.  It would also 
facilitate screening large numbers of patients for population studies.  There are 
numerous applications in which salivary testing could be promoted as specific 
antibodies targeting certain antigens can be detected.   
2. To utilize serum and salivary biomarkers in the analysis of disease severity and 
therapeutic response: 
a. MMP: A positive correlation was found between the presence of serum IgG 
antibodies against BP180-NC16a and the presence of multisite disease 
lesions (p=0.003).  A positive association was found between the presence 
of salivary IgA antibodies to B180-NC16a and the presence of oral and 
ocular lesions in MMP patients (p<0.02).  Notably, the higher the number of 
sites involved, the higher the IgG antibody level to BP180-NC16a in serum 
and whole saliva detected (p<0.02 for both).  A positive correlation was 
found between IgG antibodies to BP180-NC16a in whole saliva and disease 
severity in multisite disease patients (p=0.022).  In addition, serum and 
salivary IgG antibodies to α6β4 integrin had a positive correlation with 
severity score (p=0.037 and p=0.0055 respectively).  These results suggest 
the valuable use of ELISA, testing both serum and saliva, in monitoring the 
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patients’ clinically over the course of their treatment as oral severity scores 
and the level of antibody detection correlate. 
Sequential samples showed that the change in serum antibody titre to BP180-NC16a 
(both IgG and IgA) had a significant relationship with the change in severity score 
(p=0.048 and p=0.033 respectively).  This indicates that the level of antibodies to 
BP180-NC16a in serum follows the therapeutic response.   
b. PV: The role of IgA antibody to Dsg3 in the pathogenesis of PV has yet to 
be fully explained.  It is therefore, of much interest to further study this 
cohort of patients with both IgG and IgA antibodies to Dsg3 in an attempt to 
better understand the significance of IgA antibody in the disease 
progression.   
Sequential samples showed that the change in IgG antibody level to Dsg3 in whole 
saliva significantly related to the change in severity score (p=0.004).  This means that 
the level of antibody reflected the therapeutic response.  Although others have reported 
the detection of IgG antibody to Dsg3 in whole saliva, the potential use of whole saliva 
in monitoring patients’ disease progression has not been described.  Serum samples did 
not show the same relation in this cohort.  This could be due to the small number of 
samples tested and a shorter follow up time which was a limitation of this study in 
addition to patients already having long term treatment.   
Therefore, in both MMP and PV, serum and salivary biomarkers proved important in 
the analysis of disease severity and therapeutic response.  The potential for saliva as a 
medium for biomarker detection is increasingly being noticed.  Not only is it effective 
in the diagnosis, but it also shows potential for disease monitoring as well. 
3. To investigate whether distinct clinical phenotypes are associated with specific 
target antigens and epitopes in MMP: 
MMP is a heterogeneous disease.  Although clinical phenotypes have been described; 
pure oral, pure ocular and multisite disease, a definitive relationship between a certain 
clinical subtype and target antigens or epitopes has yet to be ascertained.  Previous 
associations between α6 and the pure oral subgroup as well as β4 and the pure ocular 
subtype have been proposed.  The cohorts’ samples were tested for reactivity against 
BP180-NC16a and the α6β4 integrin.  
Since a demarcation between MMP and controls was not shown when testing the GST 
fusion proteins (NC16a and 4574) by ELISA, reactivity to the C-terminal domain of 
BP180 was not established.  This was considered as a limitation of the study.  The 
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results show that the pure ocular subgroups had no IgG antibody reactivity to BP180-
NC16a in either serum or whole saliva.  They did however, have the highest level of 
specific IgA antibody directed to BP180-NC16a in both serum and saliva.  This denotes 
a distinct group in which IgA antibody reactivity to BP180-NC16a is detected with no 
IgG antibody.  As previously mentioned, this supports the importance of combining 
both serum and salivary testing for diagnosing and monitoring the patients.  The 
multisite disease patients had the highest level of IgG antibody against BP180-NC16a in 
serum and whole saliva.  This does not come as a surprise since patients with multisite 
involvement generally have a more active disease and BP180 is the main target antigen 
in multisite disease patients.  Consequently, it is still unclear whether clinical 
phenotypes are therefore related to specific epitopes of BP180.   
The α6β4 integrin data shows that IgG antibody to α6β4 in serum was most abundant in 
the pure oral subgroup.  The high reactivity in the pure oral subgroup to α6β4 only 
highlights the importance of this antigen with regards to this clinical phenotype.  IgG 
antibody to α6β4 in whole saliva was detected at a higher level in the multisite disease 
group.  This supports the previous findings regarding the higher level of IgG detected in 
saliva in multisite disease patients especially as these patients are more likely to have 
higher serum IgG antibody levels to BP180-NC16a.  Reports in the literature mainly 
test the separate fragments as opposed to the full α6β4 integrin.  When testing of the 
separate fragments α6 and β4 by westerns blots, results showed nonspecific binding to 
α6 with minimal β4 reactivity.  Therefore, results of separate integrin reactivity were 
not established which was a limitation of this study.  Consequently, associations 
between distinct clinical phenotypes and specific target antigens and epitopes were 
speculated on but not confirmed. 
Finally: 
 Since antibodies to BP180-NC16a and α6β4 integrin can be detected in serum, 
whole saliva or both, combined testing of both serum and whole saliva should 
therefore, provide more sensitive results.   
 The detection of mucosally derived antibody requires further investigation in a 
larger cohort including patients with untreated disease and using parallel 
mucosal secretions e.g. tears will be most informative.   
 To further increase the sensitivity of saliva as a diagnostic and disease 
monitoring medium, the additional testing for reactivity with further epitopes on 
BP180, laminin 332, α6 and β4 integrin separately is likely to be most 
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informative.  The additional screening of these antigens may broaden the value 
of ELISA and may correlate more closely with disease phenotypes.   
 The novel findings have shown that not only are NC16a-specific salivary IgG 
and IgA antibodies present in MMP patients but that this medium may have a 
greater sensitivity for detecting IgA autoantibodies than serum.   
 The results support previous reports in the literature indicating the value of 
whole saliva for diagnosing PV by detecting IgG antibodies to Dsg3.  By closely 
monitoring disease severity the results also show the use of salivary anti-Dsg3 
antibodies in monitoring PV patients.   
 Further studies are needed to more fully explain the role of IgA antibodies to 
Dsg 3 in the pathogenesis and progression of PV.   
 
 Future work 
The results of this thesis give rise to further questions that need investigation in both 
MMP and PV: 
 The demonstration of SIgA antibodies for the first time suggests that testing of 
tears and vaginal washes for SIgA antibodies might elucidate the involvement of 
mucosal immune responses in MMP. 
 Biopsy of minor salivary glands and immunofluorescence testing should be 
considered to determine if there is direct involvement of salivary glands as 
targets in MMP.  In addition, collecting saliva from minor salivary glands in 
order to test for SIgA in MMP patients to determine if there is local oral 
production of SIgA antibodies. 
 Testing saliva samples against different target antigens (e.g. Laminin 332) for 
specific SIgA antibody detection would provide further insight to the extent of 
mucosal immunity involvement in MMP and antigens targeted. 
 Testing further antigens and immunoglobulin isotypes (IgG, IgA); laminin 332, 
C-terminal domain of BP180 and the separate α6 and β4 integrin fragment by 
Luminex or ELISA to investigate whether an association between specific 
clinical phenotypes and target antigens or epitopes exists in MMP. 
 Testing the total IgG fraction of MMP patients’ sera to the separate α6 and β4 
integrin fragments in Western blot for more specific results of antigen reactivity. 
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 MMP sequential samples to be tested for reactivity against the different antigens 
for both serum and saliva to gauge biomarkers for disease severity and 
therapeutic response. 
 Cytokine testing (IL-4, 5, 6, 8 TGB-β) which may elucidate the scarring capacity 
and in sequential samples whether they provide prognostic biomarkers for 
disease activity and scarring potential. 
 Immunoglobulin subclasses IgG1-4 and IgA1 and 2 and their role in 
pathogenesis.  In addition, testing for IgE and IgM antibody reactivity in serum 
and saliva to investigate their role in pathogenesis. 
 The role of IgA antibody in the pathogenesis of PV needs to be investigated.  
This could be established by mimicking animal model studies used in describing 
the role of IgG antibody in PV.  
 Testing PV sequential samples (serum and saliva) for anti-Dsg1 and 3 IgG and 
IgA antibodies in cutaneous and mucocutaneous PV to investigate disease 
severity and therapeutic response. 
 Avidity of antibodies, especially in relation to clinical phenotypes, to determine 
if the avidity of autoantibodies in an antibody mediated disease is related to 
disease activity. 
 Larger numbers of patients with MMP so that oral phenotypes can be more 
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8 Appendix  
Appendix 1 Ethical Approval 
East Central London REC 1 





Tel: 020 7794 0552 
Mr John Dart 
Consultant Ophthalmologist 
Moorfields Eye Hospital 
162 City Road 
London, EC1V 2PD 
 
14 May 2010 
 
Dear Mr Dart 
 
Study title: Autoantigen and genetic determinants of disease in 
mucous membrane pemphigoid 
REC reference: 09/H0721/54 
Amendment number: 1 
Amendment date: 24 April 2010 
 
The above amendment to include paired saliva and serum samples and to collect 
samples from race and age-matched controls, was reviewed on 14 May 2010 by the 




The members of the Committee taking part in the review gave a favourable ethical 



























































NRES Committee London - Westminster 
Research Health Authority 
Ground Floor, Skipton House 




22 November 2012 
 
Dr Jane Setterfield 
Reader/Honorary Consultant in Dermatology in relation to 
Oral Disease 
King's College London 
Floor 23 Department of Oral Medicine 







Dear Dr Setterfield 
Thank you for your letter of 04 October 2012, responding to 
the Committee‟s request for 
further information on the above research and submitting 
revised documentation. 
 
The further information was considered [in correspondence] 
by a sub-committee of the 
REC.   A list of the sub-committee members is attached. 
 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a 
favourable ethical opinion for the above research on the basis 
described in the application form, protocol and supporting 






Study title: Novel Biomarkers in the Diagnosis and Pathogenesis of 
Immunobullous Disorders 
REC reference: 12/LO/1350 
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Department of Oral Medicine  
Floor 22 Tower Wing 
Tel:  020 7188 4399 
Fax:  020 7188 4401 
Review Appointments:  020 7188 4343 
New Appointments:  020 7188 1772 
Clinic: Floor 22 Tower Wing   




Pt ID for this Study: 
 
CONSENT FORM for patients  
Title of Project: Novel Biomarkers in the Diagnosis and Pathogenesis of 
Immunobullous Disorders (REC ref: 12/LO/1350) 
 
Researchers:  Dr Jane Setterfield, Professor S Challacombe, Dr S Ali 
  Tick 
box 
 
1. I confirm that I have read and understand the information leaflet 
(Version 2 dated  04.10.12) for the above study. I have had the 
opportunity to consider the information and ask questions. 
 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
3.   I understand that my donated blood, saliva and tissue samples 
will be stored and studied in laboratories of the Department of Clinical 
and Diagnostic Sciences at Guy’s Hospital and that these may be 
used for future, ethically approved studies.  I give permission for this. 
 
4.   I understand that my serum and saliva samples previously stored 
 
Guy's Hospital 
Great Maze Pond 
London SE1 9RT 
Main switchboard:  020 7188 7188 
 
Professor S J Challacombe PhD 
FDSRCS FRCPath FMedSci 
Dr J F Setterfield BDS MBBS DCH 
DRCOG MD FRCP 
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within the Oral and Diagnostic Sciences Department at Guy’s 
Hospital may be used in this study. I also understand that these may 
be used in future ethically approved studies. I give my permission for 
this. 
 
5 I understand that relevant sections of any of my medical notes and 
data collected during the study may be looked at by researchers at 
Guy’s Hospital and the regulatory authorities or from the NHS Trust, 
where it is relevant to my participation in the study. I give permission 
for access to my records. 
 
 
6. I agree that my GP and dentist can be informed of my participation 
in this study. 
 





_________________________    _______________________    ____________ 
Name of Patient Signature  Date  
 
 
__________________________    _______________________    ____________ 
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BP180-
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1 f/c 67 10 
yrs 
 y  pos pos 10 neg neg neg neg neg neg   -/- 
2 m/c 65 19 
yrs 
 y   pos NA 0 neg neg neg neg neg neg    
3 m/c 62 15 
yrs 
 y  neg neg 0 neg neg neg neg neg neg   -/- 
4 m/c 67 9 yrs  y  neg neg 0 neg neg neg neg neg pos   -/- 
5 f/c 58 11 
yrs 
  or/C,oc pos pos 26 neg neg neg neg neg neg   +/- 
6 m/c 81 9 yrs   or/C,oc,gen neg NA 21 pos neg pos neg neg Pos˅    
7 f/c 72 12 
yrs 
  or/G,oc neg pos  8 pos neg neg neg neg neg   -/- 
8 f/c 65 7 yrs   or/G,oc pos pos 17 pos pos neg neg pos neg    
9 m/a 47 5 yrs   or/C,sk,oc,n-
ph 
pos pos 42 pos neg neg neg neg neg    
10 f/c 76 8 yrs   or/G,n-ph pos pos 12 neg neg neg neg neg pos   +/- 
11 f/c 75 7 yrs   or,sk,n-ph 
(inactive no 
oral lesions) 
pos neg 2 
pos neg pos neg neg neg 
  -/- 




pos pos 26 pos neg neg neg neg neg    
13 f/c 53 15 
yrs 
  or/G,oc  pos NA 14 neg pos neg neg pos neg    
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14 m/c 66  6 yrs   or/C,oc,n-ph pos pos 12 neg neg pos neg neg neg    
15 m/c 42 5 yrs y/G   pos neg 12 neg pos neg neg pos neg    
16 f/c 74 6 yrs y /C   pos neg 11 pos neg neg neg neg pos   +/+ IgA 
17 f/c 82 6 yrs y   pos neg 21 neg neg neg neg neg pos Pos* pos -/- 
18 f/c 64 5 yrs   or/E,o,n-ph pos neg 4 pos neg neg neg neg pos Pos* pos  
19 f/c 55 12 
yrs 
y/G   pos neg 18 neg neg neg neg neg pos Pos* pos  





  pos neg 0 
neg neg neg neg neg neg 
   
21 m/c 26 5 yrs   or/C,sk,oc,n-
ph 
pos pos 4 pos neg neg pos neg neg   +/+ IgG 









 pos neg 0 
neg neg neg neg neg pos 
  -/+ 
IgG&A 
23 f/c 64 3 yrs y /G   pos neg 12 neg neg neg neg neg neg    
24 f/a 68 5 yrs   or/C,sk,gen,
oc,n-ph 
pos NA 18 pos pos pos pos pos neg    
25 f/c 58 8 yrs y/G   pos neg 24 neg neg neg neg neg neg neg neg +/- 
26 m/c 67 10 
yrs 
  or/G,gen pos neg 8 neg neg Pos× neg neg neg Pos× pos  
27 f/c 69 12 
yrs 
  or/C,sk,oc neg pos 35 pos neg neg pos neg pos   -/- 
28 f/c 75 18   or/E,sk,oc neg NA 13 pos neg pos neg neg pos˅    
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yrs 
29 m/a 69 16 
yrs 
 y  neg neg 0 neg neg neg neg neg pos   -/+ IgA 
30 f/c 71 20 
yrs 
  or/G,oc pos neg 6 neg neg neg neg neg pos   -/- 
31 f/c 79 15 
yrs 
  or/G,n-ph no 
lesions(inact
ive) 
pos neg 0 
neg neg neg neg neg pos 
   
32 f/c 69 8 yrs y/C   pos pos 30 pos pos neg neg pos neg    
33 m/c 80 9 yrs   or/G,oc neg NA 6 pos neg pos pos neg neg    
34 m/c 80 6 yrs y/G   neg pos 12 neg neg neg neg neg pos Pos* pos  
35 m/c 78 13 
yrs 
y/C   pos neg 26 
neg neg neg neg neg pos Pos* pos 
-/+ 
IgG&A 
36 f/c 64 13 
yrs 
  or/G,oc,n-ph pos neg 15 neg neg neg neg neg neg neg neg  
37 m/c 61 12 
yrs 
  or/C,oc pos neg 17 neg neg neg neg neg neg neg neg  
38 f/c 81 15 
yrs 
  Or,oc,n-ph 
(oral 
inactive) 
neg neg 0 
neg neg pos neg neg neg 
  +/- 
39 m/c 67 12 
yrs 
  or/G,oc pos pos 12 neg neg Pos° neg neg neg neg neg  
40 m/c 44 2 yrs   or/G,oc,n-ph pos neg 14 
pos pos pos pos pos pos˅ 
  -/+ 
IgG&A 
41 m/c 87 18 
yrs 
  or/G,sk,peri pos pos 5 pos pos pos pos pos pos˅    
42 m/c 87 4 yrs   sk,oc,n-
ph,peri 
pos pos 0 neg pos neg neg pos neg    
8 APPENDICES 
174 | P a g e  
 
43 m/c 75 10 
yrs 
  oc,n-ph pos pos 0 pos neg neg neg neg neg   +/+ IgA 
44 f/c 57 2 yrs y/G   pos pos 12 pos neg neg neg neg neg   -/+ IgA 
45 m/c 83 11 
yrs 
 y   NA neg 0 neg neg pos neg neg pos˅   -/- 
46 f/c 59 8 yrs   or/E, oc neg NA 8 neg neg neg neg neg neg    
47 f/c 46 7 yrs  y  neg neg 0 neg neg pos neg neg neg   -/- 
48 m/c 48 4 yrs y/G   pos neg 6 pos neg Pos^ neg neg Pos^ neg neg  
49 m/c 77 9 yrs   or/G,sk,oc pos neg 2 pos neg pos neg neg neg   -/- 
50 f/c 58 7 yrs   or/G,sk,gen,
n-ph 
pos neg 14 pos pos neg pos pos pos    
51 f/c 47 15 
yrs 
y/G   pos neg 9 neg neg neg neg neg neg    
52 m/c 65 11 
yrs 
y/G   pos pos 12 pos neg neg pos neg neg   -/- 
53 f/c 69 6 yrs   or/G,n-ph pos neg 3 neg neg neg neg neg pos Pos* pos +/- 
54 f/c 61 13 
yrs 
  or/G,oc pos neg 1 neg pos neg neg pos neg   -/- 






  pos pos 0 
neg pos neg neg neg neg 
  -/+ IgG 
56 f/c 69 14 
yrs 
 y  neg neg 0 neg neg Pos+ neg neg pos Pos+ pos +/- 
57 f/c 49 6 yrs y/G   pos neg 10 pos neg neg neg neg pos neg neg -/+ IgG 
58 m/c 68 3 yrs y no 
lesion
s(inac
  pos pos 0 
neg neg neg neg neg neg 
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59 f/c 60 12 
yrs 
y/G   pos pos 12 pos neg Pos^ Pos pos Pos^ neg neg -/- 
60 m/c 70 3 yrs   or/C,gen,n-
ph 
pos neg 19 pos neg pos neg neg neg    
61 f/c 70 7yrs y/G   pos neg 18 neg neg neg neg neg neg    
62 m/c 71 12 
yrs 
 y   neg neg 0 neg neg neg neg neg pos Pos* pos -/+ IgG 
63 m/c 64 4 yrs   or/C,oc pos NA 23 neg pos neg neg pos neg    
64 m/c 57 7 yrs  y   pos NA 0 neg neg neg neg neg neg neg neg  
65 f/c 70 3 yrs   or/G,oc,n-ph pos NA 12 neg neg neg neg neg neg    
66 f/c 73 9 yrs y/G   NA pos 10 neg neg neg neg neg neg   +/+ IgA 
67 m/c 44 11 
yrs 
  or/C,oc pos neg 7 pos neg Pos^ Pos neg Pos^ neg neg -/- 
68 m/c 64 15 
yrs 
  Or/G,oc neg NA 8 neg neg neg neg neg pos    
69 f/c 63 7 yrs y/C   pos neg 10 pos pos pos pos pos pos˅    
70 f/c 62 9 yrs y/G   pos pos 6 neg neg neg neg neg neg    
71 f/c 83 5 yrs  y  pos NA 0 neg neg neg neg neg neg neg neg  
72 m/c 60 7 yrs   sk,oc,n-ph pos neg 0 pos neg neg neg neg neg neg neg -/- 
73 f/c 79 19 
yrs 
 y  neg NA 0 neg neg pos neg neg pos˅    
74 f/c 55 12 
yrs 
 y  pos neg 0 neg pos neg neg neg neg   -/- 
75 m/c 62 8 yrs  y  pos neg 0 neg pos pos neg neg neg   -/- 
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76 f/a 63 2 yrs  y   pos neg 0 neg pos neg neg neg neg   -/- 
77 m/c 44 2 yrs  y   neg neg 0 neg pos neg neg neg pos   -/- 
78 f/c 65 2 yrs   Or(no 
leasions) 
oc,n-ph  
pos neg 0 
neg pos neg neg neg neg 
  +/- 
79 m/c 80 6 yrs   or/C,oc,gen,
sk 
pos pos 26 neg pos neg neg pos neg pos   
80 m/c 60 3 yrs   or/C,oc,scalp pos pos 43 pos pos neg neg pos neg pos   




pos pos 12 pos neg pos pos neg pos neg   
82 m/c 89 3 yrs   or/C,oc NA neg 38 neg pos neg neg neg neg neg   
83 f/c 66 5 yrs   or/G,gen pos pos 29 neg pos neg neg neg neg neg   
84 f/c 54 2 yrs y/G   pos neg 28 neg neg neg neg neg neg neg   
85 m/c 70 5 yrs y/G   pos neg 25 pos pos pos pos neg neg neg   
86 m/c 84 10 
yrs 
  or/C,oc,n-ph NA pos  73 pos pos neg neg neg neg pos   
87 f/al
g 
29 4 yrs   or/C,n-ph,lar pos pos 23 neg pos neg neg neg neg neg   
88 f/c 79 3 yrs   or/C,oc,nas pos neg 25 neg pos neg neg neg pos neg   
89 f/c 54 4 yrs   or/G,oc pos pos 28 neg pos neg neg neg pos pos   
90 f/c 70 3 yrs   or/G,oc,nas,
gen 
pos neg 10 neg neg neg neg neg neg neg   
91 m/c 51 7 yrs   oc, sk, n-ph neg neg 0 neg pos neg neg neg neg neg   
92 m/c 88 5 yrs y/C   pos pos 37 neg pos neg neg neg neg    
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93 f/c 63 9 yrs y/C   pos pos 12  pos   pos     
94 f/c 31 12 
yrs 
y/G   pos neg 6  pos   neg     
95 m/c 89 3 yrs   or/C,peri,sk pos pos 22  neg   neg     
96 f/c 67 2 yrs y/C   pos neg 15  pos   pos     
97 f/af
r 
46 3 yrs y/C   pos pos 42  pos   pos     
98 f/c 48 6 yrs y/C   pos pos 15  pos   neg     
99 f/c 52 1 yr y/G   NA pos 20  pos   neg     
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DIF (Direct immunofluorescence), IIF (Indirect immunofluorescence), ODSS (Oral disease severity score), OIDS (Ocular inflammatory 
disease score), S (serum), P (Parotid saliva), ws (Whole saliva), SC (Secretory component i.e SIgA), or (Oral), oc (Ocular), n-ph 
(Nasopharyngeal),  gen (Genital), sk (Skin), peri (Perianal), nas (Nasal), lar (Laryngeal),  pos (Positive), neg (Negative), NA (Not Available), 
yrs (Years). 
^ Samples positive for IgA specific antibody against BP180-NC16a on ELISA in whole saliva and serum (those having parotids). 
Underlined samples positive for IgA specific antibody against BP180-NC16a on ELISA in whole saliva (having parotid) 
Underlined samples positive for IgA specific antibody against BP180-NC16a on ELISA in whole saliva (no parotids) 
* samples positive for IgA in whole and parotid saliva 
+ samples positive for IgA in serum, whole and parotid saliva 
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1 f 72 3 yrs y  pos pos 37 pos/neg pos pos pos 
2 f 59 7 yrs  y pos pos 37 pos/pos pos pos pos 
3 m 60  6 yrs y  pos pos 8 neg/neg neg neg neg 
4 f 54 5 yrs y  pos pos 13 pos/neg pos pos pos 
5 f 28 3 yrs  y pos pos 29 pos/neg pos neg pos 
6 m 20 2 yrs y  pos neg 45 pos/neg pos neg pos 
7 m 50 2 yrs y  pos pos  25 pos/neg pos pos pos 
8 m 78 5 yrs  y pos pos 17 pos/pos pos neg neg 
9 f 58 10 yrs y  pos pos 0 neg/neg neg neg neg 
10 m 45 2 yrs y  pos neg 18 neg/neg neg neg neg 
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11 m 95 22 yrs  y pos pos 11 pos/neg pos pos pos 
12 f 62 3 yrs  y pos pos 8 pos/neg pos pos pos 
13 f 61 3 yrs y  pos pos 7 pos/neg pos pos pos 
14 m 37 2 yrs y  pos pos 0 pos/neg pos pos neg 
15 f 62 10 yrs  y pos pos 17 pos/neg pos pos pos 
16 f 64 5 yrs  y pos pos 7 pos/neg pos pos pos 
17 f 66 4 yrs y  pos neg 0 neg/neg neg neg neg 
18 m 41 3 yrs y  pos pos 27 pos/neg pos pos pos 
19 f 35 3 yrs y  pos neg 0 neg/neg neg neg neg 
20 f 69 7 yrs y  pos neg 4 neg/neg neg neg neg 
21 m 16 5 yrs  y pos pos 57 pos/pos pos pos pos 
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23 f 37 6 yrs y   pos neg 6 pos/neg pos pos neg 








17 (74%) / 








DIF (Direct immunofluorescence), IIF (Indirect immunofluorescence), ODSS (Oral disease severity score), S (serum), ws (Whole saliva), pos (Positive), neg 
(Negative), NA (Not Available), yrs (Years). 
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Appendix 5 Oral disease severity score (Escudier et al., 2007): 
 
Oral Disease Severity Score (Escudier 2007) 
 
Site Site Score Activity Score (0-3) 
Outer lips (1)   
Inner lips (1)   
R Buccal mucosa (1 or 2)   
L Buccal mucosa (1 or 2)   
Gingivae (1 each segment)   
     Lower R   
     Lower central   
     Lower L   
     Upper R   
     Upper central   
     Upper L   
Dorsum of tongue (1 or 2)   
R Ventral tongue (1)   
L Ventral tongue (1)   
Floor of mouth (1 or 2)   
Hard palate (1 or 2)   
Soft palate (1 or 2)   
Oropharynx (1 or 2)   
Total   
 
Total Score   
Total Score = Site Score + Activity Score + Pain Score (1-10) 
 
Site Score 
0 if no lesion 
For the buccal mucosa 
1 if less than 50% of area affected  
2 if greater than 50% of area affected 





1 mild erythema (gingivae, papillae only or <3mm along margins) 
2 marked erythema (full thickness gingivitis, extensive atrophy or oedema on non-keratinised 
mucosa) 
3 ulceration at this site 
 
Pain Score  
Analogue scale from 0 (no discomfort) to 10 (the most severe pain they have encountered with 
this condition so far) 
The patient is asked to provide a score reflecting their pain/discomfort as an average of the 
preceding week 
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Appendix 6 List of buffers and reagents used: 
 
 PBS: pH 7.3, 137 mM sodium chloride,  2.7 mM potassium chloride, 8 mM disodium hydrogen phosphate, 2 mM sodium dihydrogen 
phosphate and distilled water (dH2O) up to 1 L. 
 PBS/ BSA/ Tween 20: PBS as above, BSA 0.5% and Tween 20 (Polyoxyethylenesorbitan monolaurate Tween 20). 
 1M Diethanolamine pH 9.8: magnesium chloride 0.1 g, 800 ml dH2O, 97 ml diethanolamine, pH adjusted to 9.8 using concentrated 10M HCL 
and make up to 1 L with dH2O. This was stored in the dark at 4°C. 
 3M NaOH pH 14: 200 ml dH2O, 24 g sodium hydroxide. 
 1XTransfer buffer pH 8.3: 70% dH2O, 20% methanol and 10% of 10X transfer buffer (250 mM Tris Base, 2.5 M glycine, 1% sodium dodecyl 
sulphate SDS). 
 De-staining buffer: 20% methanol, 10% acetic acid 70 ml dH2O 
 Washing solution: PBS/ Tween 20, PBS as described and 0.05% Polyoxyethylenesorbitan monolaurate Tween 20. 
 Carbonate/ bicarbonate buffer pH 9.6 (100 mM): 3.03 g sodium carbonate, 6.0 g sodium bicarbonate, adjust pH 9.6 using concentrated HCL 
and make up to 1 L with dH2O. 
 Phosphatase substrate (4-nitrophenyl phosphate disodium salt hexa-hydrate) tablet form (N2765, SIGMA -ALDRICH) 
 Recombinant human integrin alpha 6 beta 4 (α6β4) 50 µg (5497-A6-050 R&D systems) 
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Appendix 7 Whole saliva optimal dilution (1:10 vs 1:50) 
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The first row indicates antibody dilutions.  The first column indicates protein 




  1:250  1:500 1:1000 
No 





                                
1.03087 0.825272 0.555758 0.158264 2.54422 1.97947 2.27619 0.187914 
0.1 
µg/ml 
                                
0.937113 0.735883 0.517709 0.138291 2.4464 1.86013 2.12587 0.135618 
0.5 
µg/ml 
                                
2.62496 2.21692 1.34453 0.153824 3.05953 3.15644 3.07726 0.15152 
0.5 
µg/ml 
                                
2.54663 2.20038 1.28436 0.158267 2.94193 2.90414 2.92897 0.154988 
1 
µg/ml 
                                
2.74689 2.45965 1.31486 0.153861 3.04792 3.01316 2.96574 0.148377 
1 
µg/ml 
                                




                                




                                
0.200976 0.172364 0.165904 0.162235 0.261291 0.158929 0.16165 0.17684 
         
Plate coated with α6β4 at 3 concentrations (0.1, 
0.5, 1 µg/ml). Anti-β4 antibody at different 
dilutions (1:250.1:500,1:100) 
 
Plate  coated with α6β4 at 3 concentrations 
(0.1, 0.5, 1 µg/ml) . Anti-α6 antibody at 
different dilutions (1:250.1:500,1:100) 
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 Coating overnight 4°C (α6β4 at different concentrations in Carbonate Bicarbonate 
buffer Ph 9.6) 
 Blocking with PBS/BSA/T20 37°C 1 hr 
 Antibody diluted in PBS/BSA/T20 at different dilutions and incubated for 2 hrs 37°C 
(both anti-α6 and anti-β4) 
 Anti-species Conjugate added diluted at 1:1000 in PBS/BSA/T20 alkaline phosphatase 
linked 1 hr 37°C 
 Substrate added developed for 30 minutes 37°C 
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Appendix 9 IgA serum and saliva optimization for PV Dsg 3 plates 
 Plate 1 Dsg3 pre-coated plates:  Sample incubation 2 hrs, 1:500 anti-human 
IgA conjugate (OD at 405 nm) (PV, DC -MMP,LP-, HC, Positive control, 
Negative control) 
A): Serum                      B): Saliva 
2 0.5 0.6 
1.1 0.8 1.3 
1.4 1.1 0.7 
1.2 1 0.8 
1.3 0.7 1.1 
1 0.9 0.8 
2.6 1.9 0.8 
2 1.7 0.6 
 
 Plate 2 Dsg3 pre-coated plates: Sample incubation 1 hr, 1:1000 anti-human 
IgA conjugate (OD at 405 nm) (PV, DC -MMP,LP-, HC, Positive control, 
Negative control) 
A): Serum                B): Saliva 
0.29 0.15 0.098 
0.24 0.12 0.18 
0.23 0.3 0.13 
0.27 0.22 0.22 
0.3 0.23 0.15 
0.22 0.22 0.16 
0.25 0.27 0.7 
0.22 0.29 0.2 
 
1.9 0.99 1.5 
2.25 0.78 0.9 
3 3 1.7 
2.25 1.7 1.3 
1. 0.8 1.2 
1.5 1.8 1.8 
2.3 1.2 1.7 
1.25 1.3 0.7 
1.5 0.64 0.12 
0.8 0.73 0.2 
0.7 0.88 0.22 
0.9 0.52 0.18 
0.54 0.24 0.078 
0.34 0.12 0.17 
0.33 0.11 0.9 
0.78 0.9 0.18 
9 REFERENCES  
189 | P a g e  
 
9 References
9 REFERENCES  
190 | P a g e  
 
 
9  References 
 
AHMED, A. R. & HOMBAL, S. M. 1986. Cicatricial pemphigoid. International 
Journal of Dermatology, 25, 90-6. 
AHMED, A. R., KURGIS, B. S. & ROGERS III, R. S. 1991. Cicatricial pemphigoid. 
Journal of the American Academy of Dermatology, 24, 987-1001. 
ALPSOY, E., AKMAN-KARAKAS, A. & UZUN, S. 2015. Geographic variations in 
epidemiology of two autoimmune bullous diseases: pemphigus and bullous 
pemphigoid. Archives of Dermatological Research, 1-8. 
AMAGAI, M. 2003. Desmoglein as a target in autoimmunity and infection. Journal of 
the American Academy of Dermatology, 48, 244-252. 
AMAGAI, M., AHMED, A. R., KITAJIMA, Y., BYSTRYN, J. C., MILNER, Y., 
GNIADECKI, R., HERTL, M., PINCELLI, C., FRIDKIS-HARELI, M., 
AOYAMA, Y., FRUSIC-ZLOTKIN, M., MULLER, E., DAVID, M., 
MIMOUNI, D., VIND-KEZUNOVIC, D., MICHEL, B., MAHONEY, M. & 
GRANDO, S. 2006. Are desmoglein autoantibodies essential for the 
immunopathogenesis of pemphigus vulgaris, or just 'witnesses of disease'? 
Experimental Dermatology, 15, 815-817. 
AMAGAI, M., KLAUS-KOVTUN, V. & STANLEY, J. R. 1991. Autoantibodies 
against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell 
adhesion. Cell, 67, 869-77. 
AMAGAI, M., TSUNODA, K., SUZUKI, H., NISHIFUJI, K., KOYASU, S. & 
NISHIKAWA, T. 2000. Use of autoantigen-knockout mice in developing an 
active autoimmune disease model for pemphigus. Journal of Clinical 
Investigation, 105, 625-631. 
AMAGAI, M., TSUNODA, K., ZILLIKENS, D., NAGAI, T. & NISHIKAWA, T. 
1999. The clinical phenotype of pemphigus is defined by the anti-desmoglein 
autoantibody profile. Journal of the American Academy of Dermatology, 40, 
167-70. 
ANDREADIS D, L. G., DRAKOULAKOS D, BELAZI M, MIHAILIDOU E, 
VELKOS G, MOURELLOU-TSATSAU O, ANTONIADES D. 2006. Detection 
of Pemphigus Desmoglein 1 and Desmoglein 3 Autoantibodies and Pemphigoid 
BP180 Autoantibodies in Saliva and Comparison with Serum Values. European 
Journal of Oral Sciences, 114, 374-380. 
ANHALT, G. J., LABIB, R. S., VOORHEES, J. J., BEALS, T. F. & DIAZ, L. A. 1982. 
Induction of Pemphigus in Neonatal Mice by Passive Transfer of IgG from 
Patients with the Disease. N Engl J  Med, 306, 1189-1196. 
ARIF, S., QUDSIA, S., UROOJ, S., CHAUDRY, N., ARSHAD, A. & ANDLEEB, S. 
2015. Blueprint of quartz crystal microbalance biosensor for early detection of 
breast cancer through salivary autoantibodies against ATP6AP1. Biosensors and 
Bioelectronics, 65, 62-70. 
BAGAN J., LL MUZIO & SCULLY, C. 2005. Mucous Membrane Pemphigoid. Oral 
Diseases, 11, 197-218. 
BALDING, S. D., PROST, C., DIAZ, L. A., BERNARD, P., BEDANE, C., 
ABERDAM, D. & GIUDICE, G. J. 1996. Cicatricial pemphigoid autoantibodies 
react with multiple sites on the BP180 extracellular domain. J  Invest Dermatol, 
106, 141-146. 
9 REFERENCES  
191 | P a g e  
 
BEAN, S. F., WAISMAN, M., MICHEAL, B., THOMAS, C. I., KNOX, J. M. & 
LEVINE, M. 1972. Cicatricial pemphigoid. Immunofluorescent studies. 
Archives of Dermatology, 106, 195-199. 
BEKOU, V., THOMA-USZYNSKI, S., WENDLER, O., UTER, W., SCHWIETZKE, 
S., HUNZIKER, T., ZOUBOULIS, C. C., SCHULER, G., SOROKIN, L. & 
HERTL, M. 2005. Detection of laminin 5-specific auto-antibodies in mucous 
membrane and bullous pemphigoid sera by ELISA. J Invest Dermatol, 124, 732-
40. 
BERNARD, P., ANTONICELLI, F., BEDANE, C. & ET AL. 2013. PRevalence and 
clinical significance of anti–laminin 332 autoantibodies detected by a novel 
enzyme-linked immunosorbent assay in mucous membrane pemphigoid. J AM 
Acad Dermatol, 149, 533-540. 
BERNARD, P., PROST, C., AUCOUTURIER, P., DUREPAIRE, N., DENIS, F. & 
BONNETBLANC, J. M. 1991. The subclass distribution of IgG autoantibodies 
in cicatricial pemphigoid and epidermolysis bullosa acquisita. J  Invest 
Dermatol, 97, 259-63. 
BERNARD, P., VAILLANT, L., LABEILLE, B., BEDANE, C., ARBEILLE, B., 
DENOEUX, J. P., LORETTE, G., BONNETBLANC, J. M. & PROST, C. 1995. 
Incidence and distribution of subepidermal autoimmune bullous skin diseases in 
three French regions. Bullous Diseases French Study Group. Archives of 
Dermatology, 131, 48-52. 
BERNAUER, W., ELDER, M., LEONARD, J., WRIGHT, P. & DART, J. 1994. The 
value of biopsies in the evaluation of chronic progressive conjunctival 
cicatrisation. Graefe's Archive for Clinical and Experimental Ophthalmology, 
232, 533-537. 
BERTRAM, F., BRÖCKER, E.-B., ZILLIKENS, D. & SCHMIDT, E. 2009. 
Prospective analysis of the incidence of autoimmune bullous disorders in Lower 
Franconia, Germany. JDDG: Journal der Deutschen Dermatologischen 
Gesellschaft, 7, 434-439. 
BEUTNER, E. H., RHODES, E. L. & HOLBOROW, E. J. 1967. Autoimmunity in 
chronic bullous skin diseases. Immunofluorescent demonstration of three types 
of antibodies to skin in sera of patients with pemphigus, bullous pemphigoid and 
in other human sera. Clin Exp Immunol, 2, 141-51. 
BHOL, K., MOHIMEN, A. & AHMED, A. R. 1994. Correlation of Subclasses of IgG 
with Disease Activity in Pemphigus vulgaris. Dermatology, 189, 85-89. 
BHOL, K. C., COLON, J. E. & AHMED, A. R. 2003. Autoantibody in Mucous 
Membrane Pemphigoid Binds to an Intracellular Epitope on Human [beta]4 
Integrin and Causes Basement Membrane Zone Separation in Oral Mucosa in an 
Organ Culture Model. J Invest Dermatol, 120, 701-702. 
BHOL, K. C., DANS, M. J., SIMMONS, R. K., FOSTER, C. S., GIANCOTTI, F. G. & 
AHMED, A. R. 2000. The autoantibodies to alpha 6 beta 4 integrin of patients 
affected by ocular cicatricial pemphigoid recognize predominantly epitopes 
within the large cytoplasmic domain of human beta 4. Journal of Immunology, 
165, 2824-9. 
BHOL, K. C., GOSS, L., KUMARI, S., COLON, J. E. & AHMED, A. R. 2001. 
Autoantibodies to Human  alpha 6 Integrin in Patients with Oral Pemphigoid. 
Journal of Dental Research, 80, 1711-1715. 
BIALY-GOLAN, A. & BRENNER, S. 1996. Penicillamine-induced bullous 
dermatoses. Journal of the American Academy of Dermatology, 35, 732-742. 
BLACK, A. P. B., SENEVIRATNE, S. L., JONES, L., KING, A. S., WINSEY, S., 
ARSECULARATNE, G., WOJNAROWSKA, F. & OGG, G. S. 2004. Rapid 
9 REFERENCES  
192 | P a g e  
 
effector function of circulating NC16A-specific T cells in individuals with 
mucous membrane pemphigoid. Br J Dermatol, 151, 1160-4. 
BORRADORI, L. & SONNENBERG, A. 1999. Structure and function of 
hemidesmosomes: more than simple adhesion complexes. Journal of 
Investigative Dermatology, 112, 411-8. 
BRANDTZAEG, P. E. R. 2007. Do Salivary Antibodies Reliably Reflect Both Mucosal 
and Systemic Immunity? Annals of the New York Academy of Sciences, 1098, 
288-311. 
BUTLER, J. E., SPRADLING, J. E., ROWAT, J., EKSTRAND, J. & 
CHALLACOMBE, S. J. 1990. Humoral immunity in root caries in an elderly 
population. 2. Oral Microbiol Immunol, 5, 113-20. 
CALABRESI, V., CARROZZO, M., COZZANI, E., ARDUINO, P., BERTOLUSSO, 
G., TIRONE, F., PARODI, A., ZAMBRUNO, G. & DI ZENZO, G. 2007. Oral 
pemphigoid autoantibodies preferentially target BP180 ectodomain. Clin 
Immunol, 122, 207-13. 
CAPRONI, M., CALZOLARI, A., GIOMI, B., SANTUCCI, M., FICARRA, G. & 
FABBRI, P. 2002. IL-4, IL-5, TGF-β1 and IFN-γ mRNAs detected by a new in 
situ amplification system in cicatricial pemphigoid. Experimental Dermatology, 
11, 421-427. 
CAPRONI, M., CALZOLARI, A., SALVATORE, E., GIOMI, B., VOLPI, W., 
D'AGATA, A., SANTUCCI, M. & FABBRI, P. 2003. Cytokine profile and 
supposed contribution to scarring in cicatricial pemphigoid. Journal of Oral 
Pathology and Medicine, 32, 34-40. 
CARROZZO, M., DAMETTO, E., FASANO, M. E., BROCCOLETTI, R., CARBONE, 
M., RENDINE, S. & AMOROSO, A. 2014. Interleukin-4RA gene 
polymorphism is associated with oral mucous membrane pemphigoid. Oral 
Diseases, 20, 275-280. 
CARROZZO, M., ECOZZANI, BROCCOLETTI, R., CARBONE, G., PENTENERO, 
M., ARDUINO, P., PARODI, A. & , A. S. G. 2004. Analysis of Antigens 
Targeted by Circulating IgG and IgA Antibodies in Patients with Mucous 
Membrane Pemphigoid Predominantly Affecting the Oral Cavity. J Periodontol, 
75, 1302-1308. 
CHALLACOMBE S. J., JANE SETTERFIELD, PEPE SHIRLAW, KAREN 
HARMAN, CRISPIAN SCULLY & BLACK, A. M. M. 2001. 
Immunodiagnosis of Pemphigus and Mucous Membrane Pemphigoid. Acta 
odontol scand, 59, 226-234. 
CHALLACOMBE, S. J. 1976. Immunoglobulins in Parotid Saliva and Serum in 
Relation to Dental Caries in Man. Caries Research, 10, 165-177. 
CHALLACOMBE, S. J., RUSSELL, M. W. & HAWKES, J. 1978. Passage of intact 
IgG from plasma to the oral cavity via crevicular fluid. Clin Exp Immunol, 34, 
417-422. 
CHAN L., RAZZAQUE A., ANHALT G., BERNAUER W., COOPER K. , ELDER 
M., FINE J., FOSTER, C., G. R., HASHIMOTO T., HOANG-XUAN T., 
KIRTSCHIG G., L. S., LOZADA-NUR F., MARINKOVICH P., MONDINO 
B., PROST-SQUARCIONI C., ROGERS III R., SETTERFIELD J., WEST D., 
WOJNAROWSKA F., WOODLEY D., YANCEY K., ZILLIKENS D & J., A. 
Z. 2002. The First International Consensus on Mucous Memebrane Pemphigoid. 
Arch dermatol 138, 370-379. 
CHAN, L. S. 2012. Ocular and oral mucous membrane pemphigoid (cicatricial 
pemphigoid). Clinics in Dermatology, 30, 34-37. 
CHAN, L. S., AHMED, A. R., ANHALT, G. J., BERNAUER, W., COOPER, K. D., 
ELDER, M. J., FINE, J. D., FOSTER, C. S., GHOHESTANI, R., 
9 REFERENCES  
193 | P a g e  
 
HASHIMOTO, T., HOANG-XUAN, T., KIRTSCHIG, G., KORMAN, N. J., 
LIGHTMAN, S., LOZADA-NUR, F., MARINKOVICH, M. P., MONDINO, B. 
J., PROST-SQUARCIONI, C., ROGERS, R. S., 3RD, SETTERFIELD, J. F., 
WEST, D. P., WOJNAROWSKA, F., WOODLEY, D. T., YANCEY, K. B., 
ZILLIKENS, D. & ZONE, J. J. 2002. The first international consensus on 
mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic 
factors, medical treatment, and prognostic indicators. Arch Dermatol, 138, 370-
9. 
CHAN, L. S., HAMMERBERG, C. & COOPER, K. D. 1997. Significantly Increased 
Occurrence of HLA-DQB1[lowast]0301 Allele in Patients with Ocular 
Cicatricial Pemphigoid. J Invest Dermatol, 108, 129-132. 
CHEN, M., CHAN, L. S., CAI, X., O'TOOLE, E. A., SAMPLE, J. C. & WOODLEY, 
D. T. 1997. Development of an ELISA for rapid detection of anti-type VII 
collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol, 
108, 68-72. 
CHENG, S. W., KOBAYASHI, M., KINOSHITA-KURODA, K., TANIKAWA, A., 
AMAGAI, M. & NISHIKAWA, T. 2002. Monitoring disease activity in 
pemphigus with enzyme-linked immunosorbent assay using recombinant 
desmogleins 1 and 3. Br J Dermatol, 147, 261-5. 
CHENG, Y.-S. L., REES, T. & WRIGHT, J. 2014. A review of research on salivary 
biomarkers for oral cancer detection. Clinical and Transational Medicine, 3, 3-
3. 
CHENG, Y. S., REES, T. D., WRIGHT, J. M. & PLEMONS, J. M. 2001. Childhood 
oral pemphigoid: a case report and review of the literature. Journal of Oral 
Pathology and Medicine, 30, 372-7. 
CHIAPPIN, S., ANTONELLI, G., GATTI, R. & DE PALO, E. F. 2007. Saliva 
specimen: A new laboratory tool for diagnostic and basic investigation. Clinica 
Chimica Acta, 383, 30-40. 
CHING, K. H., BURBELO, P. D., GONZALEZ-BEGNE, M., ROBERTS, M. E., 
COCA, A., SANZ, I. & IADAROLA, M. J. 2011. Salivary anti-Ro60 and anti-
Ro52 antibody profiles to diagnose Sjogren's Syndrome. Journal of Dental 
Research, 90, 445-9. 
CHRISTOPHORIDIS, S., BUDINGER, L., BORRADORI, L., HUNZIKER, T., 
MERK, H. F. & HERTL, M. 2000. IgG, IgA and IgE autoantibodies against the 
ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and 
linear IgA bullous dermatosis. Br J Dermatol, 143, 349-355. 
CSORBA, K., SCHMIDT, S., FLOREA, F., ISHII, N., HASHIMOTO, T., HERTL, M., 
KARPATI, S., BRUCKNER-TUDERMAN, L., NISHIE, W. & SITARU, C. 
2011. Development of an ELISA for sensitive and specific detection of IgA 
autoantibodies against BP180 in pemphigoid diseases. Orphanet J Rare Dis, 6, 
31. 
DANESHPAZHOOH, M., CHAMS-DAVATCHI, C., KHAMESIPOUR, A., 
MANSOORI, P., TAHERI, A., FIROOZ, A., MORTAZAVI, H., ESMAILI, N. 
& DOWLATI, Y. 2007. Desmoglein 1 and 3 enzyme-linked immunosorbent 
assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, 
severity, and disease activity. Journal of the European Academy of Dermatology 
and Venereology, 21, 1319-24. 
DANTZIG, P. 1973. Circulating antibodies in cicatricial pemphigoid. Archives of 
Dermatology, 108, 264-6. 
DESAI, N., ALLEN, J., ALI, I., VENNING, V. & WOJNAROWSKA, F. 2008. 
Autoantibodies to basement membrane proteins BP180 and BP230 are 
9 REFERENCES  
194 | P a g e  
 
commonly detected in normal subjects by immunoblotting. Australasian Journal 
of Dermatology, 49, 137-141. 
DI ZENZO, G., CARROZZO, M. & CHAN, L. S. 2014. Urban legend series: mucous 
membrane pemphigoid. Oral Diseases, 20, 35-54. 
DING, X., AOKI, V., MASCARO, J. M., JR., LOPEZ-SWIDERSKI, A., DIAZ, L. A. 
& FAIRLEY, J. A. 1997. Mucosal and mucocutaneous (generalized) pemphigus 
vulgaris show distinct autoantibody profiles. J Invest Dermatol, 109, 592-6. 
DOMLOGE-HULTSCH, N., ANHALT, G. J., GAMMON, W. R., LAZAROVA, Z., 
BRIGGAMAN, R., WELCH, M., JABS, D. A., HUFF, C. & YANCEY, K. B. 
1994. Antiepiligrin cicatricial pemphigoid: A subepithelial bullous disorders. 
Archives of Dermatology, 130, 1521-1529. 
EGAN, C. A., LAZAROVA, Z., DARLING, T. N., YEE, C. & YANCEY, K. B. 2003. 
Anti-Epiligrin Cicatricial Pemphigoid: Clinical Findings, Immunopathogenesis, 
and Significant Associations. Medicine, 82, 177-186. 
ENGVALL, E. & PERLMANN, P. 1972. Enzyme-Linked Immunosorbent Assay, Elisa. 
The Journal of Immunology, 109, 129-135. 
ESCUDIER, M., AHMED, N., SHIRLAW, P., SETTERFIELD, J., TAPPUNI, A., 
BLACK, M. M. & CHALLACOMBE, S. J. 2007. A scoring system for mucosal 
disease severity with special reference to oral lichen planus. Br J Dermatol, 157, 
765-70. 
ESMAILI, N., MORTAZAVI, H., KAMYAB-HESARI, K., AGHAZADEH, N., 
DANESHPAZHOOH, M., KHANI, S. & CHAMS-DAVATCHI, C. 2015. 
Diagnostic accuracy of BP180 NC16a and BP230-C3 ELISA in serum and 
saliva of patients with bullous pemphigoid. Clin Exp Dermatol, 40, 324-330. 
EYRE, R. W. & STANLEY, J. R. 1988. Identification of pemphigus vulgaris antigen 
extracted from normal human epidermis and comparison with pemphigus 
foliaceus antigen. Journal of Clinical Investigation, 81, 807-12. 
FENNICHE, S., RYM BENMOUSLY, HYAET MARRAK, ASMA DHAOUI, FEIZA 
BEN AMMAR & MOKHTAR, A. I. 2006. Neonatal Pemphigus Vulgaris in an 
Infant Born to a Mother with Pemphigus Vulgaris in Remission. Pediatric 
Dermatology, 23, 124-127. 
FINE, J. D., NEISES, G. R. & KATZ, S. I. 1984. Immunofluorescence and 
immunoelectron microscopic studies in cicatricial pemphigoid. J Invest 
Dermatol, 82, 39-43. 
FLORIANO, P. N., CHRISTODOULIDES, N., MILLER, C. S., EBERSOLE, J. L., 
SPERTUS, J., ROSE, B. G., KINANE, D. F., NOVAK, M. J., STEINHUBL, S., 
ACOSTA, S., MOHANTY, S., DHARSHAN, P., YEH, C.-K., REDDING, S., 
FURMAGA, W. & MCDEVITT, J. T. 2009. Use of Saliva-Based Nano-Biochip 
Tests for Acute Myocardial Infarction at the Point of Care: A Feasibility Study. 
Clinical Chemistry, 55, 1530-1538. 
GAMMON, W. R., BRIGGAMAN, R. A., INMAN, A. O., QUEEN, L. L. & 
WHEELER, C. E. 1984. Differentiating Anti-Lamina Lucida and Anti-
Sublamina Densa Anti-Bmz Antibodies by Indirect Immunofluorescence on 
1.0m Sodium Chloride-Separated Skin. J Invest Dermatol, 82, 139-144. 
GIANCOTTI, F. G. 1996. Signal transduction by the α6β4 integrin: charting the path 
between laminin binding and nuclear events. Journal of Cell Science, 109, 1165-
1172. 
GNIADECKI, R. 2006. Desmoglein autoimmunity in the pathogenesis of pemphigus. 
Autoimmunity, 39, 541-7. 
GONZALEZ, S., AGUILERA, S., ALLIENDE, C., URZUA, U., QUEST, A. F., 
HERRERA, L., MOLINA, C., HERMOSO, M., EWERT, P., BRITO, M., 
ROMO, R., LEYTON, C., PEREZ, P. & GONZALEZ, M. J. 2011. Alterations 
9 REFERENCES  
195 | P a g e  
 
in type I hemidesmosome components suggestive of epigenetic control in the 
salivary glands of patients with Sjogren's syndrome. Arthritis Rheum, 63, 1106-
15. 
GREENBERG, M. S. & GLICK, M. 2003. Burket's oral medicine : diagnosis & 
treatment, Hamilton, Ont., BC Decker. 
GRIFFITH, M. R., FUKUYAMA, K., TUFFANELLI, D. & SILVERMAN, S., JR. 
1974. Immunofluorescent studies in mucous membrane pemphigoid. Archives of 
Dermatology, 109, 195-9. 
GROTH, S., RECKE, A., VAFIA, K., LUDWIG, R. J., HASHIMOTO, T., 
ZILLIKENS, D. & SCHMIDT, E. 2011. Development of a simple enzyme-
linked immunosorbent assay for the detection of autoantibodies in anti-p200 
pemphigoid. Br J Dermatol, 164, 76-82. 
GUSHI, M., YAMAMOTO, Y., MINE, Y., AWAZAWA, R., NONAKA, K., TAIRA, 
K., ASATO, Y., HAGIWARA, K. & UEZATO, H. 2008. Neonatal pemphigus 
vulgaris. Journal of Dermatology, 35, 529-35. 
HALLAJI, Z., MORTAZAVI, H., LAJEVARDI, V., TAMIZIFAR, B., 
AMIRZARGAR, A., DANESHPAZHOOH, M. & CHAMS-DAVATCHI, C. 
2010. Serum and salivary desmoglein 1 and 3 enzyme-linked immunosorbent 
assay in pemphigus vulgaris: correlation with phenotype and severity. J Eur 
Acad Dermatol Venereol, 24, 275-80. 
HARDY, K. M., PERRY, H. O., PINGREE, G. C. & KIRBY, T. J., JR. 1971. Benign 
mucous membrane pemphigoid. Arch Dermatol, 104, 467-75. 
HARMAN, K., SEED, P. T., GRATIAN, M. J., BHOGAL, B., BLACK, M. M. & 
CHALLACOMBE, S. J. 2000a. The severity of cutaneous and oral pemphigus is 
related to desmoglein 1 and desmoglein 3 antibody levels. Journal of Oral 
Pathology and Medicine, 29, 473. 
HARMAN, K. E., GRATIAN, M. J., BHOGAL, B. S., CHALLACOMBE, S. J. & 
BLACK, M. M. 2000b. The use of two substrates to improve the sensitivity of 
indirect immunofluorescence in the diagnosis of pemphigus. Br J Dermatol, 
142, 1135-1139. 
HARMAN, K. E., GRATIAN, M. J., SEED, P. T., BHOGAL, B. S., 
CHALLACOMBE, S. J. & BLACK, M. M. 2000c. Diagnosis of pemphigus by 
ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the 
major pemphigus antigens, desmoglein 1 and 3. Clin Expl Dermatol, 25, 236-40. 
HASAN, S., AHMED, S., KHAN, N. I. & TARANNUM, F. 2011. Pemphigus 
vulgaris—a case report and detailed review of literature. Indian Journal of 
Dentistry, 2, 113-119. 
HASHIMOTO, T. 2001. Immunopathology of IgA pemphigus. Clinics in Dermatology, 
19, 683-689. 
HASHIMOTO, T. 2003. Recent advances in the study of the pathophysiology of 
pemphigus. Archives of Dermatological Research, 295, S2-S11. 
HASHIMOTO, T., KOMAI, A., FUTEI, Y., NISHIKAWA, T. & AMAGAI, M. 2001. 
Detection of iga autoantibodies to desmogleins by an enzyme-linked 
immunosorbent assay: The presence of new minor subtypes of iga pemphigus. 
Archives of Dermatology, 137, 735-738. 
HASHIMOTO, T. & NISHIKAWA, T. 2015. Nomenclature for diseases with IgA anti-
keratinocyte cell surface autoantibodies. Br J Dermatol. 
HAYAKAWA, T., FURUMURA, M., FUKANO, H., LI, X., ISHII, N., HAMADA, T., 
OHATA, C., TSURUTA, D., SHIMOZATO, K. & HASHIMOTO, T. 2014. 
Diagnosis of oral mucous membrane pemphigoid by means of combined 
serologic testing. Oral Surgery, Oral Medicine, Oral Pathology and Oral 
Radiology, 117, 483-496. 
9 REFERENCES  
196 | P a g e  
 
HAYASHI, I., SHINKUMA, S., SHIMIZU, S., NATSUGA, K., UJIIE, H., YASUI, C., 
TSUCHIYA, K., NISHIE, W. & SHIMIZU, H. 2011. Mucous membrane 
pemphigoid with generalized blisters: IgA and IgG autoantibodies target both 
laminin-332 and type XVII collagen. Br J Dermatol. 
HERTL, M., EMING, R. & VELDMAN, C. 2006. T cell control in autoimmune bullous 
skin disorders. J Clin Invest, 116, 1159-66. 
HEYMANN, W. R. 2009. Enzyme-linked Immunosorbent Assay and Immunobullous 
Disease. Journal of the American Academy of Dermatology, 60, 676-678. 
HOLMGREN, J. & CZERKINSKY, C. 2005. Mucosal immunity and vaccines. Nat 
Med, 11, S45-53. 
HOSSEEIN MORTAZAVI, A. K., ZAHRA SEYEDIN, IMAN VASHEGHANI 
FARAHANI, AND MARYAM DANESHPAZHOOH 2015. Salivary 
Desmoglein Enzyme-Linked Immunosorbent Assay for Diagnosis of Pemphigus 
Vulgaris: A Noninvasive Alternative Test to Serum Assessment. BioMed 
Research International, Volume 2015 7. 
HU, S., VISSINK, A., ARELLANO, M., ROOZENDAAL, C., ZHOU, H., 
KALLENBERG, C. G. & WONG, D. T. 2011. Identification of autoantibody 
biomarkers for primary Sjogren's syndrome using protein microarrays. 
Proteomics, 11, 1499-507. 
ISHII, K., AMAGAI, M., HALL, R. P., HASHIMOTO, T., TAKAYANAGI, A., 
GAMOU, S., SHIMIZU, N. & NISHIKAWA, T. 1997. Characterization of 
autoantibodies in pemphigus using antigen-specific enzyme-linked 
immunosorbent assays with baculovirus-expressed recombinant desmogleins. 
Journal of Immunology, 159, 2010-7. 
JAMORA, M. J. J., JIAO, D. & BYSTRYN, J.-C. 2003. Antibodies to desmoglein 1 
and 3, and the clinical phenotype of pemphigus vulgaris. Journal of the 
American Academy of Dermatology, 48, 976-977. 
JANEWAY CA JR, T. P., WALPORT M, ET AL. . 2001. Immunobiology: The Immune 
System in Health and Disease. 5th edition. New York: Garland Science; The 
mucosal immune system. 
JORDAN RE, T. C. T. S. A. L. 1971. Direct immunofluorescent studies of pemphigus 
and bullous pemphigoid. Archives of Dermatology, 103, 486-491. 
JUDD, K. P. & LEVER, W. F. 1979. Correlation of antibodies in skin and serum with 
disease severity in pemphigus. Archives of Dermatology, 115, 428-432. 
KANWAR, A. J., AJITH, A. C. & NARANG, T. 2006. Pemphigus in North India. 
Journal of Cutaneous Medicine and Surgery, 10, 21-25. 
KAUFMAN, E. & LAMSTER, I. B. 2002. The Diagnostic Applications of Saliva— A 
Review. Critical Reviews in Oral Biology and Medicine, 13, 197-212. 
KELLY, S. E. & WOJNAROWSKA, F. 1988. The Use of Chemically Split Tissue in 
the Detection of Circulating Anti-Basement Membrane Zone Antibodies in 
Bullous Pemphigoid and Cicatricial Pemphigoid. Br J Dermatol, 118, 31-40. 
KHARFI, M., KHALED, A., ANANE, R., FAZAA, B. & KAMOUN, M. R. 2010. 
Early onset childhood cicatricial pemphigoid: a case report and review of the 
literature. Pediatric Dermatology, 27, 119-24. 
KIRZHNER, M. & JAKOBIEC, F. A. 2011. Ocular cicatricial pemphigoid: a review of 
clinical features, immunopathology, differential diagnosis, and current 
management. Seminars in Ophthalmology, 26, 270-7. 
KORMAN, N. 1988. Pemphigus. J Am Acad Dermatol, 18, 1219-38. 
KOWALEWSKI, C., HASHIMOTO, T., AMAGAI, M., JABLONSKA, S., 
MACKIEWICZ, W. & WOZNIAK, K. 2006. IgA/IgG Pemphigus: A New 
Atypical Subset of Pemphigus? Acta Dermato-Venereologica, 86, 357-358. 
9 REFERENCES  
197 | P a g e  
 
KRISHNA PRASAD, R. B., SHARMA, A. & BABU, H. M. 2013. An insight into 
salivary markers in oral cancer. Dental Research Journal, 10, 287-295. 
KUMARI, S., BHOL, K. C., SIMMONS, R. K., RAZZZAQUE, M. S., LETKO, E., 
FOSTER, C. S. & AHMED, A. R. 2001. Identification of ocular cicatricial 
Pemphigoid antibody binding site(s) in human beta 4 integrin. Investigative 
Ophthalmology & Visual Science, 42, 379-385. 
KWON, E. J., YAMAGAMI, J., NISHIKAWA, T. & AMAGAI, M. 2008. Anti-
desmoglein IgG autoantibodies in patients with pemphigus in remission. Journal 
of the European Academy of Dermatology and Venereology, 22, 1070-5. 
LAFFITTE, E., BURKHARD, P. R., FONTAO, L., JAUNIN, F., SAURAT, J. H., 
CHOFFLON, M. & BORRADORI, L. 2005. Bullous pemphigoid antigen 1 
isoforms: potential new target autoantigens in multiple sclerosis? British Journal 
of Dermatology, 152, 537-540. 
LANGAN, S. M., SMEETH, L., HUBBARD, R., FLEMING, K. M., SMITH, C. J. P. & 
WEST, J. 2008. Bullous pemphigoid and pemphigus vulgaris--incidence and 
mortality in the UK: population based cohort study. BMJ, 337, a180-a180. 
LARA-CORRALES, I. & POPE, E. 2010. Autoimmune blistering diseases in children. 
Seminars in Cutaneous Medicine and Surgery, 29, 85-91. 
LAWRENCE, H. P. 2002. Salivary markers of systemic disease: noninvasive diagnosis 
of disease and monitoring of general health. J Can Dent Assoc, 68, 170-4. 
LAZAROVA, Z., YEE, C., DARLING, T., BRIGGAMAN, R. A. & YANCEY, K. B. 
1996. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters 
in neonatal mice. Journal of Clinical Investigation, 98, 1509-1518. 
LE POTTIER, L., DEVAUCHELLE, V., FAUTREL, A., DARIDON, C., SARAUX, 
A., YOUINOU, P. & PERS, J.-O. 2009. Ectopic Germinal Centers Are Rare in 
Sjögren’s Syndrome Salivary Glands and Do Not Exclude Autoreactive B Cells. 
The Journal of Immunology, 182, 3540-3547. 
LEE, E. H., KIM, Y. H., KIM, S., KIM, S. E. & KIM, S. C. 2012. Usefulness of 
Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 
for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid. Ann 
Dermatol, 24, 45-55. 
LEE, J. B., LIU, Y. & HASHIMOTO, T. 2003. Cicatricial pemphigoid sera specifically 
react with the most C-terminal portion of BP180. Journal of Dermatological 
Science, 32, 59-64. 
LENZ, P., AMAGAI, M., VOLC-PLATZER, B., STINGL, G. & KIRNBAUER, R. 
1999. Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool. 
Archives of Dermatology, 135, 143-8. 
LEONARD, J. N., HOBDAY, C. M., HAFFENDEN, G. P., GRIFFITHS, C. E. M., 
POWLES, A. V., WRIGHT, P. & FRY, L. 1988. Immunofluorescent studies in 
ocular cicatricial pemphigoid. Br J Dermatol, 118, 209-217. 
LEONARD, J. N., WRIGHT, P., WILLIAMS, D. M., GILKES, J. J., HAFFENDEN, G. 
P., MCMINN, R. M. & FRY, L. 1984. The relationship between linear IgA 
disease and benign mucous membrane pemphigoid. Br J Dermatol, 110, 307-14. 
LETKO E., KAILASH BHOL, C. STEPHEN FOSTER & AND A, R. A. 2000. 
Influence of Intravenous Immunoglobulin Therapy on Serum Levels of Anti-B4 
Antibodies in Ocular Cicatricial Pemphigoid A Correlation with Disease 
Activiy. Current Eye Research, 21, 646-654. 
LEVERKUS, M., BHOL, K., HIRAKO, Y., PAS, H., SITARU, C., BAIER, G., 
BRÖCKER, E. B., JONKMAN, M. F., AHMED, A. R. & ZILLIKENS, D. 
2001. Cicatricial pemphigoid with circulating autoantibodies to β4 integrin, 
bullous pemphigoid 180 and bullous pemphigoid 230. Br J Dermatol, 145, 998-
1004. 
9 REFERENCES  
198 | P a g e  
 
LIU, Z., DIAZ, L. A., TROY, J. L., TAYLOR, A. F., EMERY, D. J., FAIRLEY, J. A. 
& GIUDICE, G. J. 1993. A passive transfer model of the organ-specific 
autoimmune disease, bullous pemphigoid, using antibodies generated against the 
hemidesmosomal antigen, BP180. Journal of Clinical Investigation, 92, 2480-
2488. 
MACPHERSON, A., MCCOY, K., JOHANSEN, F., E. & BRANDTZAEG, P. 2008. 
The immune geography of IgA induction and function. Mucosal Immunology, 1, 
11-22. 
MANDEL, I. D. 1990. The diagnostic uses of saliva. Journal of Oral Pathology and 
Medicine, 19, 119-125. 
MANTIS, N. J., ROL, N. & CORTHESY, B. 2011. Secretory IgA's complex roles in 
immunity and mucosal homeostasis in the gut. Mucosal Immunol, 4, 603-611. 
MARCZINOVITS, I., KOVÁCS, L., GYÖRGY, A., TÓTH, G. K., DORGAI, L., 
MOLNÁR, J. & POKORNY, G. 2005. A peptide of human muscarinic 
acetylcholine receptor 3 is antigenic in primary Sjögren's syndrome. Journal of 
Autoimmunity, 24, 47-54. 
MENTINK, L. F., DE JONG, M. C. J. M., KLOOSTERHUIS, G. J., ZUIDERVEEN, J., 
JONKMAN, M. F. & PAS, H. H. 2007. Coexistence of IgA antibodies to 
desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and 
paraneoplastic pemphigus. Br J Dermatol, 156, 635-641. 
MESTECKY, J. 1987. The common mucosal immune system and current strategies for 
induction of immune responses in external secretions. Journal of Clinical 
Immunology, 7, 265-276. 
MEYER, J. R., MIGLIORATI, C. A., DANIELS, T. E. & GREENSPAN, J. S. 1985. 
Localization of Basement-Membrane Components in Mucous-Membrane 
Pemphigoid. Journal of Investigative Dermatology, 84, 105-107. 
MICHEL, B. & KO, C. S. 1977. An organ culture model for the study of pemphigus 
acantholysis. Br J Dermatol, 96, 295-302. 
MILLER, C. S., FOLEY, J. D., BAILEY, A. L., CAMPELL, C. L., HUMPHRIES, R. 
L., CHRISTODOULIDES, N., FLORIANO, P. N., SIMMONS, G., 
BHAGWANDIN, B., JACOBSON, J. W., REDDING, S. W., EBERSOLE, J. L. 
& MCDEVITT, J. T. 2010. Current developments in salivary diagnostics. 
Biomarkers in Medicine, 4, 171-189. 
MIYAMOTO, S., CHIKAZU, D., YASUDA, T., ENOMOTO, A., OH-I, T., HIRAKO, 
Y., TSUCHISAKA, A., YASUKOCHI, A., SOGAME, R., TEYE, K., KOGA, 
H., ISHII, N., QIAN, H., LI, X. & HASHIMOTO, T. 2014. A case of oral 
mucous membrane pemphigoid with IgG antibodies to integrin α6β4. Br J 
Dermatol. 
MONDINO, B. J., BROWN, S. I. & RABIN, B. S. 1978. HLA antigens in ocular 
cicatricial pemphigoid. British Journal of Ophthalmology, 62, 265-267. 
MORTAZAVI, H., SHAHDI, M., AMIRZARGAR, A. A., NARAGHI, Z. S., 
VALIKHANI, M., DANESHPAZHOOH, M., VASHEGHANI-FARAHANI, 
A., SEDAGHAT, M. & CHAMS-DAVATCHI, C. 2009. Desmoglein ELISA in 
the diagnosis of pemphigus and its correlation with the severity of pemphigus 
vulgaris. Iranian Journal of Allergy Asthma and Immunology, 8, 53-6. 
MURAKAMI H., SHOJI NISHIOKA, JANE SETTERFIELD, BALBIR S. BHOGAL, 
MARTIN M. BLACK, DETLEF ZILIKENS, KIM B. YANCEY, SHAWN D. 
BALDING, GOERGE J. GIUDICE, UIS A. DIAZ, TAKEJI NISHIKAWA, 
CHIE KIYOKAWA & HASHIMOTO, A. T. 1998. Analysis of Anitgens 
Targeted by Circulating IgG and IgA Autoantibodies in 50 Patients with 
Cicatricial Pemphigoid. Journal of Dermatological Science, 17, 39-44. 
9 REFERENCES  
199 | P a g e  
 
NG, V., KOH, D., FU, Q. & CHIA, S.-E. 2003. Effects of storage time on stability of 
salivary immunoglobulin A and lysozyme. Clinica Chimica Acta, 338, 131-134. 
OYAMA, N., SETTERFIELD, J. F., POWELL, A. M., SAKUMA-OYAMA, Y., 
ALBERT, S., BHOGAL, B. S., VAUGHAN, R. W., KANEKO, F., 
CHALLACOMBE, S. J. & BLACK, M. M. 2006. Bullous pemphigoid antigen 
II (BP180) and its soluble extracellular domains are major autoantigens in 
mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles 
and disease severity. Br J Dermatol, 154, 90-8. 
PARISI, E., RAGHAVENDRA, S., WERTH, V. P. & SOLLECITO, T. P. 2003. 
Modification to the approach of the diagnosis of mucous membrane 
pemphigoid: A case report and literature review. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod, 95, 182-6. 
PAYNE, A., HANAKAWA, Y., AMAGAI, M. & STANLEY, J. 2004. Desmosomes 
and disease: Pemphigus and bullous impetigo. Current Opinion in Cell Biology, 
16, 536-543. 
PERCIVAL, R. S., CHALLACOMBE, S. & MARSH, P. D. 1994. Flow Rates of 
Resting Whole and Stimulated Parotid Saliva in Relation to Age and Gender. 
Journal of Dental Research, 73, 1416-1420. 
PFAFFE, T., COOPER-WHITE, J., BEYERLEIN, P., KOSTNER, K. & 
PUNYADEERA, C. 2011. Diagnostic potential of saliva: current state and 
future applications. Clin Chem, 57, 675-87. 
PISANTI, S., Y. SHARAV, E. KOUFMAN & POSNER, A. L. N. 1974. Pemphigus 
Vulgaris: Incidence in Jews of different Ethnic Groups, According to Age, sex, 
and Initial Lesion. Oral Medicine, 38, 382-387. 
PORRO, A. M., CAETANO, L. D. V. N., MAEHARA, L. D. S. N. & ENOKIHARA, 
M. M. D. S. 2014. Non-classical forms of pemphigus: pemphigus herpetiformis, 
IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus. Anais 
Brasileiros de Dermatologica, 89, 96-106. 
POWELL, A. M., SAKUMA-OYAMA, Y., OYAMA, N. & BLACK, M. M. 2005. 
Collagen XVII/BP180: a collagenous transmembrane protein and component of 
the dermoepidermal anchoring complex. Clin Exp Dermatol, 30, 682-7. 
RABELO, D. F., NGUYEN, T., CAUFIELD, B. A. & AHMED, A. R. 2014. Mucous 
membranepemphigoid in two half-sisters. The potential roles of autoantibodies 
to beta4 integrin subunits and HLA-DQbeta1*0301. J Dermatol Case Rep, 8, 9-
12. 
RASHID, K. A., GURCAN, H. M. & AHMED, A. R. 2006a. Antigen specificity in 
subsets of mucous membrane pemphigoid. J Invest Dermatol, 126, 2631-6. 
RASHID, K. A., STERN, J. N. H. & AHMED, A. R. 2006b. Identification of an epitope 
within human integrin alpha 6 subunit for the binding of autoantibody and its 
role in basement membrane separation in oral pemphigold. Journal of 
Immunology, 176, 1968-1977. 
RAZZAQUE, A. 1980. Pemphigus: current concepts. Annals of Internal Medicine, 92, 
396-405. 
ROGERS, R. S., 3RD, PERRY, H. O., BEAN, S. F. & JORDON, R. E. 1977. 
Immunopathology of cicatricial pemphigoid: studies of complement deposition. 
Journal of Investigative Dermatology, 68, 39-43. 
RUOCCO, V., ROSSI, A., ARGENZIANO, G., ASTARITA, C., ALVIGGI, L., 
FARZATI, B. & PAPALEO, G. 1978. Pathogenicity of the intercellular 
antibodies of pemphigus and their periodic removal from the circulation by 
plasmapheresis. Br J Dermatol, 98, 237-241. 
SAKUMA-OYAMA, Y., POWELL, A. M., OYAMA, N., ALBERT, S., BHOGAL, B. 
S. & BLACK, M. M. 2004. Evaluation of a BP180-NC16a enzyme-linked 
9 REFERENCES  
200 | P a g e  
 
immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J 
Dermatol, 151, 126-31. 
SAMI, N. 2011. Approach to Patients with autoimmune Mucocutaneous Blistering 
Disease. Dermatologic therapy, 24, 173-186. 
SAMI, N., BHOL, K. C. & AHMED, A. R. 2002. Treatment of oral pemphigoid with 
intravenous immunoglobulin as monotherapy. Long-term follow-up: influence 
of treatment on antibody titres to human α6 integrin. Clin Exp Immunology, 129, 
533-540. 
SCHMIDT A. & KOCH, A. P. J. 2007. Desmosomes  Just cell adhesion or is there 
more. Cell adhesion and Migration, 1, 28-32. 
SCHMIDT, E., DAHNRICH, C., ROSEMANN, A., PROBST, C., KOMOROWSKI, 
L., SASCHENBRECKER, S., SCHLUMBERGER, W., STOCKER, W., 
HASHIMOTO, T., BROCKER, E. B., RECKE, A., ROSE, C. & ZILLIKENS, 
D. 2010. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation 
of disease activity with serum autoantibody levels in individual pemphigus 
patients. Exp Dermatol, 19, 458-63. 
SCHMIDT, E., REIMER, S., KRUSE, N., BRÖCKER, E. B. & ZILLIKENS, D. 2001a. 
The IL-8 release from cultured human keratinocytes, mediated by antibodies to 
bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp 
Immunology, 124, 157-162. 
SCHMIDT, E., SKROBEK, C., KROMMINGA, A., HASHIMOTO, T., MESSER, G., 
BRÖCKER, E. B., YANCEY, K. B. & ZILLIKENS, D. 2001b. Cicatricial 
pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and 
extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol, 145, 
778-783. 
SCHMIDT, E. & ZILLIKENS, D. 2010. Modern diagnosis of autoimmune blistering 
skin diseases. Autoimmun Rev, 10, 84-9. 
SCHMIDT, E. & ZILLIKENS, D. 2013. Pemphigoid diseases. The Lancet, 381, 320-
332. 
SCIUBBA, J. J. 2011. Autoimmune oral mucosal diseases: clinical, etiologic, 
diagnostic, and treatment considerations. Dental Clinics of North America, 55, 
89-103. 
SETTERFIELD, J. 2009. Clinicopathological Associations in Mucous Membrane 
Pemphigoid. Doctor of Medicine Thesis, University of London. 
SETTERFIELD , J., J. THERON, R.W. VAUGHAN, K.I. WELSH, E. MALLON, E. 
WOJNAROWSKA, S.J. CHALLACOMBE & BLACK, A. M. M. 2001. 
Mucous Membrane Pemphigoid: HLA-DQB1*0301 is Associated with All 
Clinical Sites of Involvement and May be Linked to Antibasement Membrane 
igG Production. Br J Dermatol, 145, 406-414. 
SETTERFIELD , J., P. SHIRLAW, B.S. BHOGAL, S.J. CHALLACOMBE & BLACK, 
M. M. 1999. Cicatricial Pemphigoid: Serial Titres of Circulating IgG and IgA 
Antibasement Membrane Antibodies Correlates with Disease Activity. Br J 
Dermatol, 140, 645-650. 
SETTERFIELD J., P.J. SHIRLAW, M. KERR-MUIR, S. NEIL, B.S. BHOGAL, P. 
MPRGAN, K. TELLING, S.J. CHALLACOMBE & BLACK, A. M. M. 1998. 
Mucous Membrane Pemphigoid: a Dual circulating Antibody Response with 
IgG and IgA Signifies a More Severe and Persistent Disease. Br J Dermatol, 
138. 
SHKLAR, G. & MCCARTHY, P. L. 1959. Oral manifestations of benign mucous 
membrane pemphigus (mucous membrane pemphigoid); review of the literature 
and report of fifteen cases. Oral Surgery, Oral Medicine, Oral Pathology, 12, 
950-66. 
9 REFERENCES  
201 | P a g e  
 
SILVERMAN JR, S., GORSKY, M., LOZADA-NUR, F. & LIU, A. 1986. Oral mucous 
membrane pemphigoid: A study of sixty-five patients. Oral Surgery, Oral 
Medicine, Oral Pathology, 61, 233-237. 
SISTIG, S., V. VUCIEVIC-BORAS, J LUKAC & KUSIC, A. Z. 2002. Salivary IgA 
and IgG Subclasses in Oral Mucosal Diseases. Oral Dis, 8, 282-286. 
SNEDDON, I. B. 1962. Cicatricial pemphigoid and skin grafts. Archives of 
Dermatology, 86, 226-8. 
SOLANO-LÓPEZ, G., CONCHA-GARZÓN, M. J., SÁNCHEZ-PÉREZ, J., HIRAKO, 
Y., LI, X., ISHII, N., HASHIMOTO, T. & DAUDÉN, E. 2014. Pure ocular 
mucous membrane pemphigoid reactive with both β4 integrin and the BP180 C-
terminal domain. Br J Dermatol, 172, 542-544. 
SONMEZOGLU, M., BAYSAL, B., ERGEN, A. & BARUT, S. G. 2005. Detection and 
evaluation of salivary antibodies to Helicobacter pylori in dyspeptic patients. Int 
J Clin Pract, 59, 433-6. 
SONNENBERG, A., CALAFAT, J., JANSSEN, H., DAAMS, H., VAN DER RAAIJ-
HELMER, L., FALCIONI, R., KENNEL, S. J., APLIN, J. D., BAKER, J. & 
LOIZIDOU, M. 1991. Integrin alpha 6/beta 4 complex is located in 
hemidesmosomes, suggesting a major role in epidermal cell-basement 
membrane adhesion. The Journal of Cell Biology, 113, 907-917. 
SPAETH, S., RIECHERS, R., BORRADORI, L., ZILLIKENS, D., BÜDINGER, L. & 
HERTL, M. 2001. IgG, IgA and IgE autoantibodies against the ectodomain of 
desmoglein 3 in active pemphigus vulgaris. Br J Dermatol, 144, 1183-1188. 
STANLEY, J. R., TANAKA, T., MUELLER, S., KLAUS-KOVTUN, V. & ROOP, D. 
1988. Isolation of complementary DNA for bullous pemphigoid antigen by use 
of patients' autoantibodies. Journal of Clinical Investigation, 82, 1864-70. 
STOTT, D. I., HIEPE, F., HUMMEL, M., STEINHAUSER, G. & BEREK, C. 1998. 
Antigen-driven clonal proliferation of B cells within the target tissue of an 
autoimmune disease. The salivary glands of patients with Sjögren's syndrome. 
Journal of Clinical Investigation, 102, 938-946. 
STRECKFUS, C., BIGLER, L., DELLINGER, T., DAI, X., KINGMAN, A. & 
THIGPEN, J. T. 2000. The Presence of Soluble c-erbB-2 in Saliva and Serum 
among Women with Breast Carcinoma: A Preliminary Study. Clinical Cancer 
Research, 6, 2363-2370. 
SU, L., LV, X. & MIAO, J. 2008. Integrin β4 in Neural Cells. NeuroMolecular 
Medicine, 10, 316-321. 
SUZUKI, S. & NAITOH, Y. 1990. Amino acid sequence of a novel integrin beta 4 
subunit and primary expression of the mRNA in epithelial cells. The EMBO 
Journal, 9, 757-763. 
SZODORAY, P., ALEX, P., JONSSON, M. V., KNOWLTON, N., DOZMOROV, I., 
NAKKEN, B., DELALEU, N., JONSSON, R. & CENTOLA, M. 2005. Distinct 
profiles of Sjögren's syndrome patients with ectopic salivary gland germinal 
centers revealed by serum cytokines and BAFF. Clinical Immunology, 117, 168-
176. 
TAGHIPOUR K. & WOJNAROWSKA, A. F. 2009. Autoimmune and Other Blistering 
Diseases. Medicine, 37, 291-297. 
TAJIMA, M., MITSUHASHI, Y., IRISAWA, R., AMAGAI, M., HASHIMOTO, T. & 
TSUBOI, R. 2010. IgA pemphigus reacting exclusively to desmoglein 3. EurJ 
Dermatol, 20, 626-9. 
TAMURA, R. N., ROZZO, C., STARR, L., CHAMBERS, J., REICHARDT, L. F., 
COOPER, H. M. & QUARANTA, V. 1990. Epithelial integrin alpha 6 beta 4: 
complete primary structure of alpha 6 and variant forms of beta 4. The Journal 
of Cell Biology, 111, 1593-1604. 
9 REFERENCES  
202 | P a g e  
 
TAYLOR, R. F. 1967. Modern treatment of severe "shrinkage of the conjunctiva". 
British Journal of Ophthalmology, 51, 31-43. 
TCHERNEV, G. & ORFANOS, C. E. 2006. Antigen mimicry, epitope spreading and 
the pathogenesis of pemphigus. Tissue Antigens, 68, 280-286. 
THEOFILOPOULOS, A. N. 1995. The basis of autoimmunity: part II genetic 
predisposition. Immunology Today, 16, 150-159. 
THORNE, J. E., ANHALT, G. J. & JABS, D. A. 2004. Mucous membrane pemphigoid 
and pseudopemphigoid. Ophthalmology, 111, 45-52. 
TOMASI, T. B. 1972. Secretory Immunoglobulins. New England Journal of Medicine, 
287, 500-506. 
TORCHIA, D., CAPRONI, M., VOLPI, W. & FABBRI, P. 2009. Naturally occurring 
regulatory T cells in mucous membrane pemphigoid lesions. Acta 
Dermatovenerologica Alpina, Pannonica, et Adriatica, 18, 3-6. 
TYAGI, S., BHOL, K., NATARAJAN, K., LIVIR-RALLATOS, C., FOSTER, C. S. & 
AHMED, A. R. 1996. Ocular cicatricial pemphigoid antigen: Partial sequence 
and biochemical characterization. Proceedings of the National Academy of 
Sciences of the United States of America, 93, 14714-14719. 
UJIIE, H., SHIBAKI, A., NISHIE, W., SAWAMURA, D., WANG, G., TATEISHI, Y., 
LI, Q., MORIUCHI, R., QIAO, H., NAKAMURA, H., AKIYAMA, M. & 
SHIMIZU, H. 2010. A Novel Active Mouse Model for Bullous Pemphigoid 
Targeting Humanized Pathogenic Antigen. J Immunol, 184, 2166-2174. 
VAILLY, J., PULKKINEN, L., MIQUEL, C., CHRISTIANO, A. M., GERECKE, D., 
BURGESON, R. E., UITTO, J., ORTONNE, J.-P. & MENEGUZZI, G. 1995. 
Identification of a Homozygous One-Basepair Deletion in Exon 14 of the 
LAMB3 in a Patient with Herlitz Junctional Epidermolysis Bullosa and Prenatal 
Diagnosis in a Family at Risk for Recurrence. J Investig Dermatol, 104, 462-
466. 
VAN JOOST, T. & VAN'T VEEN, A. J. 1993. Drug-induced cicatricial pemphigoid 
and acquired epidermolysis bullosa. Clinics in Dermatology, 11, 521-7. 
VAN NIEUW AMERONGEN, A., BOLSCHER, J. G. M. & VEERMAN, E. C. I. 2004. 
Salivary proteins: protective and diagnostic value in cariology? Caries 
Research, 38, 247-53. 
WANG, Q., YU, Q., LIN, Q. & DUAN, Y. 2015. Emerging salivary biomarkers by 
mass spectrometry. Clinica Chimica Acta, 438, 214-221. 
WIELAND C. N., NNEKA I. COMFERE, LAWRENCE E. GIBSON, AMY L. 
WEAVER, PATRICIA K. KRAUSE & MURRAY, A. J. A. 2010. Anti-Bullous 
Pemphigoid 180 and 230 Antibodies in a Sample of Unaffected Subjects. Arch 
Dermatol 146, 21-25. 
WILSON, C. L., WOJNAROWSKA, F., DEAN, D. & PASRICHA, J. S. 1993. IgG 
subclasses in pemphigus in Indian and UK populations. Clin Exp Dermatol, 18, 
226-230. 
WONG, D. T. 2006. Salivary diagnostics powered by nanotechnologies, proteomics and 
genomics. The Journal of the American Dental Association, 137, 313-321. 
YANG, J., TEZEL, G., PATIL, R. V., ROMANO, C. & WAX, M. B. 2001. Serum 
Autoantibody against Glutathione S-Transferase in Patients with Glaucoma. 
Investigative Ophthalmology and Visual Science, 42, 1273-1276. 
YEH, S. W., BABAR AHMED, NAVEED SAMI & AHMED, A. R. 2003. Blistering 
disorders: Diagnosis and Treatment. Dermatologic Therapy, 16, 214-223. 
YOKOYAMA, T., MATSUDA, S., TAKAE, Y., WADA, N., NISHIKAWA, T., 
AMAGAI, M. & KOYASU, S. 2011. Antigen-independent development of 
Foxp3+ regulatory T cells suppressing autoantibody production in experimental 
pemphigus vulgaris. Int Immunol, 23, 365-73. 
9 REFERENCES  
203 | P a g e  
 
ZHANG, L., FARRELL, J. J., ZHOU, H., ELASHOFF, D., AKIN, D., PARK, N. H., 
CHIA, D. & WONG, D. T. 2010. Salivary Transcriptomic Biomarkers for 
Detection of Resectable Pancreatic Cancer. Gastroenterology, 138, 949-957.e7. 
ZILLIKENS, D. 1999. Acquired skin diseases of Hemidesmosomes. Journal of 
Dermatological Science, 20, 134-154. 
ZONE, J. J., TAYLOR, T. B., MEYER, L. J. & PETERSEN, M. J. 1998. The 97 kDa 
Linear IgA Bullous Disease Antigen Is Identical to a Portion of the Extracellular 
Domain of the 180 kDa Bullous Pemphigoid Antigen, BPAg2. J Invest 
Dermatol, 110, 207-210. 
 
 
